| 1 |
Chen X, Dai W, Li H, Yan Z, Liu Z, He L. Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease. Drug Deliv 2023;30:2160518. [PMID: 36576203 DOI: 10.1080/10717544.2022.2160518] [Reference Citation Analysis]
|
| 2 |
Bilal A, Pratley RE. Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes. Endocrinol Metab Clin North Am 2023;52:355-75. [PMID: 36948784 DOI: 10.1016/j.ecl.2022.10.010] [Reference Citation Analysis]
|
| 3 |
Wang Z, Zhai J, Zhang T, He L, Ma S, Zuo Q, Zhang G, Wang Y, Guo Y. Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress. Biochem Biophys Res Commun 2023;653:53-61. [PMID: 36857900 DOI: 10.1016/j.bbrc.2023.01.084] [Reference Citation Analysis]
|
| 4 |
Sephien A, Ghobrial M, Reljic T, Prida X, Nerella N, Kumar A. Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews. Int J Cardiol 2023;377:79-85. [PMID: 36455697 DOI: 10.1016/j.ijcard.2022.11.052] [Reference Citation Analysis]
|
| 5 |
Kawade S, Ogiso K, Shayo SC, Obo T, Arimura A, Hashiguchi H, Deguchi T, Nishio Y. Luseogliflozin and caloric intake restriction increase superoxide dismutase 2 expression, promote antioxidative effects, and attenuate aortic endothelial dysfunction in diet-induced obese mice. J Diabetes Investig 2023;14:548-59. [PMID: 36729938 DOI: 10.1111/jdi.13981] [Reference Citation Analysis]
|
| 6 |
Krishnan A, Shankar M, Lerma EV, Wiegley N; GlomCon Editorial Team. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator? Kidney Med 2023;5:100608. [PMID: 36915368 DOI: 10.1016/j.xkme.2023.100608] [Reference Citation Analysis]
|
| 7 |
Yang T, Zhang D. Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury. Ageing Res Rev 2023;86:101884. [PMID: 36801379 DOI: 10.1016/j.arr.2023.101884] [Reference Citation Analysis]
|
| 8 |
Schechter M, Wiviott SD, Raz I, Goodrich EL, Rozenberg A, Yanuv I, Murphy SA, Zelniker TA, Fredriksson M, Johansson PA, Leiter LA, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Cahn A, Langkilde AM, Sabatine MS, Mosenzon O. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol 2023;11:233-41. [PMID: 36878239 DOI: 10.1016/S2213-8587(23)00009-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Fatima K, Suri A, Rija A, Kalim S, Javaid S, Arif Z, Abedin MFE, Raza Y, Kalim N, Azam F, Musani S. The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Stroke and Atrial Fibrillation: A Systematic Review and Meta-Analysis. Curr Probl Cardiol 2023;48:101582. [PMID: 36584726 DOI: 10.1016/j.cpcardiol.2022.101582] [Reference Citation Analysis]
|
| 10 |
Hasebe M, Yoshiji S, Keidai Y, Minamino H, Murakami T, Tanaka D, Fujita Y, Harada N, Hamasaki A, Inagaki N. Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. Cardiovasc Diabetol 2023;22:62. [PMID: 36935489 DOI: 10.1186/s12933-023-01773-z] [Reference Citation Analysis]
|
| 11 |
Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, Davies M, Edelman S, Forst T, Giorgino F, Green J, Groop PH, Hadjadj S, J L Heerspink H, Hompesch M, Izthak B, Ji L, Kanumilli N, Mankovsky B, Mathieu C, Miszon M, Mustafa R, Nauck M, Pecoits-Filho R, Pettus J, Ranta K, Rodbard HW, Rossing P, Ryden L, Schumm-Draeger PM, Solomon SD, Škrha J, Topsever P, Vilsbøll T, Wilding J, Standl E. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol 2023;22:59. [PMID: 36927451 DOI: 10.1186/s12933-023-01788-6] [Reference Citation Analysis]
|
| 12 |
Farber A, Rosenfield K, Menard MT. Surgery or Endovascular Therapy for Chronic Limb Ischemia. Reply. N Engl J Med 2023;388:e37. [PMID: 36920772 DOI: 10.1056/NEJMc2300713] [Reference Citation Analysis]
|
| 13 |
Miyamoto Y, Honda A, Yokose S, Nagata M, Miyamoto J. The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. JCM 2023;12:2253. [DOI: 10.3390/jcm12062253] [Reference Citation Analysis]
|
| 14 |
Liu G, Zhong X, Zheng J, Zhang J, Kong W, Hu X, Min J, Xia W, Zeng T, Chen L. Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review. Diabetes Ther 2023. [PMID: 36913143 DOI: 10.1007/s13300-023-01391-8] [Reference Citation Analysis]
|
| 15 |
Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. Cardiovasc Diabetol 2023;22:54. [PMID: 36899387 DOI: 10.1186/s12933-023-01784-w] [Reference Citation Analysis]
|
| 16 |
Herring RA, Parsons I, Shojaee-Moradie F, Stevenage M, Jackson N, Manders R, Umpleby AM, Fielding BA, Davies M, Russell-Jones DL. Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise. J Clin Endocrinol Metab 2023;108:888-96. [PMID: 36274035 DOI: 10.1210/clinem/dgac617] [Reference Citation Analysis]
|
| 17 |
Ledwidge M, Dodd JD, Ryan F, Sweeney C, McDonald K, Fox R, Shorten E, Zhou S, Watson C, Gallagher J, McVeigh N, Murphy DJ, McDonald K. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial. JAMA Cardiol 2023. [PMID: 36884247 DOI: 10.1001/jamacardio.2023.0065] [Reference Citation Analysis]
|
| 18 |
Sanghavi N, Ingrassia JP, Korem S, Ash J, Pan S, Wasserman A. Cardiovascular Manifestations in Rheumatoid Arthritis. Cardiol Rev 2023. [PMID: 36729119 DOI: 10.1097/CRD.0000000000000486] [Reference Citation Analysis]
|
| 19 |
Gallo G, Lanza O, Savoia C. New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy. IJMS 2023;24:5089. [DOI: 10.3390/ijms24065089] [Reference Citation Analysis]
|
| 20 |
Clements JN, Franks R, Isaacs D, Malloy K, Meade LT, Reece SM, Reid DJ, Ward ED. Significant publications in diabetes pharmacotherapy and technology in 2020. Expert Rev Endocrinol Metab 2023;:1-12. [PMID: 36882974 DOI: 10.1080/17446651.2023.2187779] [Reference Citation Analysis]
|
| 21 |
Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Neal B, Wheeler DC, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M; CREDENCE Trial Investigators. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis 2023:S0272-6386(23)00537-1. [PMID: 36889425 DOI: 10.1053/j.ajkd.2022.12.015] [Reference Citation Analysis]
|
| 22 |
Clements JN, Franks R, Isaacs D, Malloy K, Meade LT, Reece S(, Reid DJ, Ward ED. Significant publications in diabetes pharmacotherapy and technology in 2020. Expert Review of Endocrinology & Metabolism 2023. [DOI: 10.1080/17446651.2023.2187618] [Reference Citation Analysis]
|
| 23 |
Dayem KA, Younis O, Zarif B, Attia S, AbdelSalam A. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial). Int J Cardiol 2023:S0167-5273(23)00329-7. [PMID: 36889650 DOI: 10.1016/j.ijcard.2023.03.002] [Reference Citation Analysis]
|
| 24 |
Hammad H, Shaaban A, Philips MV, Fayed A, Abdelaziz TS. Effect of sodium-glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial. Int Urol Nephrol 2023. [PMID: 36872420 DOI: 10.1007/s11255-023-03539-8] [Reference Citation Analysis]
|
| 25 |
Yamasaki S, Horiuchi T. Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases. Hematology Reports 2023;15:180-187. [DOI: 10.3390/hematolrep15010019] [Reference Citation Analysis]
|
| 26 |
O'Neill B, Yusuf A, Kurdyak P, Kiran T, Sullivan F, Chen T, Kalia S, Eisen D, Anderson E, Selby P, Campbell D. Diabetes care among individuals with and without schizophrenia in three Canadian provinces: A retrospective cohort study. Gen Hosp Psychiatry 2023;82:19-25. [PMID: 36898192 DOI: 10.1016/j.genhosppsych.2023.02.007] [Reference Citation Analysis]
|
| 27 |
Girerd N, Zannad F. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. J Intern Med 2023. [PMID: 36871279 DOI: 10.1111/joim.13620] [Reference Citation Analysis]
|
| 28 |
Almas T, Alsufyani R, Jiffry R, Subai AKA, Almesri A, Ali SA, Baqal O, Malik J, Ahmed T, Rana MN. Estimated Glomerular Filtration Rate (eGFR) Slope Assessment as a Surrogate End-point in Cardiovascular trials: Implications, Impediments, and Future Directions. Curr Probl Cardiol 2023;48:101508. [PMID: 36402218 DOI: 10.1016/j.cpcardiol.2022.101508] [Reference Citation Analysis]
|
| 29 |
Ma Y, Lin C, Cai X, Hu S, Zhu X, Lv F, Yang W, Ji L. Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis. Acta Diabetol 2023;60:435-45. [PMID: 36609865 DOI: 10.1007/s00592-022-02022-7] [Reference Citation Analysis]
|
| 30 |
Lim JH, Cho JH. RE: The Efficacy and Safety of SGLT2 Inhibitor in Kidney Transplant Recipients With Diabetes. Transplantation 2023;107:e80-1. [PMID: 36808849 DOI: 10.1097/TP.0000000000004471] [Reference Citation Analysis]
|
| 31 |
D'Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels. JAMA Intern Med 2023;183:242-54. [PMID: 36745425 DOI: 10.1001/jamainternmed.2022.6664] [Reference Citation Analysis]
|
| 32 |
Li X, Kerindongo RP, Preckel B, Kalina JO, Hollmann MW, Zuurbier CJ, Weber NC. Canagliflozin inhibits inflammasome activation in diabetic endothelial cells - Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells. Biomed Pharmacother 2023;159:114228. [PMID: 36623448 DOI: 10.1016/j.biopha.2023.114228] [Reference Citation Analysis]
|
| 33 |
Barth SD, Kostev K, Krensel M, Mathey E, Rathmann W. Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report? Exp Clin Endocrinol Diabetes 2023;131:153-61. [PMID: 35981560 DOI: 10.1055/a-1927-4454] [Reference Citation Analysis]
|
| 34 |
Hammad N, Hassanein M, Rahman M. Diabetic Kidney Care Redefined with a New Way into Remission. Endocrinol Metab Clin North Am 2023;52:101-18. [PMID: 36754487 DOI: 10.1016/j.ecl.2022.08.002] [Reference Citation Analysis]
|
| 35 |
Scheen AJ, Bonnet F. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance? Diabetes Metab 2023;49:101419. [PMID: 36640828 DOI: 10.1016/j.diabet.2023.101419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 36 |
Feng B, Yang F, Liu J, Sun Q, Meng R, Zhu D. Amelioration of diabetic kidney injury with dapagliflozin is associated with suppressing renal HMGB1 expression and restoring autophagy in obese mice. J Diabetes Complications 2023;37:108409. [PMID: 36731146 DOI: 10.1016/j.jdiacomp.2023.108409] [Reference Citation Analysis]
|
| 37 |
Jones NK, Costello HM, Monaghan MT, Stewart K, Binnie D, Marks J, Bailey MA, Culshaw GJ. Sodium-glucose cotransporter 2 inhibition does not improve the acute pressure natriuresis response in rats with type 1 diabetes. Exp Physiol 2023;108:480-90. [PMID: 36644793 DOI: 10.1113/EP090849] [Reference Citation Analysis]
|
| 38 |
Dhatariya KK, Umpierrez G. Gaps in our knowledge of managing inpatient dysglycaemia and diabetes in non-critically ill adults: A call for further research. Diabet Med 2023;40:e14980. [PMID: 36256494 DOI: 10.1111/dme.14980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 39 |
Alkabbani W, Gamble JM. Prescribing Trends of the Sodium-Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015-2021). Can J Diabetes 2023;47:153-61. [PMID: 36481264 DOI: 10.1016/j.jcjd.2022.11.002] [Reference Citation Analysis]
|
| 40 |
Grams ME, Brunskill NJ, Ballew SH, Sang Y, Coresh J, Matsushita K, Surapaneni A, Bell S, Carrero JJ, Chodick G, Evans M, Heerspink HJL, Inker LA, Iseki K, Kalra PA, Kirchner HL, Lee BJ, Levin A, Major RW, Medcalf J, Nadkarni GN, Naimark DMJ, Ricardo AC, Sawhney S, Sood MM, Staplin N, Stempniewicz N, Stengel B, Sumida K, Traynor JP, van den Brand J, Wen CP, Woodward M, Yang JW, Wang AY, Tangri N. The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts. J Am Soc Nephrol 2023;34:482-94. [PMID: 36857500 DOI: 10.1681/ASN.0000000000000050] [Reference Citation Analysis]
|
| 41 |
Freeman AM, Raman SV, Aggarwal M, Maron DJ, Bhatt DL, Parwani P, Osborne J, Earls JP, Min JK, Bax JJ, Shapiro MD. Integrating Coronary Atherosclerosis Burden and Progression with Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making. Am J Med 2023;136:260-269.e7. [PMID: 36509122 DOI: 10.1016/j.amjmed.2022.10.021] [Reference Citation Analysis]
|
| 42 |
Eraikhuemen N, Leung S, Warren SB, Lazaridis D, Smith CH, Kearson ML, Marcellus V. Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials. Am J Cardiovasc Drugs 2023;23:113-26. [PMID: 36572841 DOI: 10.1007/s40256-022-00561-6] [Reference Citation Analysis]
|
| 43 |
Lui DTW, Wu T, Tang EHM, Au ICH, Lee CH, Woo YC, Tan KCB, Wong CKH. Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong. Diabetes Res Clin Pract 2023;197:110576. [PMID: 36780955 DOI: 10.1016/j.diabres.2023.110576] [Reference Citation Analysis]
|
| 44 |
Le Y, Yang J, Li F, Jiang Y, Wei T, Wang D, Wang K, Cui X, Lin X, Yang K, Hong T, Wei R. Dapagliflozin improves pancreatic islet function by attenuating microvascular endothelial dysfunction in type 2 diabetes. Diabetes Metab Res Rev 2023;39:e3607. [PMID: 36565185 DOI: 10.1002/dmrr.3607] [Reference Citation Analysis]
|
| 45 |
Bauduceau B, Bordier L, Doucet J. Interest and place of new therapeutic classes in the treatment of elderly diabetic patients. Diabetes Metab 2023;49:101431. [PMID: 36781066 DOI: 10.1016/j.diabet.2023.101431] [Reference Citation Analysis]
|
| 46 |
Lim LL, Chow E, Chan JCN. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nat Rev Endocrinol 2023;19:151-63. [PMID: 36446898 DOI: 10.1038/s41574-022-00776-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 47 |
Gao L, Cheng Z, Su B, Su X, Song W, Guo Y, Liao L, Chen X, Li J, Tan X, Xu F, Pang S, Wang K, Ye J, Wang Y, Chen L, Sun J, Ji L. Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Obes Metab 2023;25:785-95. [PMID: 36433709 DOI: 10.1111/dom.14926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Wu VC, Chan CK, Chueh JS, Chen YM, Lin YH, Chang CC, Lin PC, Chung SD; TAIPAI group. Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments. J Am Heart Assoc 2023;12:e028146. [PMID: 36789834 DOI: 10.1161/JAHA.122.028146] [Reference Citation Analysis]
|
| 49 |
Isidto R, Danguilan R, Naidas O, Vilanueva R, Arakama MH, Paraiso LM. Emerging Role of Sodium-Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease. Int J Nephrol Renovasc Dis 2023;16:43-57. [PMID: 36852177 DOI: 10.2147/IJNRD.S387262] [Reference Citation Analysis]
|
| 50 |
Wang W, Lin R, Yang L, Wang Y, Mao B, Xu X, Yu J. Meta-Analysis of Cardiovascular Risk Factors in Offspring of Preeclampsia Pregnancies. Diagnostics (Basel) 2023;13. [PMID: 36832300 DOI: 10.3390/diagnostics13040812] [Reference Citation Analysis]
|
| 51 |
Okajima F. Paradigm sift of the medical care in diabetes. Nihon Ika Daigaku Igakkai Zasshi 2023;19:32-41. [DOI: 10.1272/manms.19.32] [Reference Citation Analysis]
|
| 52 |
Vargas-Delgado AP, Arteaga Herrera E, Tumbaco Mite C, Delgado Cedeno P, Van Loon MC, Badimon JJ. Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. Int J Mol Sci 2023;24. [PMID: 36835554 DOI: 10.3390/ijms24044144] [Reference Citation Analysis]
|
| 53 |
Cheng JWM, Colucci V, Kalus JS, Spinler SA. Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Ann Pharmacother 2023;:10600280231154021. [PMID: 36800904 DOI: 10.1177/10600280231154021] [Reference Citation Analysis]
|
| 54 |
Chan JCH, Chan MCY. SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug? Medicina (Kaunas) 2023;59. [PMID: 36837589 DOI: 10.3390/medicina59020388] [Reference Citation Analysis]
|
| 55 |
Gay HC, Yu J, Persell SD, Linder JA, Srivastava A, Isakova T, Huffman MD, Khan SS, Mutharasan RK, Petito LC, Feinstein MJ, Shah SJ, Yancy CW, Kho AN, Ahmad FS. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease. Am J Cardiol 2023;189:121-30. [PMID: 36424193 DOI: 10.1016/j.amjcard.2022.10.041] [Reference Citation Analysis]
|
| 56 |
Yanai H, Katsuyama H, Hakoshima M, Adachi H. Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study. Biomedicines 2023;11. [PMID: 36831103 DOI: 10.3390/biomedicines11020567] [Reference Citation Analysis]
|
| 57 |
Jong G, Lin T, Liao P, Huang J, Yang T, Pan L. Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users.. [DOI: 10.21203/rs.3.rs-2572260/v1] [Reference Citation Analysis]
|
| 58 |
Pandey A, D'souza MM, Pandey AS, Mir H. A Web-based Application for Risk Stratification and Optimization in Patients with Cardiovascular Disease (STOP-CVD): Pilot Study (Preprint).. [DOI: 10.2196/preprints.46533] [Reference Citation Analysis]
|
| 59 |
Nguyen BN, Nguyen L, Mital S, Bugden S, Nguyen HV. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab 2023. [PMID: 36751968 DOI: 10.1111/dom.15009] [Reference Citation Analysis]
|
| 60 |
Jo HA, Seo JH, Lee S, Yu MY, Bae E, Kim DK, Kim YS, Kim DJ, Yang SH. Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor. Sci Rep 2023;13:2026. [PMID: 36739309 DOI: 10.1038/s41598-023-28850-3] [Reference Citation Analysis]
|
| 61 |
Khan MS, Shahid I, Greene SJ, Mentz RJ, DeVore AD, Butler J. Mechanisms of current therapeutic strategies for heart failure: more questions than answers? Cardiovasc Res 2023;118:3467-81. [PMID: 36536991 DOI: 10.1093/cvr/cvac187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 62 |
Colbert GB, Madariaga HM, Gaddy A, Elrggal ME, Lerma EV. Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy. Ther Clin Risk Manag 2023;19:133-42. [PMID: 36756278 DOI: 10.2147/TCRM.S398163] [Reference Citation Analysis]
|
| 63 |
Enzan N, Matsushima S, Kaku H, Tohyama T, Nagata T, Ide T, Tsutsui H. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes. JACC Asia 2023;3:93-104. [PMID: 36873765 DOI: 10.1016/j.jacasi.2022.09.015] [Reference Citation Analysis]
|
| 64 |
Thiagaraj S, Shukla TS, Gutlapalli SD, Farhat H, Irfan H, Muthiah K, Pallipamu N, Taheri S, Khan S. The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review. Cureus 2023;15:e34942. [PMID: 36938250 DOI: 10.7759/cureus.34942] [Reference Citation Analysis]
|
| 65 |
Solomon J, Festa MC, Chatzizisis YS, Samanta R, Suri RS, Mavrakanas TA. Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. Pharmacol Ther 2023;242:108330. [PMID: 36513134 DOI: 10.1016/j.pharmthera.2022.108330] [Reference Citation Analysis]
|
| 66 |
Skeik N, Elejla SA, Sethi A, Manunga J, Mirza A. Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. Vasc Med 2023;28:62-76. [PMID: 36593757 DOI: 10.1177/1358863X221143811] [Reference Citation Analysis]
|
| 67 |
Al-Salameh A, El Bouzegaoui N, Saraval-Gross M. Diabetes and cardiovascular risk according to sex: An overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. Ann Endocrinol (Paris) 2023;84:57-68. [PMID: 36183805 DOI: 10.1016/j.ando.2022.09.023] [Reference Citation Analysis]
|
| 68 |
Shiina K, Tomiyama H, Tanaka A, Imai T, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Dohi K, Kamiya H, Kida K, Anzai T, Chikamori T, Node K; CANDLE trial investigators. Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial. Hypertens Res 2023;46:495-506. [PMID: 36380202 DOI: 10.1038/s41440-022-01085-x] [Reference Citation Analysis]
|
| 69 |
Yanai H, Adachi H, Hakoshima M, Katsuyama H. Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes. Cardiol Res 2023;14:12-21. [PMID: 36896226 DOI: 10.14740/cr1459] [Reference Citation Analysis]
|
| 70 |
Charlwood C, Chudasama J, Darling AL, Logan Ellis H, Whyte MB. Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis. Diabetes Res Clin Pract 2023;196:110239. [PMID: 36610543 DOI: 10.1016/j.diabres.2023.110239] [Reference Citation Analysis]
|
| 71 |
Engström A, Wintzell V, Melbye M, Hviid A, Eliasson B, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Pasternak B, Ueda P. Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study. Diabetes Care 2023;46:351-60. [PMID: 36508322 DOI: 10.2337/dc22-0714] [Reference Citation Analysis]
|
| 72 |
Chen HB, Meng RS, Yang YL, Yu TH. The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. Expert Opin Drug Saf 2023;22:133-40. [PMID: 36803188 DOI: 10.1080/14740338.2023.2182290] [Reference Citation Analysis]
|
| 73 |
Sollier M, Bogeat C, Ibrahim A, Garcia C, Nassouri S, Bauduceau B, Bordier L. Prise en charge de l’artériopathie des membres inférieurs chez les patients diabétiques présentant une plaie du pied. Médecine des Maladies Métaboliques 2023;17:64-69. [DOI: 10.1016/j.mmm.2022.08.008] [Reference Citation Analysis]
|
| 74 |
Nelson AJ, Pagidipati NJ, Kelsey MD, Ardissino M, Aroda VR, Cavender MA, Lopes RD, Al-Khalidi HR, Braceras R, Gaynor T, Kaltenbach LA, Kirk JK, Lingvay I, Magwire ML, O'Brien EC, Pak J, Pop-Busui R, Richardson CR, Levya M, Senyucel C, Webb L, McGuire DK, Green JB, Granger CB. Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design. Am Heart J 2023;256:2-12. [PMID: 36279931 DOI: 10.1016/j.ahj.2022.10.079] [Reference Citation Analysis]
|
| 75 |
Chlebek C, Rosen CJ. The Role of Bone Cell Energetics in Altering Bone Quality and Strength in Health and Disease. Curr Osteoporos Rep 2023;21:1-10. [PMID: 36435911 DOI: 10.1007/s11914-022-00763-6] [Reference Citation Analysis]
|
| 76 |
Borderie G, Foussard N, Larroumet A, Blanco L, Domenge F, Mohammedi K, Ducasse E, Caradu C, Rigalleau V. Albuminuric diabetic kidney disease predicts foot ulcers in type 2 diabetes. J Diabetes Complications 2023;37:108403. [PMID: 36641879 DOI: 10.1016/j.jdiacomp.2023.108403] [Reference Citation Analysis]
|
| 77 |
Velliou M, Polyzogopoulou E, Ventoulis I, Parissis J. Clinical pharmacology of SGLT-2 inhibitors in heart failure. Expert Rev Clin Pharmacol 2023;16:149-60. [PMID: 36701817 DOI: 10.1080/17512433.2023.2173574] [Reference Citation Analysis]
|
| 78 |
Osto E, Bonacina F, Pirillo A, Norata GD. Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms. Pharmacol Res 2023;188:106667. [PMID: 36657502 DOI: 10.1016/j.phrs.2023.106667] [Reference Citation Analysis]
|
| 79 |
Hinton W, Ansari AS, Whyte MB, McGovern AP, Feher MD, Munro N, de Lusignan S. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies. Diabetes Obes Metab 2023;25:501-15. [PMID: 36239122 DOI: 10.1111/dom.14893] [Reference Citation Analysis]
|
| 80 |
Yamaguchi S, Shimabukuro M, Tanaka A, Imai T, Hiramitsu S, Takahashi N, Kadokami T, Ajioka M, Suzuki M, Node K; CANDLE Trial Investigators. Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial. Diabetes Obes Metab 2023;25:354-64. [PMID: 36193841 DOI: 10.1111/dom.14876] [Reference Citation Analysis]
|
| 81 |
Bartholdy KV, Johansen ND, Landler N, Skaarup KG, Jensen J, Bressendorff I, Schou M, Christensen J, Feldt-Rasmussen B, Vaduganathan M, Solomon S, Haynes R, Persson F, Rossing P, Køber L, Zannad F, Hansen D, Biering-Sørensen T. Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial. Kidney360 2023;4:143-9. [PMID: 36649484 DOI: 10.34067/KID.0006982022] [Reference Citation Analysis]
|
| 82 |
Cai Z, Wu C, Xu Y, Cai J, Zhao M, Zu L. The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. Aging Dis 2023;14:46-62. [PMID: 36818566 DOI: 10.14336/AD.2022.0523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 83 |
Urbanek K, Cappetta D, Bellocchio G, Coppola MA, Imbrici P, Telesca M, Donniacuo M, Riemma MA, Mele E, Cianflone E, Naviglio S, Conte E, Camerino GM, Mele M, Bucci M, Castaldo G, De Luca A, Rossi F, Berrino L, Liantonio A, De Angelis A. Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome. Pharmacol Res 2023;188:106659. [PMID: 36646190 DOI: 10.1016/j.phrs.2023.106659] [Reference Citation Analysis]
|
| 84 |
Choday S, Ravi N, Parisapogu A, Ojinna BT, Sherpa ML. Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure. Cureus 2023;15:e34687. [PMID: 36909046 DOI: 10.7759/cureus.34687] [Reference Citation Analysis]
|
| 85 |
Wakasugi M, Narita I. Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020. Nephrology (Carlton) 2023;28:119-29. [PMID: 36461735 DOI: 10.1111/nep.14134] [Reference Citation Analysis]
|
| 86 |
Siriyotha S, Lukkunaprasit T, Angkananard T, Looareesuwan P, McKay GJ, Attia J, Thakkinstian A. Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial. Front Endocrinol (Lausanne) 2023;14:1094221. [PMID: 36793285 DOI: 10.3389/fendo.2023.1094221] [Reference Citation Analysis]
|
| 87 |
Dharia A, Khan A, Sridhar VS, Cherney DZI. SGLT2 Inhibitors: The Sweet Success for Kidneys. Annu Rev Med 2023;74:369-84. [PMID: 36706745 DOI: 10.1146/annurev-med-042921-102135] [Reference Citation Analysis]
|
| 88 |
Ghosal S, Sinha B, Mukherjee R. Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight. ESC Heart Fail 2023. [PMID: 36707061 DOI: 10.1002/ehf2.14296] [Reference Citation Analysis]
|
| 89 |
Maddaloni E, Cavallari I, La Porta Y, Appetecchia A, D'Onofrio L, Grigioni F, Buzzetti R, Holman RR. Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2023. [PMID: 36700422 DOI: 10.1111/dom.14986] [Reference Citation Analysis]
|
| 90 |
Cherney DZI, Bell A, Girard L, McFarlane P, Moist L, Nessim SJ, Soroka S, Stafford S, Steele A, Tangri N, Weinstein J. Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. Can J Kidney Health Dis 2023;10:20543581221150556. [PMID: 36726361 DOI: 10.1177/20543581221150556] [Reference Citation Analysis]
|
| 91 |
Connelly KA, Mazer CD, Puar P, Teoh H, Wang CH, Mason T, Akhavein F, Chang CW, Liu MH, Yang NI, Chen WS, Juan YH, Opingari E, Salyani Y, Barbour W, Pasricha A, Ahmed S, Kosmopoulos A, Verma R, Moroney M, Bakbak E, Krishnaraj A, Bhatt DL, Butler J, Kosiborod MN, Lam CSP, Hess DA, Rizzi Coelho-Filho O, Lafreniere-Roula M, Thorpe KE, Quan A, Leiter LA, Yan AT, Verma S. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation 2023;147:284-95. [PMID: 36335517 DOI: 10.1161/CIRCULATIONAHA.122.062769] [Reference Citation Analysis]
|
| 92 |
Lee KS, Noh J, Park SM, Choi KM, Kang SM, Won KC, Cho HJ, Moon MK; Committee of Clinical Practice Guidelines, Korean Diabetes Association and Committee of Clinical Practice Guidelines, Korean Society of Heart Failure. Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Int J Heart Fail 2023;5:1-20. [PMID: 36818141 DOI: 10.36628/ijhf.2022.0028] [Reference Citation Analysis]
|
| 93 |
Goldman A, Fishman B, Twig G, Raschi E, Cukierman-Yaffe T, Moshkovits Y, Pomerantz A, Ben-Zvi I, Dankner R, Maor E. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study. Cardiovasc Diabetol 2023;22:16. [PMID: 36694178 DOI: 10.1186/s12933-023-01743-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 94 |
Gregg LP, Ramsey DJ, Akeroyd JM, Jafry SA, Matheny ME, Virani SS, Navaneethan SD. Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD. Am J Kidney Dis 2023:S0272-6386(23)00038-0. [PMID: 36702340 DOI: 10.1053/j.ajkd.2022.11.017] [Reference Citation Analysis]
|
| 95 |
Ortiz A, Ferro CJ, Balafa O, Burnier M, Ekart R, Halimi JM, Kreutz R, Mark PB, Persu A, Rossignol P, Ruilope LM, Schmieder RE, Valdivielso JM, Del Vecchio L, Zoccali C, Mallamaci F, Sarafidis P; European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney Working Group of the European Society of Hypertension (ESH). Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrol Dial Transplant 2023;38:10-25. [PMID: 33944938 DOI: 10.1093/ndt/gfab167] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 96 |
Deng B, Song A, Zhang C. Cell-Cycle Dysregulation in the Pathogenesis of Diabetic Kidney Disease: An Update. Int J Mol Sci 2023;24. [PMID: 36768457 DOI: 10.3390/ijms24032133] [Reference Citation Analysis]
|
| 97 |
Podestà MA, Sabiu G, Galassi A, Ciceri P, Cozzolino M. SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. Biomedicines 2023;11. [PMID: 36830815 DOI: 10.3390/biomedicines11020279] [Reference Citation Analysis]
|
| 98 |
Santos DS, Turaça LT, Coutinho KCS, Barbosa RAQ, Polidoro JZ, Brunswick THK, Carvalho ACC, Girardi ACC. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1.. [DOI: 10.21203/rs.3.rs-2472725/v1] [Reference Citation Analysis]
|
| 99 |
Lee HF, Chuang C, Li PR, Yeh YH, Chan YH, See LC. Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Diabetol Metab Syndr 2023;15:8. [PMID: 36653811 DOI: 10.1186/s13098-023-00982-6] [Reference Citation Analysis]
|
| 100 |
Lopes AC, Lourenço O, Roque F, Morgado M. Clinical and Pharmacotherapeutic Profile of Patients with Type 2 Diabetes Mellitus Admitted to a Hospital Emergency Department. Biomedicines 2023;11. [PMID: 36830792 DOI: 10.3390/biomedicines11020256] [Reference Citation Analysis]
|
| 101 |
Marcińczyk N, Misztal T, Chabielska E, Gromotowicz-Popławska A. Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice. Sci Rep 2023;13:932. [PMID: 36650229 DOI: 10.1038/s41598-023-28225-8] [Reference Citation Analysis]
|
| 102 |
Piccinni C, Dondi L, Calabria S, Ronconi G, Pedrini A, Lapi F, Marconi E, Parretti D, Medea G, Cricelli C, Martini N, Maggioni AP. How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases. Int J Cardiol 2023;371:236-43. [PMID: 36174826 DOI: 10.1016/j.ijcard.2022.09.053] [Reference Citation Analysis]
|
| 103 |
Hasan MT, Awad AK, Shih M, Attia AN, Aboeldahab H, Bendary M, Bendary A. Meta-Analysis on the Safety and Efficacy of Sodium Glucose Cotransporters 2 Inhibitors in Patients With Heart Failure With and Without Diabetes. Am J Cardiol 2023;187:93-9. [PMID: 36459753 DOI: 10.1016/j.amjcard.2022.10.027] [Reference Citation Analysis]
|
| 104 |
Savarese G, Sharma A, Pang C, Wood R, Soleymanlou N. Patient preferences for newer oral therapies in type 2 diabetes. Int J Cardiol 2023;371:526-32. [PMID: 36096275 DOI: 10.1016/j.ijcard.2022.09.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 105 |
Andreadi A, Muscoli S, Tajmir R, Meloni M, Muscoli C, Ilari S, Mollace V, Della Morte D, Bellia A, Di Daniele N, Tesauro M, Lauro D. Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease. Int J Mol Sci 2023;24. [PMID: 36675160 DOI: 10.3390/ijms24021646] [Reference Citation Analysis]
|
| 106 |
Vergara A, Llorens-Cebrià C, Martos N, Martínez-Díaz I, Stein F, Domínguez-Báez P, Molina-Van den Bosch M, Rettel M, Benito B, Bermejo S, Pieper MP, Jacobs-Cachá C, Soler MJ. The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy. Clin Sci (Lond) 2023;137:87-104. [PMID: 36524468 DOI: 10.1042/CS20220447] [Reference Citation Analysis]
|
| 107 |
August P. Chronic Kidney Disease - Another Step Forward. N Engl J Med 2023;388:179-80. [PMID: 36630627 DOI: 10.1056/NEJMe2215286] [Reference Citation Analysis]
|
| 108 |
Belany P, Kackley ML, Zhao S, Kluwe B, Buga A, Crabtree C, Nedungadi D, Kline D, Brock G, Simonetti OP, Volek JS, Joseph JJ. Effects of Hypocaloric Low-Fat, Ketogenic and Ketogenic & Ketone Supplement diets on Aldosterone and Renin. J Clin Endocrinol Metab 2023:dgad009. [PMID: 36629058 DOI: 10.1210/clinem/dgad009] [Reference Citation Analysis]
|
| 109 |
Petroni ML, Brodosi L, Marchesini G. The treatment of diabetes in advanced liver disease: change of a paradigm. Ann Hepatol 2023;28:100772. [PMID: 36261110 DOI: 10.1016/j.aohep.2022.100772] [Reference Citation Analysis]
|
| 110 |
Weng YF, Chen CY, Hwang SJ, Huang YB. Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics. Kaohsiung J Med Sci 2023. [PMID: 36625282 DOI: 10.1002/kjm2.12635] [Reference Citation Analysis]
|
| 111 |
Ju F, Abbott GW, Li J, Wang Q, Liu T, Liu Q, Hu Z. Canagliflozin Pretreatment Attenuates Myocardial Dysfunction and Improves Postcardiac Arrest Outcomes After Cardiac Arrest and Cardiopulmonary Resuscitation in Mice. Cardiovasc Drugs Ther 2023. [PMID: 36609949 DOI: 10.1007/s10557-022-07419-8] [Reference Citation Analysis]
|
| 112 |
Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74 [PMID: 36683719 DOI: 10.3748/wjg.v29.i1.61] [Reference Citation Analysis]
|
| 113 |
Mao X, Xu DQ, Yue SJ, Fu RJ, Zhang S, Tang YP. Potential Medicinal Value of Rhein for Diabetic Kidney Disease. Chin J Integr Med 2023. [PMID: 36607584 DOI: 10.1007/s11655-022-3591-y] [Reference Citation Analysis]
|
| 114 |
Noble-Bell G, Bright-Davies C. Safe use of sodium glucose co-transporter 2 inhibitors in the management of type 2 diabetes. Nurs Stand 2023;38:61-6. [PMID: 36341593 DOI: 10.7748/ns.2022.e11959] [Reference Citation Analysis]
|
| 115 |
Sun H, Wang Z, Wang Y, Rong H, Wang D, Liu X, Jin K, Sun Z, Fan Q. Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors. Front Pharmacol 2022;13:1009025. [PMID: 36686683 DOI: 10.3389/fphar.2022.1009025] [Reference Citation Analysis]
|
| 116 |
Ji L, Jiang X, Hao Q, Cheng Z, Wang K, Pang S, Liu M, Guo Y, Chen X, Su X, Ning T, Liu J, Bian F, Li Y, Zhang Z, Song W, Sun J. Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial. Diabetes Obes Metab 2023. [PMID: 36594724 DOI: 10.1111/dom.14971] [Reference Citation Analysis]
|
| 117 |
Pistelli L, Parisi F, Correale M, Cocuzza F, Campanella F, de Ferrari T, Crea P, De Sarro R, La Cognata O, Ceratti S, Recupero T, Ruocco G, Palazzuoli A, Imbalzano E, Dattilo G. Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy-A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. J Clin Med 2023;12. [PMID: 36615178 DOI: 10.3390/jcm12010379] [Reference Citation Analysis]
|
| 118 |
Murphy E, Cooney MT, Mcevoy JW. Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. Contemporary Cardiology 2023. [DOI: 10.1007/978-3-031-16594-8_2] [Reference Citation Analysis]
|
| 119 |
Daoulah A, Elfarnawany A, Al Garni T, Hersi AS, Alshehri M, Almahmeed W, Yousif N, Abuelatta R, Alasmari A, Elsheikh-Mohamed NE, Alzahrani B, Ghani MA, Amin H, Hashmani S, Hiremath N, Alshali KZ, Elmahrouk Y, Kazim HM, Refaat W, Selim E, Jamjoom A, Feteih MN, El-Sayed O, Al-Faifi SM, Dahdouh Z, Aithal J, Ibrahim AM, Elganady A, Qutub MA, Alama MN, Abohasan A, Hassan T, Balghith M, Hussien AF, Abdulhabeeb IAM, Ahmad O, Ramadan M, Alqahtani AH, Abumelha BK, Qenawi W, Shawky A, Ghonim AA, Elmahrouk A, Alhamid S, Maghrabi M, Haddara MM, Aljohar A, Hurley WT, Alshahrani SS, Lotfi A. Outcomes of Myocardial Revascularization in Diabetic Patients With Left Main Coronary Artery Disease: A Multicenter Observational Study From Three Gulf Countries. Cardiovasc Revasc Med 2023;46:52-61. [PMID: 35961856 DOI: 10.1016/j.carrev.2022.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 120 |
Liu X, Chen Y, Liu T, Cai L, Yang X, Mou C. The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 2023;14:1115321. [PMID: 36777342 DOI: 10.3389/fendo.2023.1115321] [Reference Citation Analysis]
|
| 121 |
Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Pizzi C, Barbato E. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacol Res 2023;187:106597. [PMID: 36470546 DOI: 10.1016/j.phrs.2022.106597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 122 |
黎 人. Mechanisms of SGLT2 Inhibitors in the Treatment of Myocardial Ischemia-Reperfusion Injury in Animal Models. ACM 2023;13:2232-2240. [DOI: 10.12677/acm.2023.132313] [Reference Citation Analysis]
|
| 123 |
Medina-hernández D, Galán-arriola C, Ibáñez B. The quest for the mechanism responsible for the cardiovascular benefits of novel antidiabetic agents. REC: CardioClinics 2023;58:4-6. [DOI: 10.1016/j.rccl.2022.09.002] [Reference Citation Analysis]
|
| 124 |
Le P, Bui TC, Abramowitz J, Herman WH, Misra-Hebert AD, Rothberg MB. Trends in Use of High-Cost Antihyperglycemic Drugs Among US Adults with Type 2 Diabetes. J Gen Intern Med 2023;38:49-56. [PMID: 35484365 DOI: 10.1007/s11606-022-07621-2] [Reference Citation Analysis]
|
| 125 |
Cromer SJ, Lauffenburger JC, Levin R, Patorno E. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Diabetes Care 2023;46:65-74. [PMID: 36383481 DOI: 10.2337/dc22-0383] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 126 |
Lee KS, Noh J, Park SM, Choi KM, Kang SM, Won KC, Cho HJ, Moon MK. Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Diabetes Metab J 2023;47:10-26. [PMID: 36727161 DOI: 10.4093/dmj.2022.0420] [Reference Citation Analysis]
|
| 127 |
Johannes CB, Beachler DC, Layton JB, Danysh HE, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf 2023;46:157-74. [PMID: 36528670 DOI: 10.1007/s40264-022-01263-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 128 |
Lyu B, Hwang YJ, Selvin E, Jameson BC, Chang AR, Grams ME, Shin JI. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study. J Gen Intern Med 2023;38:107-14. [PMID: 35831767 DOI: 10.1007/s11606-022-07726-8] [Reference Citation Analysis]
|
| 129 |
Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia 2023;66:23-32. [PMID: 36255460 DOI: 10.1007/s00125-022-05815-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 130 |
Chalmers J, Wang N. Advances on Long-Term Antihypertensive Treatment and Diabetes. Blood Pressure Disorders in Diabetes Mellitus 2023. [DOI: 10.1007/978-3-031-13009-0_21] [Reference Citation Analysis]
|
| 131 |
代 琳. Analysis of the Value of SGLT2i Combined with GLP-1RAs in Cardiovascular Benefit of Elderly T2DM Patients. ACM 2023;13:2736-2743. [DOI: 10.12677/acm.2023.132386] [Reference Citation Analysis]
|
| 132 |
Schechter M, Jongs N, Chertow GM, Mosenzon O, McMurray JJV, Correa-Rotter R, Rossing P, Langkilde AM, Sjöström CD, Toto RD, Wheeler DC, Heerspink HJL. Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD. Ann Intern Med 2023;176:59-66. [PMID: 36469914 DOI: 10.7326/M22-2115] [Reference Citation Analysis]
|
| 133 |
Pollack R, Raz I, Wiviott SD, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Mosenzon O, Langkilde AM, Gause-Nilsson IAM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Cahn A. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. Diabetes Care 2023;46:156-64. [PMID: 36399721 DOI: 10.2337/dc22-1318] [Reference Citation Analysis]
|
| 134 |
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023;46:S191-202. [PMID: 36507634 DOI: 10.2337/dc23-S011] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 135 |
Diallo A, Carlos-Bolumbu M, Renard PE, Galtier F. Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials. Diabetes Obes Metab 2023;25:166-76. [PMID: 36057779 DOI: 10.1111/dom.14859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 136 |
Roumeliotis S, Mallamaci F, Zoccali C. Diabetic Chronic Kidney Disease in Type 2 Diabetes Mellitus (Albuminuric/Non-albuminuric). Blood Pressure Disorders in Diabetes Mellitus 2023. [DOI: 10.1007/978-3-031-13009-0_16] [Reference Citation Analysis]
|
| 137 |
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023;46:S158-90. [PMID: 36507632 DOI: 10.2337/dc23-S010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 138 |
Sheu A, Greenfield JR, White CP, Center JR. Contributors to impaired bone health in type 2 diabetes. Trends Endocrinol Metab 2023;34:34-48. [PMID: 36435679 DOI: 10.1016/j.tem.2022.11.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 139 |
Ansari S, Miras AD. Multimodal Care for Diabetes Combining Pharmacotherapy and Metabolic Surgery. Obesity, Bariatric and Metabolic Surgery 2023. [DOI: 10.1007/978-3-030-60596-4_102] [Reference Citation Analysis]
|
| 140 |
Xie Y, Wei Y, Li D, Pu J, Ding H, Zhang X. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. J Cardiovasc Pharmacol 2023;81:4-14. [PMID: 36607775 DOI: 10.1097/FJC.0000000000001380] [Reference Citation Analysis]
|
| 141 |
Goh KG, Zakaria MH, Raja Azwan RN, Bhajan Singh KK, Badrul Hisham MH, Hussein Z. Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia. Diabetes Metab Syndr 2023;17:102680. [PMID: 36473336 DOI: 10.1016/j.dsx.2022.102680] [Reference Citation Analysis]
|
| 142 |
Kreutz R, Algharably EAE. New Antidiabetic Agents: Relevance to Cardiovascular Outcomes. Blood Pressure Disorders in Diabetes Mellitus 2023. [DOI: 10.1007/978-3-031-13009-0_20] [Reference Citation Analysis]
|
| 143 |
Redon J, Martinez F. Hypertension and Type 2 Diabetes. Blood Pressure Disorders in Diabetes Mellitus 2023. [DOI: 10.1007/978-3-031-13009-0_3] [Reference Citation Analysis]
|
| 144 |
Li J, Ji C, Zhang W, Lan L, Ge W. Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis. J Diabetes Complications 2023;37:108362. [PMID: 36462459 DOI: 10.1016/j.jdiacomp.2022.108362] [Reference Citation Analysis]
|
| 145 |
Kamalumpundi V, Shams E, Tucker C, Cheng L, Peterson J, Thangavel S, Ofori O, Correia M. Corrigendum to "Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes" [Biochem. Pharmacol. 206 (2022) 115304]. Biochem Pharmacol 2023;207:115349. [PMID: 36459847 DOI: 10.1016/j.bcp.2022.115349] [Reference Citation Analysis]
|
| 146 |
Abu-Alfa AK, Atallah PJ, Azar ST, Dagher EC, Echtay AS, El-Amm MA, Hazkial HG, Kassab RY, Medlej RC, Mohamad MA; Lebanese Consortium for Early, Comprehensive Management of Type 2 Diabetes (LCECMD). Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications. Diabetes Ther 2023;14:11-28. [PMID: 36517708 DOI: 10.1007/s13300-022-01340-x] [Reference Citation Analysis]
|
| 147 |
Wright WL, Urquhart S, Brunton S. Beyond Blood Glucose and Blood Pressure Control in Type 2 Diabetes: Alternative Management Strategies to Prevent the Development and Progression of CKD. J Prim Care Community Health 2023;14:21501319231153599. [PMID: 36935560 DOI: 10.1177/21501319231153599] [Reference Citation Analysis]
|
| 148 |
Lee HW, Huang CC, Yang CY, Leu HB, Huang PH, Wu TC, Lin SJ, Chen JW. Renal function during hospitalization and outcome in Chinese patients with acute decompensated heart failure: A retrospective study and literature review. Clin Cardiol 2023;46:57-66. [PMID: 36345665 DOI: 10.1002/clc.23934] [Reference Citation Analysis]
|
| 149 |
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Jeffrie Seley J, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 13. Older Adults: Standards of Care in Diabetes-2023. Diabetes Care 2023;46:S216-29. [PMID: 36507638 DOI: 10.2337/dc23-S013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 150 |
李 欢. Research Progress in Treatment of Diabetic Proteinuria. ACM 2023;13:1252-1260. [DOI: 10.12677/acm.2022.132173] [Reference Citation Analysis]
|
| 151 |
Seravalle G, Grassi G. Diabetes and Sympathetic Nervous System. Blood Pressure Disorders in Diabetes Mellitus 2023. [DOI: 10.1007/978-3-031-13009-0_10] [Reference Citation Analysis]
|
| 152 |
Pruett JE, Romero DG, Yanes Cardozo LL. Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors. Front Endocrinol (Lausanne) 2023;14:951099. [PMID: 36875461 DOI: 10.3389/fendo.2023.951099] [Reference Citation Analysis]
|
| 153 |
Akiyama H, Nishimura A, Morita N, Yajima T. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. Front Endocrinol (Lausanne) 2023;14:1111984. [PMID: 36793276 DOI: 10.3389/fendo.2023.1111984] [Reference Citation Analysis]
|
| 154 |
Bidulka P, Mathur R, Lugo-Palacios DG, O'Neill S, Basu A, Silverwood RJ, Charlton P, Briggs A, Smeeth L, Adler AI, Douglas IJ, Khunti K, Grieve R. Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: A cross-sectional study. Diabetes Obes Metab 2023;25:282-92. [PMID: 36134467 DOI: 10.1111/dom.14874] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 155 |
Chan GC, Ng JK, Chow KM, Szeto CC. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study. Diabetes Res Clin Pract 2023;195:110200. [PMID: 36481225 DOI: 10.1016/j.diabres.2022.110200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 156 |
He J, Xi Y, Lam H, Du K, Chen D, Dong Z, Xiao J. Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Diabetes Res 2023;2023:8818502. [PMID: 36873813 DOI: 10.1155/2023/8818502] [Reference Citation Analysis]
|
| 157 |
Senn J, Fischli S. Medical therapy. Visceral and Ectopic Fat 2023. [DOI: 10.1016/b978-0-12-822186-0.00014-6] [Reference Citation Analysis]
|
| 158 |
Nguyen IT, Joles JA, Verhaar MC, Lamb HJ, Dekkers IA. Obesity in relation to cardiorenal function. Visceral and Ectopic Fat 2023. [DOI: 10.1016/b978-0-12-822186-0.00006-7] [Reference Citation Analysis]
|
| 159 |
Khadanga S, Barrett K, Sheahan KH, Savage PD. Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure: A REVIEW AND PRACTICAL RECOMMENDATIONS FOR CARDIAC REHABILITATION. J Cardiopulm Rehabil Prev 2023;43:1-7. [PMID: 36576423 DOI: 10.1097/HCR.0000000000000761] [Reference Citation Analysis]
|
| 160 |
Halvorsen YD, Lock JP, Frias JP, Tinahones FJ, Dahl D, Conery AL, Freeman MW. A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab 2023;25:293-301. [PMID: 36178197 DOI: 10.1111/dom.14875] [Reference Citation Analysis]
|
| 161 |
Yoshikawa T. New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading? J Cardiol 2023;81:26-32. [PMID: 35227538 DOI: 10.1016/j.jjcc.2022.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 162 |
Butt MI, Aljamei H, Riazuddin M, AlHaqbani L, Albalwi R, Abothenain FFM, Alagla NAM, Waheed N. Efficacy and safety of empagliflozin: a "real-world" experience from Saudi Arabia. Ann Saudi Med 2023;43:50-6. [PMID: 36739502 DOI: 10.5144/0256-4947.2023.50] [Reference Citation Analysis]
|
| 163 |
Natesan V. Therapeutics in Metabolic Diseases. Advances in Experimental Medicine and Biology 2023. [DOI: 10.1007/978-981-19-5642-3_17] [Reference Citation Analysis]
|
| 164 |
Copur S, Yildiz A, Basile C, Tuttle KR, Kanbay M. Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury? J Nephrol 2023;36:31-43. [PMID: 35962863 DOI: 10.1007/s40620-022-01422-w] [Reference Citation Analysis]
|
| 165 |
Lin Y, Mok M, Harrison J, Battistella M, Farrell A, Leung M, Cheung C. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review. Transplant Rev (Orlando) 2023;37:100729. [PMID: 36427372 DOI: 10.1016/j.trre.2022.100729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 166 |
Lim CE, Pasternak B, Eliasson B, Danaei G, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol 2022:zwac315. [PMID: 36582120 DOI: 10.1093/eurjpc/zwac315] [Reference Citation Analysis]
|
| 167 |
Chirila A, Nguyen ME, Tinmouth J, Halperin IJ. Preparing for Colonoscopy in People with Diabetes: A Review with Suggestions for Clinical Practice. J Can Assoc Gastroenterol 2023;6:26-36. [PMID: 36789141 DOI: 10.1093/jcag/gwac035] [Reference Citation Analysis]
|
| 168 |
Doğruel H, Atlım HT, Aydemir M, Yılmaz N, Sarı R. Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus. Ir J Med Sci 2022. [PMID: 36580225 DOI: 10.1007/s11845-022-03262-w] [Reference Citation Analysis]
|
| 169 |
Hsieh CY, Sung SF. From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors. Int J Mol Sci 2022;24. [PMID: 36613795 DOI: 10.3390/ijms24010351] [Reference Citation Analysis]
|
| 170 |
Lee MC, Hua YM, Yang CT, Kuo FH, Chang WT, Tang HJ, Siong Toh H, Lin YM, Chen SY, Chang HY, Liao CT. Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. Medicine (Baltimore) 2022;101:e32489. [PMID: 36595871 DOI: 10.1097/MD.0000000000032489] [Reference Citation Analysis]
|
| 171 |
Bouchi R, Kondo T, Ohta Y, Goto A, Tanaka D, Satoh H, Yabe D, Nishimura R, Harada N, Kamiya H, Suzuki R, Yamauchi T. A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes. Diabetol Int 2023;14:1-14. [PMID: 36636161 DOI: 10.1007/s13340-022-00605-x] [Reference Citation Analysis]
|
| 172 |
Bouchi R, Kondo T, Ohta Y, Goto A, Tanaka D, Satoh H, Yabe D, Nishimura R, Harada N, Kamiya H, Suzuki R, Yamauchi T; JDS Committee on Consensus Statement Development. A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes. J Diabetes Investig 2023;14:151-64. [PMID: 36562245 DOI: 10.1111/jdi.13960] [Reference Citation Analysis]
|
| 173 |
Wang N, Zoungas S, Chalmers J. Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes. Presse Med 2022;52:104160. [PMID: 36565752 DOI: 10.1016/j.lpm.2022.104160] [Reference Citation Analysis]
|
| 174 |
Pathan MDF, Akter N, Selim S, Saifuddin M, Qureshi NK, Kamrul-Hasan ABM, Hannan MA, Ahmed MAU, Mustari M, Chakraborty AK. Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh. Diabetes Metab Syndr Obes 2022;15:4011-21. [PMID: 36578878 DOI: 10.2147/DMSO.S380544] [Reference Citation Analysis]
|
| 175 |
Gnudi L. Renal disease in patients with type 2 diabetes: Magnitude of the problem, risk factors and preventive strategies. Presse Med 2022;52:104159. [PMID: 36565753 DOI: 10.1016/j.lpm.2022.104159] [Reference Citation Analysis]
|
| 176 |
Zhou Z, Wang D, Wu J. Role of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension. IJDDP 2022. [DOI: 10.53941/ijddp.v1i1.175] [Reference Citation Analysis]
|
| 177 |
Kao TW, Huang CC. Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. Front Cardiovasc Med 2022;9:1086672. [PMID: 36606275 DOI: 10.3389/fcvm.2022.1086672] [Reference Citation Analysis]
|
| 178 |
Yi TW, Atiquzzaman M, Zheng Y, Smyth B, Jardine M, Levin A. Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study. Can J Kidney Health Dis 2022;9:20543581221145068. [PMID: 36578697 DOI: 10.1177/20543581221145068] [Reference Citation Analysis]
|
| 179 |
Marx N, Cheng AYY, Agarwal R, Greene SJ, Abuhantash H. Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe. Eur Heart J Suppl 2022;24:L29-37. [PMID: 36545231 DOI: 10.1093/eurheartjsupp/suac114] [Reference Citation Analysis]
|
| 180 |
Forycka J, Hajdys J, Krzemińska J, Wilczopolski P, Wronka M, Młynarska E, Rysz J, Franczyk B. New Insights into the Use of Empagliflozin-A Comprehensive Review. Biomedicines 2022;10. [PMID: 36552050 DOI: 10.3390/biomedicines10123294] [Reference Citation Analysis]
|
| 181 |
Mori Y, Duru OK, Tuttle KR, Fukuma S, Taura D, Harada N, Inagaki N, Inoue K. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Clin Endocrinol Metab 2022;108:221-31. [PMID: 36217306 DOI: 10.1210/clinem/dgac591] [Reference Citation Analysis]
|
| 182 |
Yang L, Rong GC, Wu QN. Diabetic foot ulcer: Challenges and future. World J Diabetes 2022; 13(12): 1014-1034 [DOI: 10.4239/wjd.v13.i12.1014] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 183 |
Li X, Wu H, Peng H, Jiang H. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis. Front Endocrinol (Lausanne) 2022;13:1078686. [PMID: 36589800 DOI: 10.3389/fendo.2022.1078686] [Reference Citation Analysis]
|
| 184 |
Mohan V, Wangnoo S, Das S, Dhediya R, Gaurav K. Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review. World J Diabetes 2022; 13(12): 1168-1183 [DOI: 10.4239/wjd.v13.i12.1168] [Reference Citation Analysis]
|
| 185 |
Pruett JE, Lirette ST, Romero DG, Yanes Cardozo LL. Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women. J Endocr Soc 2022;7:bvac191. [PMID: 36601021 DOI: 10.1210/jendso/bvac191] [Reference Citation Analysis]
|
| 186 |
Han JX, Luo LL, Wang YC, Miyagishi M, Kasim V, Wu SR. SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis. Acta Pharmacol Sin 2022. [PMID: 36509902 DOI: 10.1038/s41401-022-01031-0] [Reference Citation Analysis]
|
| 187 |
Lu ZQ, McCourt E, Goodhew K, Gupta D, Chuan F, Mok L, Peters R, Ha T, Fowler D, Dobbyn DM, Hetherington J, Challa P, Kannan S, Korczyk D, Russell A, Mugwagwa AN. Secular trends in the utility of SGLT-2 inhibitors in heart failure patients with type 2 diabetes mellitus across Metro South Health hospitals in South-East Queensland. Intern Med J 2022. [PMID: 36504292 DOI: 10.1111/imj.15993] [Reference Citation Analysis]
|
| 188 |
Yuyun MF, Kinlay S, Singh JP, Joseph J. Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. ESC Heart Failure 2022. [DOI: 10.1002/ehf2.14248] [Reference Citation Analysis]
|
| 189 |
Zhao X, Liu S, Wang X, Chen Y, Pang P, Yang Q, Lin J, Deng S, Wu S, Fan G, Wang B. Diabetic cardiomyopathy: Clinical phenotype and practice. Front Endocrinol (Lausanne) 2022;13:1032268. [PMID: 36568097 DOI: 10.3389/fendo.2022.1032268] [Reference Citation Analysis]
|
| 190 |
Ng NM, Ng YS, Chu TK, Lau P. Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study. BMC Prim Care 2022;23:317. [PMID: 36476327 DOI: 10.1186/s12875-022-01928-z] [Reference Citation Analysis]
|
| 191 |
Mcewan P, Ponikowski P, Shiri T, Rosano GM, Coats AJS, Dorigotti F, Ramirez de Arellano A, Jankowska EA. Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: A multinational study. Journal of Medical Economics 2022. [DOI: 10.1080/13696998.2022.2155375] [Reference Citation Analysis]
|
| 192 |
Birker S, Meier JJ, Nauck MA. Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review. Sci Rep 2022;12:21069. [PMID: 36473887 DOI: 10.1038/s41598-022-25296-x] [Reference Citation Analysis]
|
| 193 |
Tornyos D, Meuer M, Lukács R, El Alaoui El Abdallaoui O, Kupó P, Faludi R, Komócsi A. Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials. Front Cardiovasc Med 2022;9:1041200. [PMID: 36545024 DOI: 10.3389/fcvm.2022.1041200] [Reference Citation Analysis]
|
| 194 |
Ballister B, Hernandez RL, Quffa LH, Franck AJ. Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit. Journal of Pharmacy Practice 2022. [DOI: 10.1177/08971900221144399] [Reference Citation Analysis]
|
| 195 |
Alkas J, Bosi A, Sjölander A, Barany P, Elinder C, Fu EL, Carrero JJ. Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project. J Nephrol 2022. [DOI: 10.1007/s40620-022-01505-8] [Reference Citation Analysis]
|
| 196 |
Ohte N, Tanaka A, Kitada S, Yamada T, Eguchi K, Teragawa H, Takeishi Y, Kodama K, Seo Y, Node K. Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: a sub analysis of the CANDLE trial. Journal of Cardiology 2022. [DOI: 10.1016/j.jjcc.2022.11.012] [Reference Citation Analysis]
|
| 197 |
Canney M, Gunning HM, Zheng Y, Rose C, Jauhal A, Hur SA, Sahota A, Reich HN, Barbour SJ. The Risk of Cardiovascular Events in Individuals With Primary Glomerular Diseases. Am J Kidney Dis 2022;80:740-50. [PMID: 35659570 DOI: 10.1053/j.ajkd.2022.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 198 |
Timmons JG, Littlejohn L, Boyle JG, Petrie JR. Recent developments in adjunct therapies for type 1 diabetes. Expert Opin Investig Drugs 2022;31:1311-20. [PMID: 36655950 DOI: 10.1080/13543784.2022.2159806] [Reference Citation Analysis]
|
| 199 |
Fujita H, Otomo H, Takahashi Y, Yamada Y. Dual inhibition of SGLT2 and DPP-4 promotes natriuresis and improves glomerular hemodynamic abnormalities in KK/Ta-Ins2 mice with progressive diabetic kidney disease. Biochemical and Biophysical Research Communications 2022;635:84-91. [DOI: 10.1016/j.bbrc.2022.10.034] [Reference Citation Analysis]
|
| 200 |
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022;65:1925-66. [PMID: 36151309 DOI: 10.1007/s00125-022-05787-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 37.0] [Reference Citation Analysis]
|
| 201 |
Suzuki Y, Kaneko H, Yano Y, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I. Glycemic status and the association of change in blood pressure with incident cardiovascular disease. Am Heart J 2022;254:48-56. [PMID: 35872125 DOI: 10.1016/j.ahj.2022.07.005] [Reference Citation Analysis]
|
| 202 |
Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, Depasquale E, Farrero M, García-guereta L, Jamero G, Khush K, Lavee J, Pouch S, Patel J, Michaud C, Shullo M, Schubert S, Angelini A, Carlos L, Mirabet S, Patel J, Pham M, Urschel S, Kim K, Miyamoto S, Chih S, Daly K, Grossi P, Jennings D, Kim I, Lim HS, Miller T, Potena L, Velleca A, Eisen H, Bellumkonda L, Danziger-isakov L, Dobbels F, Harkess M, Kim D, Lyster H, Peled Y, Reinhardt Z. The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. The Journal of Heart and Lung Transplantation 2022. [DOI: 10.1016/j.healun.2022.10.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 203 |
Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chen WJ. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors. Diabetologia 2022;65:2032-43. [PMID: 35945333 DOI: 10.1007/s00125-022-05772-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 204 |
Kim Y, Kim W, Kim JK, Moon JY, Park S, Park CW, Park HS, Song SH, Yoo TH, Lee SY, Lee EY, Lee J, Jin K, Cha DR, Cha JJ, Han SY; Korean Diabetic Kidney Disease Working Group. Blood Pressure Control in Patients with Diabetic Kidney Disease. Electrolyte Blood Press 2022;20:39-48. [PMID: 36688208 DOI: 10.5049/EBP.2022.20.2.39] [Reference Citation Analysis]
|
| 205 |
Sewell J, Johnson R. Managing Diabetes. Physician Assistant Clinics 2022. [DOI: 10.1016/j.cpha.2022.10.007] [Reference Citation Analysis]
|
| 206 |
Sun X, Wang G. Renal outcomes with sodium-glucose cotransporters 2 inhibitors. Front Endocrinol (Lausanne) 2022;13:1063341. [PMID: 36531469 DOI: 10.3389/fendo.2022.1063341] [Reference Citation Analysis]
|
| 207 |
Desai RJ, Glynn RJ, Everett BM, Schneeweiss S, Wexler DJ, Bessette LG, Déruaz-Luyet A, Vedin O, Brodovicz K, Patorno E. Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care. Am Heart J 2022;254:203-15. [PMID: 36150454 DOI: 10.1016/j.ahj.2022.09.008] [Reference Citation Analysis]
|
| 208 |
Wang Y, Liao J, Chen K, Su H, Liu P, Chen Y, Tsuei Y, Tsai C, Huang S. Lumbrokinase regulates endoplasmic reticulum stress to improve neurological deficits in ischemic stroke. Neuropharmacology 2022;221:109277. [DOI: 10.1016/j.neuropharm.2022.109277] [Reference Citation Analysis]
|
| 209 |
Lu Y, Wu H, Zhu T, Li X, Zuo J, Hasan AA, Reichetzeder C, Delic D, Yard B, Klein T, Krämer BK, Zhang Z, Wang X, Yin L, Dai Y, Zheng Z, Hocher B. Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy. Biomedicine & Pharmacotherapy 2022;156:113947. [DOI: 10.1016/j.biopha.2022.113947] [Reference Citation Analysis]
|
| 210 |
Ramani J, Shah H, Vyas VK, Sharma M. A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports 2022;6:100074. [DOI: 10.1016/j.ejmcr.2022.100074] [Reference Citation Analysis]
|
| 211 |
Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, Depasquale E, Farrero M, García-guereta L, Jamero G, Khush K, Lavee J, Pouch S, Patel J, Michaud C, Shullo M, Schubert S, Angelini A, Carlos L, Mirabet S, Patel J, Pham M, Urschel S, Kim K, Miyamoto S, Chih S, Daly K, Grossi P, Jennings D, Kim I, Lim HS, Miller T, Potena L, Velleca A, Eisen H, Bellumkonda L, Danziger-isakov L, Dobbels F, Harkess M, Kim D, Lyster H, Peled Y, Reinhardt Z. The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. The Journal of Heart and Lung Transplantation 2022. [DOI: 10.1016/j.healun.2022.09.023] [Reference Citation Analysis]
|
| 212 |
Demarsilis A, Reddy N, Boutari C, Filippaios A, Sternthal E, Katsiki N, Mantzoros C. Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism 2022;137:155332. [DOI: 10.1016/j.metabol.2022.155332] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 213 |
Marilly E, Cottin J, Cabrera N, Cornu C, Boussageon R, Moulin P, Lega JC, Gueyffier F, Cucherat M, Grenet G. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia 2022;65:2000-10. [PMID: 35925319 DOI: 10.1007/s00125-022-05773-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 214 |
Giaccari A. What Is the Best Medicine for Chronic Kidney Disease in Diabetes? Diabetes Care 2022;45:2814-6. [PMID: 36455128 DOI: 10.2337/dci22-0029] [Reference Citation Analysis]
|
| 215 |
Assiri AA, Alahmari KA, Alqhtani NS, AlShamrani NA, Mubarak AS, Alshehri KM, Alselmi AA. Prevalence of cardiovascular events among patients with type 2 diabetes in the west region of Saudi Arabia. Saudi Pharm J 2022;30:1825-9. [PMID: 36601500 DOI: 10.1016/j.jsps.2022.10.012] [Reference Citation Analysis]
|
| 216 |
Diallo A, Carlos-Bolumbu M, Galtier F. Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis. EClinicalMedicine 2022;54:101697. [PMID: 36263397 DOI: 10.1016/j.eclinm.2022.101697] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 217 |
Huttunen R, Sainio A, Hjelt A, Haapanen-saaristo A, Määttä J, Rummukainen P, Paatero I, Järveläinen H. Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos. Biomedicine & Pharmacotherapy 2022;156:113882. [DOI: 10.1016/j.biopha.2022.113882] [Reference Citation Analysis]
|
| 218 |
Lamprea-Montealegre JA, Madden E, Tummalapalli SL, Chu CD, Peralta CA, Du Y, Singh R, Kong SX, Tuot DS, Shlipak MG, Estrella MM. Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease. Diabetes Care 2022;45:2900-6. [PMID: 36156061 DOI: 10.2337/dc22-0614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 219 |
Abrahami D, Tesfaye H, Yin H, Vine S, Hicks B, Yu OHY, Campeau L, Platt RW, Schneeweiss S, Patorno E, Azoulay L. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care 2022;45:2907-17. [PMID: 36170656 DOI: 10.2337/dc22-1174] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 220 |
Bakis H, Pfirmann P, Combe C, Rigothier C. À qui un néphrologue doit-il prescrire un iSGLT2 ? Indications of SGLT2 inhibitors in kidney disease: who, why and when? Nephrol Ther 2022;18:6S17-24. [PMID: 36585121 DOI: 10.1016/S1769-7255(22)00649-6] [Reference Citation Analysis]
|
| 221 |
Bakkar N, Alzaim I, El-yazbi A. Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease. Clinical Science 2022;136:1631-1651. [DOI: 10.1042/cs20220404] [Reference Citation Analysis]
|
| 222 |
Brust-Sisti L, Rudawsky N, Gonzalez J, Brunetti L. The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. Pharmacy (Basel) 2022;10. [PMID: 36548322 DOI: 10.3390/pharmacy10060166] [Reference Citation Analysis]
|
| 223 |
Antsiferov MB, Demidov NA, Balberova MA, Lobanova OV, Mudrikova IG, Gusenbekova DG. Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow). Diabetes mellitus 2022;25:439-448. [DOI: 10.14341/dm12929] [Reference Citation Analysis]
|
| 224 |
Kuriyama S, Matsumoto K. Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects. Jpn J Clin Pharmacol Ther 2022;53:249-262. [DOI: 10.3999/jscpt.53.6_249] [Reference Citation Analysis]
|
| 225 |
Rasmussen DGK, Hansen MK, Blair J, Jatkoe TA, Neal B, Karsdal MA, Genovese F. Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial. Cardiovasc Diabetol 2022;21:261. [PMID: 36443792 DOI: 10.1186/s12933-022-01666-7] [Reference Citation Analysis]
|
| 226 |
Olagunju A, Yamani N, Kenny D, Mookadam M, Mookadam F, Unzek S. Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. World J Cardiol 2022; 14(11): 599-616 [DOI: 10.4330/wjc.v14.i11.599] [Reference Citation Analysis]
|
| 227 |
Dutka M, Bobiński R, Francuz T, Garczorz W, Zimmer K, Ilczak T, Ćwiertnia M, Hajduga MB. SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives. Cancers (Basel) 2022;14. [PMID: 36497303 DOI: 10.3390/cancers14235811] [Reference Citation Analysis]
|
| 228 |
Chu CD, Powe NR, Shlipak MG, Scherzer R, Tummalapalli SL, Estrella MM, Tuot DS. Albuminuria testing and nephrology care among insured US adults with chronic kidney disease: a missed opportunity. BMC Prim Care 2022;23:299. [PMID: 36434513 DOI: 10.1186/s12875-022-01910-9] [Reference Citation Analysis]
|
| 229 |
Shamkhalova MS, Sukhareva OY, Shestakova MV. Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease. Terapevticheskii arkhiv 2022;94:1188-1196. [DOI: 10.26442/00403660.2022.10.201883] [Reference Citation Analysis]
|
| 230 |
Furuya F, Fujita Y, Matsuo N, Minamino H, Oguri Y, Isomura N, Ikeda K, Takesue K, Li Y, Kondo A, Mano F, Inagaki N. Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin. EBioMedicine 2022;86:104342. [PMID: 36423374 DOI: 10.1016/j.ebiom.2022.104342] [Reference Citation Analysis]
|
| 231 |
Katsiki N, Kazakos K, Triposkiadis F. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2143263] [Reference Citation Analysis]
|
| 232 |
Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022;400:1788-801. [PMID: 36351458 DOI: 10.1016/S0140-6736(22)02074-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 233 |
Lin M, Shan Y, Hu X, Zhou H, Chen Z, Li D, Gao M, Yang S, Zhang W, Wang M. Short term effects of sodium-glucose cotransporter 2 inhibitors on lipid regulation in coronary artery disease patients undergoing Percutaneous Coronary Intervention: A Propensity-Matched Analysis.. [DOI: 10.21203/rs.3.rs-2270625/v1] [Reference Citation Analysis]
|
| 234 |
Sundra T, Kelty E, Rendle D. Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: A case series. Equine Veterinary Education 2022. [DOI: 10.1111/eve.13738] [Reference Citation Analysis]
|
| 235 |
Sang H, Wan Y, Ma Z, Zhang S, Zhao Q. Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1022020] [Reference Citation Analysis]
|
| 236 |
Devineni D, Akbarpour M, Gong Y, Wong ND. Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program. Cardiovasc Drugs Ther 2022. [DOI: 10.1007/s10557-022-07403-2] [Reference Citation Analysis]
|
| 237 |
Rong X, Zhu Y, Wen B, Liu K, Li X, Gou Q, Chen X. Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.973129] [Reference Citation Analysis]
|
| 238 |
Sciatti E, Gori M, D’elia E, Iacovoni A, Senni M. Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible. European Heart Journal Supplements 2022;24:I153-I159. [DOI: 10.1093/eurheartjsupp/suac106] [Reference Citation Analysis]
|
| 239 |
Totade M, Gaidhane SA. Role of Ertugliflozin in the Management of Diabetes Mellitus. Cureus 2022. [DOI: 10.7759/cureus.31404] [Reference Citation Analysis]
|
| 240 |
Layman SN, Elliott WV, Neu DW, Howard TG, Hamby A. Alogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes. Journal of Pharmacy Practice 2022. [DOI: 10.1177/08971900221135656] [Reference Citation Analysis]
|
| 241 |
Wang D, Liu J, Zhong L, Li S, Zhou L, Zhang Q, Li M, Xiao X. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1045235] [Reference Citation Analysis]
|
| 242 |
Ke J, Pan J, Lin H, Gu J. Diabetic cardiomyopathy: a brief summary on lipid toxicity. ESC Heart Failure 2022. [DOI: 10.1002/ehf2.14224] [Reference Citation Analysis]
|
| 243 |
Sciannameo V, Fadini GP, Bottigliengo D, Avogaro A, Baldi I, Gregori D, Berchialla P. Assessment of Glucose Lowering Medications' Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes. Int J Environ Res Public Health 2022;19. [PMID: 36429543 DOI: 10.3390/ijerph192214825] [Reference Citation Analysis]
|
| 244 |
Wang Q, Ju F, Li J, Liu T, Zuo Y, Abbott GW, Hu Z. Empagliflozin protects against renal ischemia/reperfusion injury in mice. Sci Rep 2022;12:19323. [PMID: 36369319 DOI: 10.1038/s41598-022-24103-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 245 |
Rikin S, Deccy S, Zhang C, Crandall J, Deng Y, Golestaneh L. Care Gaps in Sodium-Glucose Cotransporter-2 Inhibitor and Renin Angiotensin System Inhibitor Prescriptions for Patients with Diabetic Kidney Disease. J Gen Intern Med 2022. [PMID: 36352203 DOI: 10.1007/s11606-022-07863-0] [Reference Citation Analysis]
|
| 246 |
Wolff G, Lin Y, Akbulut C, Brockmeyer M, Parco C, Hoss A, Sokolowski A, Westenfeld R, Kelm M, Roden M, Schlesinger S, Kuss O. Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes. ESC Heart Fail 2023;10:552-67. [PMID: 36337026 DOI: 10.1002/ehf2.14213] [Reference Citation Analysis]
|
| 247 |
Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, Parati G, Rossignol P, Schlaich MP, Teo KK, Townsend RR, Tsioufis C, Weber MA, Weber T, Böhm M. Hypertension management in patients with cardiovascular comorbidities. European Heart Journal 2022. [DOI: 10.1093/eurheartj/ehac395] [Reference Citation Analysis]
|
| 248 |
Inturi R, Raju MD, Basaveswara Rao MV, Inturi S. PHARMACOKINETIC INVESTIGATION OF REMOGLIFLOZIN IN RAT PLASMA SAMPLES BY HIGH-THROUGHPUT HPLC-MS-MS. Int J App Pharm 2022. [DOI: 10.22159/ijap.2022v14i6.45700] [Reference Citation Analysis]
|
| 249 |
Golubovskaya DP, Karetnikova VN, Oleinik IR, Barbarash OL. A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors. Racionalʹnaâ farmakoterapiâ v kardiologii 2022;18:606-613. [DOI: 10.20996/1819-6446-2022-10-08] [Reference Citation Analysis]
|
| 250 |
Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S, Zhao J. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol 2022;21:232. [DOI: 10.1186/s12933-022-01676-5] [Reference Citation Analysis]
|
| 251 |
Lee C, Wu M, Lui D, Fong C, Ren Q, Yu S, Yuen M, Chow W, Huang J, Xu A, Yiu K, Lam K. Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. Cardiovasc Diabetol 2022;21:231. [DOI: 10.1186/s12933-022-01646-x] [Reference Citation Analysis]
|
| 252 |
Sun W, Kong APS, Yan BP. Impact of early initiation of sodium-glucose cotransporter 2 inhibitor on cardiovascular outcomes in people with diabetes and known or at risk of atherosclerotic cardiovascular disease: Propensity score matched analysis. PLoS One 2022;17:e0277321. [PMID: 36331955 DOI: 10.1371/journal.pone.0277321] [Reference Citation Analysis]
|
| 253 |
Zhang G, Zuo Q, Ma S, He L, Wang Z, Zhai J, Zhang T, Wang Y, Guo Y. Metabolomic analysis of the effect of canagliflozin on HFpEF rats and its underlying mechanism.. [DOI: 10.21203/rs.3.rs-1886973/v1] [Reference Citation Analysis]
|
| 254 |
Jo HA, Seo J, Lee S, Yu M, Bae E, Kim DK, Kim YS, Kim DJ, Yang SH. Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor.. [DOI: 10.21203/rs.3.rs-2204618/v1] [Reference Citation Analysis]
|
| 255 |
Jamil S, Zainab A, Arora AKMS, Shaik TA, Khemani V, Mekowulu FC, Aschalew YN, Khan S. Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials. Cureus 2022;14:e31898. [PMID: 36579248 DOI: 10.7759/cureus.31898] [Reference Citation Analysis]
|
| 256 |
Shah BR, Phatak S, Phatak P, Shah HB, Phatak I, Shah DB. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience. Cureus 2022;14:e31842. [PMID: 36579232 DOI: 10.7759/cureus.31842] [Reference Citation Analysis]
|
| 257 |
Konta Y, Saito E, Sato K, Furuta K, Miyauchi K, Furukawa A, Sato H, Yamamoto T. Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor. Intern Med 2022;61:3239-43. [PMID: 35283386 DOI: 10.2169/internalmedicine.9011-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 258 |
Zhai MZ, Avorn J, Liu J, Kesselheim AS. Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients. JAMA Netw Open 2022;5:e2240117. [PMID: 36346634 DOI: 10.1001/jamanetworkopen.2022.40117] [Reference Citation Analysis]
|
| 259 |
Beimler J. [New aspects of pharmacological nephroprotection]. Inn Med (Heidelb) 2022;63:1200-7. [PMID: 35380212 DOI: 10.1007/s00108-022-01297-w] [Reference Citation Analysis]
|
| 260 |
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022;102:S1-S127. [PMID: 36272764 DOI: 10.1016/j.kint.2022.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 261 |
Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease. Diabetes Obes Metab 2022;24:2138-47. [PMID: 35676798 DOI: 10.1111/dom.14799] [Reference Citation Analysis]
|
| 262 |
Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, Vedin O, Sumin M, Zwiener I, Hernandez AF, Butler J. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am Heart J 2022;253:86-98. [PMID: 35595091 DOI: 10.1016/j.ahj.2022.05.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 263 |
TODAY Study Group, TODAY Study Group. Long-term Outcomes Among Young Adults With Type 2 Diabetes Based on Durability of Glycemic Control: Results From the TODAY Cohort Study. Diabetes Care 2022;45:2689-97. [PMID: 36190810 DOI: 10.2337/dc22-0784] [Reference Citation Analysis]
|
| 264 |
Luo J, Feldman R, Rothenberger S, Korytkowski M, Fischer MA, Gellad WF. Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System. J Gen Intern Med 2022;37:3562-9. [PMID: 35048301 DOI: 10.1007/s11606-021-07331-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 265 |
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45:2753-86. [PMID: 36148880 DOI: 10.2337/dci22-0034] [Cited by in Crossref: 56] [Cited by in F6Publishing: 24] [Article Influence: 56.0] [Reference Citation Analysis]
|
| 266 |
D'Marco L, Guerra-Torres X, Viejo I, Lopez-Romero L, Yugueros A, Bermídez V. Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria. touchREV Endocrinol 2022;18:102-5. [PMID: 36694889 DOI: 10.17925/EE.2022.18.2.102] [Reference Citation Analysis]
|
| 267 |
Neumiller JJ, Lienhard FJ, Alicic RZ, Tuttle KR. Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors. touchREV Endocrinol 2022;18:106-15. [PMID: 36694888 DOI: 10.17925/EE.2022.18.2.106] [Reference Citation Analysis]
|
| 268 |
Kishima H, Mine T, Fukuhara E, Kitagaki R, Asakura M, Ishihara M. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation. JACC Clin Electrophysiol 2022;8:1393-404. [PMID: 36424008 DOI: 10.1016/j.jacep.2022.08.004] [Reference Citation Analysis]
|
| 269 |
Lee CH, Wu MZ, Lui DT, Chan DS, Fong CH, Shiu SW, Wong Y, Lee AC, Lam JK, Woo YC, Lam KS, Yiu KK, Tan KC. Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus. Diabetes Metab J 2022;46:843-54. [PMID: 35483674 DOI: 10.4093/dmj.2021.0319] [Reference Citation Analysis]
|
| 270 |
Shah AS, Zeitler PS, Wong J, Pena AS, Wicklow B, Arslanian S, Chang N, Fu J, Dabadghao P, Pinhas-Hamiel O, Urakami T, Craig ME. ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. Pediatr Diabetes 2022;23:872-902. [PMID: 36161685 DOI: 10.1111/pedi.13409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 271 |
Sarraju A, Bakris G, Cannon CP, Cherney D, Damaraju C, Figtree GA, Gogate J, Greene T, Heerspink HJ, Januzzi JL, Neal B, Jardine MJ, Blais J, Kosiborod M, Levin A, Lingvay I, Weir MR, Perkovic V, Mahaffey KW. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. Journal of the American College of Cardiology 2022;80:1721-1731. [DOI: 10.1016/j.jacc.2022.08.772] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 272 |
Suzuki Y, Kaneko H, Okada A, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Node K, Nangaku M, Yasunaga H, Komuro I. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors. Kidney Int 2022;102:1147-53. [PMID: 35961884 DOI: 10.1016/j.kint.2022.05.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 273 |
Swart EC, Neilson LM, Munshi KD, Peasah SK, Henderson R, Good CB. Trends in add-on medications following metformin monotherapy for type 2 diabetes. JMCP 2022;28:1253-1259. [DOI: 10.18553/jmcp.2022.28.11.1253] [Reference Citation Analysis]
|
| 274 |
Koshino A, Schechter M, Sen T, Vart P, Neuen BL, Neal B, Arnott C, Perkovic V, Ridker PM, Tuttle KR, Hansen MK, Heerspink HJL. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS. Diabetes Care 2022;45:2644-52. [PMID: 36134918 DOI: 10.2337/dc22-0866] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 275 |
Xu M, Zheng J, Hou T, Lin H, Wang T, Wang S, Lu J, Zhao Z, Li M, Xu Y, Ning G, Bi Y, Wang W. SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study. Diabetes Care 2022;45:2718-28. [PMID: 36161993 DOI: 10.2337/dc22-0323] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 276 |
Echouffo-Tcheugui JB, Turchin A, Rosenson RS, Fonarow GC, Goyal A, de Lemos JA, Arnold SV. Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry. Am J Med 2022;135:1336-41. [PMID: 35872090 DOI: 10.1016/j.amjmed.2022.06.016] [Reference Citation Analysis]
|
| 277 |
Zhao JZ, Weinhandl ED, Carlson AM, St Peter WL. Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States. Kidney Med 2023;5:100564. [PMID: 36593878 DOI: 10.1016/j.xkme.2022.100564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 278 |
Perera P, O'Donnabhain R, Fazio T, Johnson D, Lange P. 'A Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Service'. Clin Med Insights Cardiol 2022;16:11795468221133607. [PMID: 36329805 DOI: 10.1177/11795468221133607] [Reference Citation Analysis]
|
| 279 |
Zhang Y, Wang J, Jiang L, Wang T, Li Z, Fu X, Huang W, Xiao Y, Wang S, Zhao J. Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetol Metab Syndr 2022;14:156. [PMID: 36303247 DOI: 10.1186/s13098-022-00929-3] [Reference Citation Analysis]
|
| 280 |
Vergara A, Jacobs-cacha C, Llorens-cebria C, Ortiz A, Martinez-diaz I, Martos N, Dominguez-báez P, Van den Bosch MM, Bermejo S, Pieper MP, Benito B, Soler MJ. Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice. IJMS 2022;23:12823. [DOI: 10.3390/ijms232112823] [Reference Citation Analysis]
|
| 281 |
Gregg LP, Navaneethan SD. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders? Nephrol Dial Transplant 2022:gfac284. [PMID: 36264349 DOI: 10.1093/ndt/gfac284] [Reference Citation Analysis]
|
| 282 |
Gao J, Xue G, Zhan G, Wang X, Li J, Yang X, Xia Y. Benefits of SGLT2 inhibitors in arrhythmias. Front Cardiovasc Med 2022;9:1011429. [DOI: 10.3389/fcvm.2022.1011429] [Reference Citation Analysis]
|
| 283 |
Davidson JA, Sukor N, Hew FL, Mohamed M, Hussein Z. Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations. J Diabetes Investig 2023;14:167-82. [PMID: 36260389 DOI: 10.1111/jdi.13915] [Reference Citation Analysis]
|
| 284 |
Lee H, Chuang C, Li P, Yeh Y, Chan Y, See L. Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors Cover title: SGLT2i versus DPP4i in T2D patients after PAD revascularization.. [DOI: 10.21203/rs.3.rs-2159012/v1] [Reference Citation Analysis]
|
| 285 |
Lim J, Hwang IC, Choi HM, Yoon YE, Cho GY. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. PLoS One 2022;17:e0269414. [PMID: 36251654 DOI: 10.1371/journal.pone.0269414] [Reference Citation Analysis]
|
| 286 |
Xu C, He L, Zhang J, Xu L, Dong J, Liao L. The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis. Metabolites 2022;12. [PMID: 36295882 DOI: 10.3390/metabo12100979] [Reference Citation Analysis]
|
| 287 |
Gong C, Shen SC, Zhang K, Zhou L, Shen JJ, Zhao JY, Ding SG, Ma LK, Gao H. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials. Front Cardiovasc Med 2022;9:926979. [PMID: 36312269 DOI: 10.3389/fcvm.2022.926979] [Reference Citation Analysis]
|
| 288 |
Gallwitz B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front Endocrinol 2022;13:1004044. [DOI: 10.3389/fendo.2022.1004044] [Reference Citation Analysis]
|
| 289 |
Kanorskiy SG. New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-17-44-51] [Reference Citation Analysis]
|
| 290 |
Siao WZ, Chen YH, Tsai CF, Lee CM, Jong GP. Diabetes Mellitus and Heart Failure. J Pers Med 2022;12:1698. [PMID: 36294837 DOI: 10.3390/jpm12101698] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 291 |
Payudis AN, Efremova OA, Kamyshnikova LA, Pavlova IS, Dudchenko OV, Khamnagadaev II, Golivets TP. Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus. Klinicist 2022;16:10-16. [DOI: 10.17650/1818-8338-2022-16-2-k656] [Reference Citation Analysis]
|
| 292 |
Deng Y, Ghamsari F, Lu A, Yu J, Zhao L, Kho AN. Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease. J Clin Transl Endocrinol 2022;30:100309. [PMID: 36620756 DOI: 10.1016/j.jcte.2022.100309] [Reference Citation Analysis]
|
| 293 |
Gronda E, Vanoli E, Iacoviello M, Caldarola P, Gabrielli D, Tavazzi L. The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney. Int J Mol Sci 2022;23:11987. [PMID: 36233288 DOI: 10.3390/ijms231911987] [Reference Citation Analysis]
|
| 294 |
Prázný M, Suplotova L, Gumprecht J, Kamenov Z, Fülöp T, Medvedchikov A, Rosenzweig D, Aleksandric M. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study. Cardiovasc Diabetol 2022;21:203. [PMID: 36209118 DOI: 10.1186/s12933-022-01631-4] [Reference Citation Analysis]
|
| 295 |
Hojná S, Kotsaridou Z, Vaňourková Z, Rauchová H, Behuliak M, Kujal P, Kadlecová M, Zicha J, Vaněčková I. Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease. Biomedicines 2022;10:2509. [PMID: 36289772 DOI: 10.3390/biomedicines10102509] [Reference Citation Analysis]
|
| 296 |
Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing 2022;51. [PMID: 36201329 DOI: 10.1093/ageing/afac201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 297 |
Bletsa E, Paschou SA, Tsigkou V, Stampouloglou PK, Vasileiou V, Kassi GN, Oikonomou E, Siasos G. The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review. Hormones (Athens) 2022. [PMID: 36197637 DOI: 10.1007/s42000-022-00403-9] [Reference Citation Analysis]
|
| 298 |
Xi Y, Chen D, Dong Z, Zhang J, Lam H, He J, Du K, Chen C, Guo J, Xiao J. Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy. Front Cardiovasc Med 2022;9:999254. [PMID: 36277768 DOI: 10.3389/fcvm.2022.999254] [Reference Citation Analysis]
|
| 299 |
Abe M, Matsuoka T, Kawamoto S, Miyasato K, Kobayashi H. Toward Revision of the ‘Best Practice for Diabetic Patients on Hemodialysis 2012’. Kidney and Dialysis 2022;2:495-511. [DOI: 10.3390/kidneydial2040045] [Reference Citation Analysis]
|
| 300 |
Zhuo M, D'Andrea E, Paik JM, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Patorno E. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes. JAMA Netw Open 2022;5:e2235995. [PMID: 36219443 DOI: 10.1001/jamanetworkopen.2022.35995] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 301 |
Narita K, Hoshide S, Kario K. The role of blood pressure management in stroke prevention: current status and future prospects. Expert Review of Cardiovascular Therapy 2022;20:829-838. [DOI: 10.1080/14779072.2022.2137490] [Reference Citation Analysis]
|
| 302 |
Ferrannini G, Savarese G, Cosentino F. SGLT2 Inhibitors in Type 2 Diabetes Mellitus. Heart Failure Clinics 2022;18:551-559. [DOI: 10.1016/j.hfc.2022.03.009] [Reference Citation Analysis]
|
| 303 |
Peng X, Chen S, Wang Y, Jin M, Mei F, Bao Y, Liao X, Chen Y, Gong W. SGLT2i reduces renal injury by improving mitochondrial metabolism and biogenesis. Molecular Metabolism 2022. [DOI: 10.1016/j.molmet.2022.101613] [Reference Citation Analysis]
|
| 304 |
Lee C, Columbo JA, Stone DH, Creager MA, Henkin S. Preoperative evaluation and perioperative management of patients undergoing major vascular surgery. Vasc Med 2022;27:496-512. [PMID: 36214163 DOI: 10.1177/1358863X221122552] [Reference Citation Analysis]
|
| 305 |
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV Jr, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract 2022;28:923-1049. [PMID: 35963508 DOI: 10.1016/j.eprac.2022.08.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 306 |
Pollack R, Cahn A. SGLT2 Inhibitors and Safety in Older Patients. Heart Failure Clinics 2022;18:635-643. [DOI: 10.1016/j.hfc.2022.03.002] [Reference Citation Analysis]
|
| 307 |
Balletshofer B, Böckler D, Diener H, Heckenkamp J, Ito W, Katoh M, Lawall H, Malyar N, Qui HJ, Reimer P, Rittig K, Zähringer M. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG). Diabetologie und Stoffwechsel 2022;17:S354-S364. [DOI: 10.1055/a-1908-0612] [Reference Citation Analysis]
|
| 308 |
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, Wan W, Zhu M, Huang ES, Philipson L, Laiteerapong N. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med 2022;175:1392-400. [PMID: 36191315 DOI: 10.7326/M21-2941] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 309 |
Li HL, Tse YK, Chandramouli C, Hon NW, Cheung CL, Lam LY, Wu M, Huang JY, Yu SY, Leung KL, Fei Y, Feng Q, Ren Q, Cheung BMY, Tse HF, Verma S, Lam CSP, Yiu KH. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. J Clin Endocrinol Metab 2022;107:3442-51. [PMID: 36181458 DOI: 10.1210/clinem/dgac558] [Reference Citation Analysis]
|
| 310 |
Nelson AJ, Harrington JL, Kolkailah AA, Pagidipati NJ, Mcguire DK. Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. Heart Failure Clinics 2022;18:597-607. [DOI: 10.1016/j.hfc.2022.03.007] [Reference Citation Analysis]
|
| 311 |
Takahashi H, Suganuma Y, Ohno T, Nishimura R. Trends in clinical characteristics and factors associated with initial prescription of SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus. Diabetol Int 2022;13:606-14. [PMID: 36117921 DOI: 10.1007/s13340-022-00577-y] [Reference Citation Analysis]
|
| 312 |
Rastogi T, Girerd N. SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction. Heart Failure Clinics 2022;18:561-577. [DOI: 10.1016/j.hfc.2022.03.006] [Reference Citation Analysis]
|
| 313 |
Vallon V. Renoprotective Effects of SGLT2 Inhibitors. Heart Fail Clin 2022;18:539-49. [PMID: 36216484 DOI: 10.1016/j.hfc.2022.03.005] [Reference Citation Analysis]
|
| 314 |
Baliga RR, Bhatt DL, Bossone E. SGLT2 Inhibitors Are Lifesavers in Heart Failure. Heart Failure Clinics 2022;18:xi-xiv. [DOI: 10.1016/j.hfc.2022.07.001] [Reference Citation Analysis]
|
| 315 |
Williams S, Raheim SA, Khan MI, Rubab U, Kanagala P, Zhao SS, Marshall A, Brown E, Alam U. Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2022.09.002] [Reference Citation Analysis]
|
| 316 |
Jhund PS. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics 2022;18:579-586. [DOI: 10.1016/j.hfc.2022.03.010] [Reference Citation Analysis]
|
| 317 |
Skrabic R, Kumric M, Vrdoljak J, Rusic D, Skrabic I, Vilovic M, Martinovic D, Duplancic V, Ticinovic Kurir T, Bozic J. SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. Biomedicines 2022;10:2458. [PMID: 36289720 DOI: 10.3390/biomedicines10102458] [Reference Citation Analysis]
|
| 318 |
Alicic R, Nicholas SB. Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century. Mayo Clin Proc 2022;97:1904-19. [PMID: 36202498 DOI: 10.1016/j.mayocp.2022.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 319 |
Kula AJ. Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD. Pediatr Nephrol 2022;37:2267-76. [PMID: 35088160 DOI: 10.1007/s00467-022-05456-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 320 |
Chen H, Yang Y, Yu T, Li Y. SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175354] [Reference Citation Analysis]
|
| 321 |
Tong L, Adler SG. Diabetic kidney disease treatment: new perspectives. Kidney Res Clin Pract 2022;41:S63-73. [DOI: 10.23876/j.krcp.21.288] [Reference Citation Analysis]
|
| 322 |
Ghosal PS, Sinha B, Mukherjee R. Heterogeneity in cardiovascular deaths or hospitalizations for heart failure from cardiovascular outcome trials is linked to weight: A meta-regression analysis.. [DOI: 10.21203/rs.3.rs-2113284/v1] [Reference Citation Analysis]
|
| 323 |
Alicic RZ, Neumiller JJ, Galindo RJ, Tuttle KR. Use of Glucose-Lowering Agents in Diabetes and CKD. Kidney Int Rep 2022;7:2589-607. [PMID: 36506243 DOI: 10.1016/j.ekir.2022.09.018] [Reference Citation Analysis]
|
| 324 |
Brunetti VC, St-Jean A, Dell'Aniello S, Fisher A, Yu OHY, Bugden SC, Daigle JM, Hu N, Alessi-Severini S, Shah BR, Ronksley PE, Lix LM, Ernst P, Filion KB; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. BMC Endocr Disord 2022;22:241. [PMID: 36175881 DOI: 10.1186/s12902-022-01140-1] [Reference Citation Analysis]
|
| 325 |
Greenberg BH. Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. Cardiology Discovery 2022;Publish Ahead of Print. [DOI: 10.1097/cd9.0000000000000060] [Reference Citation Analysis]
|
| 326 |
Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Sato K, Terauchi Y, Tamura K, Kanamori A. Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Sci Rep 2022;12:16106. [PMID: 36167964 DOI: 10.1038/s41598-022-20313-5] [Reference Citation Analysis]
|
| 327 |
Wakisaka M, Nakamura K, Kitazono T. The Presence of Sodium Glucose Co-Transporter 2 in Mesangial Cells and Pericytes and Its Roles in Mesangial Lesions and in Capillaries under Diabetic and Ischemic Conditions. Diabetes Res Clin Pract 2022;:110096. [PMID: 36174778 DOI: 10.1016/j.diabres.2022.110096] [Reference Citation Analysis]
|
| 328 |
Bhalla S, Alqabandi Y, Nandula SA, Boddepalli CS, Gutlapalli SD, Lavu VK, Abdelwahab Mohamed Abdelwahab R, Huang R, Potla S, Hamid P. Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. Cureus 2022. [DOI: 10.7759/cureus.29579] [Reference Citation Analysis]
|
| 329 |
Choi H, Goldman J. Effects of Antidiabetic Medications on the Risk of Bone Fracture in Patients With Type 2 Diabetes Mellitus. ADCES in Practice 2022. [DOI: 10.1177/2633559x221122789] [Reference Citation Analysis]
|
| 330 |
Suissa K, Schneeweiss S, Douros A, Yin H, Patorno E, Azoulay L. Obesity as a modifier of the Cardiovascular effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes. Diabetes Res Clin Pract 2022;:110094. [PMID: 36167266 DOI: 10.1016/j.diabres.2022.110094] [Reference Citation Analysis]
|
| 331 |
Qin C, Wang Y, Zhao L, Zhang J, Ren H, Zou Y, Wu Y, Wang T, Zhao Y, Zhang R, Xu H, Zhang J, Cooper ME, Liu F. Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline. Diabetes Metab Syndr Obes 2022;15:2847-56. [PMID: 36148023 DOI: 10.2147/DMSO.S381052] [Reference Citation Analysis]
|
| 332 |
Tye SC, Jongs N, Coca SG, Sundström J, Arnott C, Neal B, Perkovic V, Mahaffey KW, Vart P, Heerspink HJL. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure. Cardiovasc Diabetol 2022;21:194. [PMID: 36151557 DOI: 10.1186/s12933-022-01619-0] [Reference Citation Analysis]
|
| 333 |
Pignatelli P, Baratta F, Buzzetti R, D'Amico A, Castellani V, Bartimoccia S, Siena A, D'Onofrio L, Maddaloni E, Pingitore A, Chiariello GA, Santilli F, Pastori D, Cocomello N, Violi F, Del Ben M, Cammisotto V, Carnevale R. The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. Antioxidants (Basel) 2022;11. [PMID: 36290601 DOI: 10.3390/antiox11101878] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 334 |
Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, Fortmann SP, Green JB, Kahn SE, Kirkman MS, Krause-Steinrauf H, Larkin ME, Phillips LS, Pop-Busui R, Steffes M, Tiktin M, Tripputi M, Wexler DJ, Younes N; GRADE Study Research Group. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022;387:1075-88. [PMID: 36129997 DOI: 10.1056/NEJMoa2200436] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 335 |
Nair R, Mody R, Yu M, Cowburn S, Konig M, Prewitt T. Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study. Diabetes Ther 2022. [PMID: 36131064 DOI: 10.1007/s13300-022-01320-1] [Reference Citation Analysis]
|
| 336 |
Mizutani G, Horii T, Oikawa Y, Atsuda K, Shimada A. Real-world risk of lower-limb amputation associated with sodium-glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan. J Diabetes Investig 2022. [PMID: 36124433 DOI: 10.1111/jdi.13906] [Reference Citation Analysis]
|
| 337 |
Heyman SN, Raz I, Dwyer JP, Weinberg Sibony R, Lewis JB, Abassi Z. Diabetic Proteinuria Revisited: Updated Physiologic Perspectives. Cells 2022;11:2917. [PMID: 36139492 DOI: 10.3390/cells11182917] [Reference Citation Analysis]
|
| 338 |
Huang W, Chen YY, Li ZQ, He FF, Zhang C. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. Int J Mol Sci 2022;23:10882. [PMID: 36142794 DOI: 10.3390/ijms231810882] [Reference Citation Analysis]
|
| 339 |
Adamu U, Mpanya D, Patel A, Tsabedze N. Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. Journal of Endocrinology, Metabolism and Diabetes of South Africa 2022. [DOI: 10.1080/16089677.2022.2113206] [Reference Citation Analysis]
|
| 340 |
Li J, Zhou L, Gong H. New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.903902] [Reference Citation Analysis]
|
| 341 |
Salvatore T, Galiero R, Caturano A, Vetrano E, Loffredo G, Rinaldi L, Catalini C, Gjeloshi K, Albanese G, Di Martino A, Docimo G, Sardu C, Marfella R, Sasso FC. Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. Biomedicines 2022;10:2274. [DOI: 10.3390/biomedicines10092274] [Reference Citation Analysis]
|
| 342 |
Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Namba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nishii N, Fuke S, Yoshikawa M, Nakamura K, Ito H, Ejiri K, Miyoshi T, Nakamura K, Ito H, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Namba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nishii N, Sato T, Fuke S, Yoshikawa M, Sugiyama H, Imai M, Gotoh N, Segawa T, Noda T, Koshiji M; The MUSCAT-HF Study Investigators. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-19371-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 343 |
Lee Y, Dong Y, Yang W, Wu L, Lin J, Chang C. Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study. Front Pharmacol 2022;13:869804. [DOI: 10.3389/fphar.2022.869804] [Reference Citation Analysis]
|
| 344 |
Sarker A, Ramesh AS, Munoz C, Jamil D, Tran HH, Mansoor M, Butt SR, Satnarine T, Ratna P, Hamid P. Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.29069] [Reference Citation Analysis]
|
| 345 |
Kroeger H, Kessel F, Sradnick J, Todorov V, Gembardt F, Hugo C. Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice. Front Physiol 2022;13:982722. [DOI: 10.3389/fphys.2022.982722] [Reference Citation Analysis]
|
| 346 |
Marfella R, Scisciola L, D'Onofrio N, Maiello C, Trotta MC, Sardu C, Panarese I, Ferraraccio F, Capuano A, Barbieri M, Balestrieri ML, Napoli C, Paolisso G. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacol Res 2022;184:106448. [PMID: 36096423 DOI: 10.1016/j.phrs.2022.106448] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
|
| 347 |
Kansara A, Mubeen F, Shakil J. SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. Methodist DeBakey Cardiovascular Journal 2022;18:62-72. [DOI: 10.14797/mdcvj.1120] [Reference Citation Analysis]
|
| 348 |
Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, Franzese M, Puocci A, De Angelis A, Sportiello L, Marfella R, Barbieri M. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1008922] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 349 |
Wu VC, Chiu K, Wang C, Hsu C, Tu H, Huang Y, Chang C, Huang C, Kuo C, Chen S, Chu P, Chang S. Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.934193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 350 |
Kodera S, Morita H, Nishi H, Takeda N, Ando J, Komuro I. Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan. Circ J 2022. [PMID: 36070962 DOI: 10.1253/circj.CJ-22-0086] [Reference Citation Analysis]
|
| 351 |
Iketani R, Imai S. Impact of breakthrough trials on prescription trends of sodium-glucose cotransporter-2 inhibitors in Japan: An interrupted time-series analysis. J Clin Pharm Ther 2022. [PMID: 36068684 DOI: 10.1111/jcpt.13768] [Reference Citation Analysis]
|
| 352 |
Niu CY, Yang SF, Ou SM, Wu CH, Huang PH, Hung CL, Lin CC, Li SY. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease. J Am Heart Assoc 2022;:e026407. [PMID: 36062622 DOI: 10.1161/JAHA.122.026407] [Reference Citation Analysis]
|
| 353 |
Sanoudou D, Mantzoros CS, Hill MA. Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome? Metabolism 2022;:155309. [PMID: 36067806 DOI: 10.1016/j.metabol.2022.155309] [Reference Citation Analysis]
|
| 354 |
Zawada A, Ratajczak AE, Rychter AM, Szymczak-tomczak A, Dobrowolska A, Krela-kaźmierczak I. Treatment of Diabetes and Osteoporosis—A Reciprocal Risk? Biomedicines 2022;10:2191. [DOI: 10.3390/biomedicines10092191] [Reference Citation Analysis]
|
| 355 |
Agewall S. Prevention is still the key to success. European Heart Journal - Cardiovascular Pharmacotherapy 2022;8:537-538. [DOI: 10.1093/ehjcvp/pvac046] [Reference Citation Analysis]
|
| 356 |
Egers M, Hynes M. Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. Journal of Kidney Care 2022;7:216-224. [DOI: 10.12968/jokc.2022.7.5.216] [Reference Citation Analysis]
|
| 357 |
Chu C, Delić D, Alber J, Feger M, Xiong Y, Luo T, Hasan AA, Zeng S, Gaballa MM, Chen X, Yin L, Klein T, Elitok S, Krämer BK, Föller M, Hocher B. Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model. Biomedicine & Pharmacotherapy 2022;153:113357. [DOI: 10.1016/j.biopha.2022.113357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 358 |
Uehara-Watanabe N, Okuno-Ozeki N, Nakamura I, Nakata T, Nakai K, Yagi-Tomita A, Ida T, Yamashita N, Kamezaki M, Kirita Y, Matoba S, Tamagaki K, Kusaba T. Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin. Heliyon 2022;8:e10615. [PMID: 36148274 DOI: 10.1016/j.heliyon.2022.e10615] [Reference Citation Analysis]
|
| 359 |
Zaawari A, Sahar AN. Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control. Annals of Medicine and Surgery 2022;81:104536. [DOI: 10.1016/j.amsu.2022.104536] [Reference Citation Analysis]
|
| 360 |
Gao Y, Feng S, Wen Y, Tang T, Wang B, Liu B. Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming. eBioMedicine 2022;83:104215. [DOI: 10.1016/j.ebiom.2022.104215] [Reference Citation Analysis]
|
| 361 |
Wang J, Li D, Ju W, Wang H. A Network Pharmacology to Explore the Potential Targets of Canagliflozin and Dapagliflozin in Treating Atherosclerosis. JVD 2022;1:53-70. [DOI: 10.3390/jvd1010007] [Reference Citation Analysis]
|
| 362 |
Márquez DF, Rodríguez-sánchez E, de la Morena JS, Ruilope LM, Ruiz-hurtado G. Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. Nefrología 2022;42:519-530. [DOI: 10.1016/j.nefro.2021.10.003] [Reference Citation Analysis]
|
| 363 |
Seo DH, Suh YJ, Cho Y, Ahn SH, Seo S, Hong S, Lee YH, Choi YJ, Lee E, Kim SH. Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice. Yonsei Med J 2022;63:825-33. [PMID: 36031782 DOI: 10.3349/ymj.2022.63.9.825] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 364 |
Márquez DF, Rodríguez-Sánchez E, de la Morena JS, Ruilope LM, Ruiz-Hurtado G. Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. Nefrologia (Engl Ed) 2022;42:519-30. [PMID: 36792306 DOI: 10.1016/j.nefroe.2021.10.008] [Reference Citation Analysis]
|
| 365 |
de Paula LJC, Uchida AH, Rezende PC, Soares P, Scudeler TL. Protective or Inhibitory Effect of Pharmacological Therapy on Cardiac Ischemic Preconditioning: A Literature Review. Curr Vasc Pharmacol 2022;20:409-28. [PMID: 35986546 DOI: 10.2174/1570161120666220819163025] [Reference Citation Analysis]
|
| 366 |
Khakde S, Jawaid H, Yasmin F, Binte Ali M, Rehman A. Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. Minerva Endocrinol 2022;47. [DOI: 10.23736/s2724-6507.20.03221-6] [Reference Citation Analysis]
|
| 367 |
Pozo Garcia L, Thomas SS, Rajesh H, Navaneethan SD. Progress in the management of patients with diabetes and chronic kidney disease. Curr Opin Nephrol Hypertens 2022;31:456-63. [PMID: 35894280 DOI: 10.1097/MNH.0000000000000811] [Reference Citation Analysis]
|
| 368 |
Harrington J, Petrie MC, Anker SD, Bhatt DL, Jones SW, Udell JA, Hernandez AF, Butler J. Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review. JAMA Cardiol 2022. [PMID: 36044233 DOI: 10.1001/jamacardio.2022.2847] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 369 |
Dedov II, Shestakova MV, Mayorov AY, Mokrysheva NG, Vikulova OK, Galstyan GR, Kuraeva TL, Peterkova VA, Smirnova OM, Starostina EG, Surkova EV, Sukhareva OY, Tokmakova AY, Shamkhalova MS, Jarek-martynova IR, Artemova EV, Beshlieva DD, Bondarenko ON, Volevodz NN, Gomova IS, Grigoryan OR, Dzhemilova ZN, Esayan RM, Ibragimova LI, Kalashnikov VY, Kononenko IV, Laptev DN, Lipatov DV, Melnikova OG, Mikhina MS, Michurova MS, Motovilin OG, Nikonova TV, Rozhivanov RV, Sklyanik IA, Shestakova EA. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition. Diabetes mellitus 2022;24:1-148. [DOI: 10.14341/dm12802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 370 |
Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun 2022;6:3073-82. [PMID: 36039537 DOI: 10.1002/hep4.2069] [Reference Citation Analysis]
|
| 371 |
Mirzazada V, Sultanova S, Ismayilova N, Huseynova A, Nurmammadova G, Ismayilova S, Aliyeva A. Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure. Cardiovascular Diseases [Working Title] 2022. [DOI: 10.5772/intechopen.106391] [Reference Citation Analysis]
|
| 372 |
Laksono S, Hosea GT, Nurusshofa Z. Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies. Brown Journal of Hospital Medicine 2022;1. [DOI: 10.56305/001c.37850] [Reference Citation Analysis]
|
| 373 |
Fırat SN, Kuşkonmaz ŞM, Çaydere M, Şeneş M, Hücümenoğlu S, Çulha C. Renoprotective effects of dapagliflozin in an iron overload non-diabetic rat model. Adv Med Sci 2022;67:311-5. [PMID: 36037575 DOI: 10.1016/j.advms.2022.08.001] [Reference Citation Analysis]
|
| 374 |
Wang YW, Lin JH, Yang CS. Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Medicine (Baltimore) 2022;101:e30072. [PMID: 36042668 DOI: 10.1097/MD.0000000000030072] [Reference Citation Analysis]
|
| 375 |
Gan T, Song Y, Guo F, Qin G. Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease. Mol Biol Rep 2022. [PMID: 36002651 DOI: 10.1007/s11033-022-07758-7] [Reference Citation Analysis]
|
| 376 |
Karpushev AV, Mikhailova VB, Klimenko ES, Kulikov AN, Ivkin DY, Kaschina E, Okovityi SV. SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart. IJMS 2022;23:9559. [DOI: 10.3390/ijms23179559] [Reference Citation Analysis]
|
| 377 |
Teo YH, Chia AZQ, Teo YN, Chong EY, Syn NL, Cheong JYA, Ong HT, Wee CF, Ting AZH, Tan JTA, Li TYW, Kong WKF, Lee CH, Chan MY, Wong RCC, Yeo TC, Chai P, Sia CH. The impact of sodium-glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials. J Hypertens 2022. [PMID: 36018229 DOI: 10.1097/HJH.0000000000003280] [Reference Citation Analysis]
|
| 378 |
Tai S, Fu L, Zhang N, Yang R, Zhou Y, Xing Z, Wang Y, Zhou S. Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2022;21:161. [PMID: 35999546 DOI: 10.1186/s12933-022-01599-1] [Reference Citation Analysis]
|
| 379 |
Ramírez Rincón A, Saldarriaga Betancur S, García Ramos AF, González Arango J, Estupiñán Vargas V. Tratamiento farmacológico del paciente que vive con diabetes mellitus tipo 2. CES Med 2022;36:81-105. [DOI: 10.21615/cesmedicina.6672] [Reference Citation Analysis]
|
| 380 |
Liberale L, Kraler S, Puspitasari YM, Bonetti NR, Akhmedov A, Ministrini S, Montecucco F, Marx N, Lehrke M, Hartmann NUK, Beer JH, Wenzl FA, Paneni F, Lüscher TF, Camici GG. SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation. Cardiovasc Res 2022:cvac126. [PMID: 35993135 DOI: 10.1093/cvr/cvac126] [Reference Citation Analysis]
|
| 381 |
Camm AJ, Sabbour H, Schnell O, Summaria F, Verma A. Managing thrombotic risk in patients with diabetes. Cardiovasc Diabetol 2022;21:160. [PMID: 35996159 DOI: 10.1186/s12933-022-01581-x] [Reference Citation Analysis]
|
| 382 |
Yildiz M, Lavie CJ, Morin DP, Oktay AA. The complex interplay between diabetes mellitus and atrial fibrillation. Expert Rev Cardiovasc Ther 2022. [PMID: 35984314 DOI: 10.1080/14779072.2022.2115357] [Reference Citation Analysis]
|
| 383 |
Çamcı S, Yılmaz E. Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction. Medicina (Kaunas) 2022;58. [PMID: 36013595 DOI: 10.3390/medicina58081128] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 384 |
Jia Y, Li D, Yu J, Jiang W, Liao X, Zhao Q. Potential diabetic cardiomyopathy therapies targeting pyroptosis: A mini review. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.985020] [Reference Citation Analysis]
|
| 385 |
Zaini LM, Kartasasmita AS, Gondhowiardjo TD, Syukri M, Lesmana R. Potential molecular mechanism of action of sodium-glucose co-transporter 2 inhibitors in the prevention and management of diabetic retinopathy. Expert Review of Ophthalmology. [DOI: 10.1080/17469899.2022.2111302] [Reference Citation Analysis]
|
| 386 |
Shiraki A, Oyama JI, Shimizu T, Nakajima T, Yokota T, Node K. Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure. Eur J Pharmacol 2022;931:175194. [PMID: 35987253 DOI: 10.1016/j.ejphar.2022.175194] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 387 |
Koufakis T, Doumas M, Zebekakis P, Kotsa K. Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces? Expert Opin Pharmacother 2022. [PMID: 35962542 DOI: 10.1080/14656566.2022.2113385] [Reference Citation Analysis]
|
| 388 |
Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, Pace C, Betella N, Favacchio G, Bulgheroni M, Bucciarelli L, Massari G, Mascardi C, Girelli A, Morpurgo PS, Folli F, Luzi L, Mirani M, Pintaudi B, Bertuzzi F, Berra C, Fiorina P. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res 2022;183:106396. [PMID: 35970329 DOI: 10.1016/j.phrs.2022.106396] [Reference Citation Analysis]
|
| 389 |
Jogimahanti A, Honan K, Ahmed T, Leon-novelo L, Khair T. The Effect of SGLT-2 inhibitors and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis.. [DOI: 10.21203/rs.3.rs-1930982/v1] [Reference Citation Analysis]
|
| 390 |
Lee S, Choi D, Kim C, Suh Y, Hong S, Ahn C, Kim J, Kim B, Ko Y, Choi D, Park E, Jang Y, Nam C, Hong M. Prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with diabetes mellitus: A nationwide retrospective cohort study. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.954704] [Reference Citation Analysis]
|
| 391 |
Wu YJ, Wang SB, Wang LS. SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction? Am J Cardiovasc Drugs 2022. [PMID: 35947249 DOI: 10.1007/s40256-022-00545-6] [Reference Citation Analysis]
|
| 392 |
Umanath K, Testani JM, Lewis JB. "Dip" in eGFR: Stay the Course With SGLT-2 Inhibition. Circulation 2022;146:463-5. [PMID: 35939546 DOI: 10.1161/CIRCULATIONAHA.122.060823] [Reference Citation Analysis]
|
| 393 |
Pelle MC, Provenzano M, Busutti M, Porcu CV, Zaffina I, Stanga L, Arturi F. Up-Date on Diabetic Nephropathy. Life (Basel) 2022;12:1202. [PMID: 36013381 DOI: 10.3390/life12081202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 394 |
Wu J, Liu Y, Wei X, Zhang X, Ye Y, Li W, Su X. Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.915455] [Reference Citation Analysis]
|
| 395 |
Peyton KJ, Behnammanesh G, Durante GL, Durante W. Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. Int J Mol Sci 2022;23. [PMID: 35955910 DOI: 10.3390/ijms23158777] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 396 |
Li JW, Arnott C, Heerspink HJL, MBiostat QL, Cannon CP, Wheeler DC, Charytan DM, Barraclough J, Figtree GA, Agarwal R, Bakris G, de Zeeuw D, Greene T, Levin A, Pollock C, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Neal B, Jardine MJ. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. J Am Heart Assoc 2022;:e025045. [PMID: 35929472 DOI: 10.1161/JAHA.121.025045] [Reference Citation Analysis]
|
| 397 |
Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferović PM, Wanner C. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol 2022;21:144. [PMID: 35927730 DOI: 10.1186/s12933-022-01575-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 398 |
Voorrips SN, Saucedo-orozco H, Sánchez-aguilera PI, De Boer RA, Van der Meer P, Westenbrink BD. Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure? IJMS 2022;23:8631. [DOI: 10.3390/ijms23158631] [Reference Citation Analysis]
|
| 399 |
Iwamoto M, Kubota T, Sakurai Y, Wada N, Shioda S, Yamauchi T, Kadowaki T, Kubota N. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes. Pharmacol Res Perspect 2022;10:e00971. [PMID: 35707828 DOI: 10.1002/prp2.971] [Reference Citation Analysis]
|
| 400 |
Ohkoshi-yamada M, Kamimura K, Kimura A, Tanaka Y, Nagayama I, Yakubo S, Abe H, Yokoo T, Sakamaki A, Kamimura H, Terai S. Effects of a selective PPARα modulator, sodium-glucose cotransporter 2 inhibitor, and statin on the myocardial morphology of medaka nonalcoholic fatty liver disease model. Biochemical and Biophysical Research Communications 2022. [DOI: 10.1016/j.bbrc.2022.07.117] [Reference Citation Analysis]
|
| 401 |
Khan MS, Shahid I, Butler J. Reporting and Definition of Kidney Death in Heart Failure Clinical Trials. Current Problems in Cardiology 2022. [DOI: 10.1016/j.cpcardiol.2022.101382] [Reference Citation Analysis]
|
| 402 |
Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. Clin Cardiol 2022;45:831-8. [PMID: 35855557 DOI: 10.1002/clc.23843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 403 |
Miyamoto S, Heerspink HJL, de Zeeuw D, Toyoda M, Suzuki D, Hatanaka T, Nakamura T, Kamei S, Murao S, Hida K, Ando S, Akai H, Takahashi Y, Koya D, Kitada M, Sugano H, Nunoue T, Nakamura A, Sasaki M, Nakatou T, Fujimoto K, Kawanami D, Wada T, Miyatake N, Yoshida M, Shikata K; CANPIONE study Investigators. Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study. Diabetes Obes Metab 2022;24:1429-38. [PMID: 35491532 DOI: 10.1111/dom.14731] [Reference Citation Analysis]
|
| 404 |
Feraille E, Sassi A, Olivier V, Arnoux G, Martin PY. Renal water transport in health and disease. Pflugers Arch 2022;474:841-52. [PMID: 35678906 DOI: 10.1007/s00424-022-02712-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 405 |
Dong YH, Chang CH, Lin JW, Yang WS, Wu LC, Toh S. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study. Diabetes Obes Metab 2022;24:1623-37. [PMID: 35491533 DOI: 10.1111/dom.14741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 406 |
Mancini GBJ, O'Meara E, Zieroth S, Bernier M, Cheng AYY, Cherney DZI, Connelly KA, Ezekowitz J, Goldenberg RM, Leiter LA, Nesrallah G, Paty BW, Piché ME, Senior P, Sharma A, Verma S, Woo V, Darras P, Grégoire J, Lonn E, Stone JA, Yale JF, Yeung C, Zimmerman D. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Can J Cardiol 2022;38:1153-67. [PMID: 35961754 DOI: 10.1016/j.cjca.2022.04.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 407 |
Ali MU, Mancini GBJ, Fitzpatrick-Lewis D, Lewis R, Jovkovic M, Zieroth S, O'Meara E, Connelly KA, Sherifali D. The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis. Can J Cardiol 2022;38:1201-10. [PMID: 35961756 DOI: 10.1016/j.cjca.2022.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 408 |
Marchiori E, Rodionov RN, Peters F, Magnussen C, Nordanstig J, Gombert A, Spanos K, Jarzebska N, Behrendt C. SGLT2 Inhibitors and Peripheral Vascular Events. Heart Failure Clinics 2022. [DOI: 10.1016/j.hfc.2022.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 409 |
Zhao JZ, Weinhandl ED, Carlson AM, St. Peter WL. Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States. Kidney Medicine 2022;4:100510. [DOI: 10.1016/j.xkme.2022.100510] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 410 |
Shah N, Perkovic V, Kotwal S. Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. Expert Rev Clin Pharmacol 2022. [PMID: 35912871 DOI: 10.1080/17512433.2022.2108402] [Reference Citation Analysis]
|
| 411 |
Lui DTW, Au ICH, Tang EHM, Cheung CL, Lee CH, Woo YC, Wu T, Tan KCB, Wong CKH. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. EClinicalMedicine 2022;50:101510. [PMID: 35784442 DOI: 10.1016/j.eclinm.2022.101510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 412 |
Jin Q, Luk AO, Lau ESH, Tam CHT, Ozaki R, Lim CKP, Wu H, Jiang G, Chow EYK, Ng JK, Kong APS, Fan B, Lee KF, Siu SC, Hui G, Tsang CC, Lau KP, Leung JY, Tsang MW, Kam G, Lau IT, Li JK, Yeung VT, Lau E, Lo S, Fung S, Cheng YL, Chow CC, Huang Y, Lan HY, Szeto CC, So WY, Chan JCN, Ma RCW; Hong Kong Diabetes Biobank Study Group. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank. Am J Kidney Dis 2022;80:196-206.e1. [PMID: 34999159 DOI: 10.1053/j.ajkd.2021.11.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 413 |
Kuchay MS, Misra A. Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes? Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2022;16:102580. [DOI: 10.1016/j.dsx.2022.102580] [Reference Citation Analysis]
|
| 414 |
van Dalem J, Werkman NCC, van den Bergh JP, Rossi B, Viggers R, Eastell R, Burden AM, Stehouwer CDA, Klungel OH, Brouwers MCGJ, Driessen JHM. Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: A population-based cohort study. Diabetes Res Clin Pract 2022;190:109993. [PMID: 35842030 DOI: 10.1016/j.diabres.2022.109993] [Reference Citation Analysis]
|
| 415 |
Seidu S, Almaqhawi A, Abdool M, Kunutsor SK, Davies MJ, Khunti K. Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus a stepwise approach in newly diagnosed or treatment-naïve type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2022;24:1469-82. [PMID: 35434901 DOI: 10.1111/dom.14715] [Reference Citation Analysis]
|
| 416 |
Cao H, Liu T, Wang L, Ji Q. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis. Diabetes Obes Metab 2022;24:1448-57. [PMID: 35665989 DOI: 10.1111/dom.14702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 417 |
Lazzaroni E, Lunati ME, Montefusco L, Pastore I, Chebat E, Cimino V, Morpurgo PS, Muratori M, Plebani L, Bolla A, Rossi A, Vallone L, Gandolfi A, Tinari C, D'Addio F, Nasr MB, Loretelli C, Scaranna C, Bellante R, Manfrini R, Muratori F, Franzetti I, Orsi E, Gazzaruso C, Ghelardi R, Desenzani P, Genovese S, Girelli A, Folli F, Berra C, Fiorina P. Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study. Pharmacol Res 2022;183:106374. [PMID: 35908663 DOI: 10.1016/j.phrs.2022.106374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 418 |
Song X, Lv Y, Huang N, Sun J, Yang T, Wang X, Zhang J, Zhou Z, Gao H, Li J, Zhang W, Yin H, Wei Q, Wang K, Li L. Clinical Characteristics of Inpatients With New-Onset Diabetes Mellitus in Eastern China: Based on Novel Clustering Analysis. Front Endocrinol 2022;13:927661. [DOI: 10.3389/fendo.2022.927661] [Reference Citation Analysis]
|
| 419 |
Memon RA, Akbariromani H, Vohra RR, Kundi H, Saleem RF, Ghaffari MA, Haas D, Khan A. Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis. Cureus 2022. [DOI: 10.7759/cureus.27277] [Reference Citation Analysis]
|
| 420 |
Karamichalakis N, Kolovos V, Paraskevaidis I, Tsougos E. A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation. J Cardiovasc Dev Dis 2022;9:236. [PMID: 35893226 DOI: 10.3390/jcdd9080236] [Reference Citation Analysis]
|
| 421 |
Michelassi S. SGLT2 inhibitors: suggestions from the amphibian world. G Clin Nefrol Dial 2022;34:63-69. [DOI: 10.33393/gcnd.2022.2423] [Reference Citation Analysis]
|
| 422 |
Scheen AJ. Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opin Drug Metab Toxicol 2022. [PMID: 35876091 DOI: 10.1080/17425255.2022.2105693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 423 |
Chen X, Wang CY, Ko Y. An investigation of physicians' prescribing behaviors related to antidiabetic agents for Type 2 diabetes mellitus patients and associated factors in Taiwan. Curr Med Res Opin 2022;:1-19. [PMID: 35866660 DOI: 10.1080/03007995.2022.2105539] [Reference Citation Analysis]
|
| 424 |
Frundi DS, Kettig E, Popp LL, Hoffman M, Dumartin M, Hughes M, Lamy E, Fru YJW, Bano A, Muka T, Wilhelm M. Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.907385] [Reference Citation Analysis]
|
| 425 |
Lim VG, He H, Lachlan T, Ng GA, Kyrou I, Randeva HS, Osman F. Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die. Europace 2022;24:1052-7. [PMID: 35080624 DOI: 10.1093/europace/euab321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 426 |
Oyama K, Raz I, Cahn A, Goodrich EL, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2022. [PMID: 35857296 DOI: 10.1001/jamacardio.2022.2006] [Reference Citation Analysis]
|
| 427 |
Zügner E, Yang H, Kotzbeck P, Boulgaropoulos B, Sourij H, Hagvall S, Elmore CS, Esterline R, Moosmang S, Oscarsson J, Pieber TR, Peng X, Magnes C. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism. IJMS 2022;23:7966. [DOI: 10.3390/ijms23147966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 428 |
Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein H, Müller-Wieland D, Nauck MA, Wiesner T, Siegel E. Therapy of Type 2 Diabetes. Exp Clin Endocrinol Diabetes 2022. [PMID: 35839797 DOI: 10.1055/a-1624-3449] [Reference Citation Analysis]
|
| 429 |
Kurczyński D, Hudzik B, Jagosz M, Zabierowski J, Nowak J, Tomasik A, Badziński A, Rozentryt P, Gąsior M. Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. JCDD 2022;9:225. [DOI: 10.3390/jcdd9070225] [Reference Citation Analysis]
|
| 430 |
Sezai A, Tanaka A, Imai T, Kida K, Sekino H, Murohara T, Sata M, Suzuki N, Node K; CANDLE Trial Investigators. Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial. Biomedicines 2022;10. [PMID: 35884961 DOI: 10.3390/biomedicines10071656] [Reference Citation Analysis]
|
| 431 |
Rodríguez-espinosa D, Guzman-bofarull J, De La Fuente-mancera JC, Maduell F, Broseta JJ, Farrero M. Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach. Front Physiol 2022;13:913580. [DOI: 10.3389/fphys.2022.913580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 432 |
Gori M, D’elia E, Sciatti E, Senni M. Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy. Card Fail Rev 2022;8:e26. [DOI: 10.15420/cfr.2022.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 433 |
Dong B, Lv R, Wang J, Che L, Wang Z, Huai Z, Wang Y, Xu L. The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture. Front Endocrinol 2022;13:918350. [DOI: 10.3389/fendo.2022.918350] [Reference Citation Analysis]
|
| 434 |
Kwon CH, Kim YJ, Kim MJ, Cha MJ, Cho MS, Nam GB, Choi KJ, Kim J. Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation. Am J Cardiol 2022:S0002-9149(22)00583-5. [PMID: 35810007 DOI: 10.1016/j.amjcard.2022.05.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 435 |
Chan Y, Chao T, Chen S, Kao Y, Huang C, Chu P. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. European Heart Journal - Quality of Care and Clinical Outcomes 2022. [DOI: 10.1093/ehjqcco/qcac040] [Reference Citation Analysis]
|
| 436 |
Kurata Y, Nangaku M. Dapagliflozin for the treatment of chronic kidney disease. Expert Review of Endocrinology & Metabolism. [DOI: 10.1080/17446651.2022.2099373] [Reference Citation Analysis]
|
| 437 |
Ferrannini G, Rosenthal N, Hansen MK, Ferrannini E. Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program. Cardiovasc Diabetol 2022;21:127. [PMID: 35787704 DOI: 10.1186/s12933-022-01558-w] [Reference Citation Analysis]
|
| 438 |
Takashima M, Nakamura K, Kiyohara T, Wakisaka Y, Hidaka M, Takaki H, Yamanaka K, Shibahara T, Wakisaka M, Ago T, Kitazono T. Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects. Commun Biol 2022;5:653. [PMID: 35780235 DOI: 10.1038/s42003-022-03605-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 439 |
Sharaf El Din UAA, Salem MM, Abdulazim DO. Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease. Nefrologia (Engl Ed) 2022;42:390-403. [PMID: 36460429 DOI: 10.1016/j.nefroe.2022.08.001] [Reference Citation Analysis]
|
| 440 |
Wazir N, Rehman SU. Evaluating Impact of Empagliflozin on Lipid Profile of Patients of Type 2 Diabetes Mellitus. J Gandhara Med Dent Sci 2022;9:20-24. [DOI: 10.37762/jgmds.9-3.174] [Reference Citation Analysis]
|
| 441 |
Jensen J, Omar M, Kistorp C, Gustafsson F, Køber L, Møller JE, Schou M. Sodium-glucose co-transporter-2 inhibitors in heart failure with reduced ejection fraction: Current evidence and future perspectives. Basic Clin Pharmacol Toxicol 2022;131:5-17. [PMID: 35510595 DOI: 10.1111/bcpt.13739] [Reference Citation Analysis]
|
| 442 |
Dagogo-Jack S, Cannon CP, Cherney DZI, Cosentino F, Liu J, Pong A, Gantz I, Frederich R, Mancuso JP, Pratley RE. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV. Diabetes Obes Metab 2022;24:1245-54. [PMID: 35266296 DOI: 10.1111/dom.14691] [Reference Citation Analysis]
|
| 443 |
Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein HH, Müller-wieland D, Nauck MA, Wiesner T, Siegel E. Therapie des Typ-2-Diabetes. Diabetologie 2022;18:623-656. [DOI: 10.1007/s11428-022-00921-5] [Reference Citation Analysis]
|
| 444 |
Kumar R, Bainey KR. Percutaneous coronary intervention with peripheral artery disease in the contemporary era: Still life or limb? Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.1022] [Reference Citation Analysis]
|
| 445 |
Yang Z, Li T, Xian J, Chen J, Huang Y, Zhang Q, Lin X, Lu H, Lin Y. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy. FASEB J 2022;36:e22410. [PMID: 35713937 DOI: 10.1096/fj.202200243R] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 446 |
D’elia JA, Bayliss GP, Weinrauch LA. The Diabetic Cardiorenal Nexus. IJMS 2022;23:7351. [DOI: 10.3390/ijms23137351] [Reference Citation Analysis]
|
| 447 |
Botana M, Escalada J, Merchante Á, Reyes R, Rozas P. Prevention of Cardiorenal Complications with Sodium-Glucose Cotransporter Type 2 Inhibitors: A Narrative Review. Diabetes Ther 2022;13:5-17. [PMID: 35704166 DOI: 10.1007/s13300-022-01277-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 448 |
Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, Sejersten Ripa M, Bonaca MP. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab 2022;24:1288-99. [PMID: 35332654 DOI: 10.1111/dom.14700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 449 |
Norhammar A, Bodegard J, Eriksson JW, Haller H, Linssen GCM, Banerjee A, Karasik A, Mamouris P, Tangri N, Taveira-Gomes T, Maggioni AP, Botana M, Thuresson M, Okami S, Yajima T, Kadowaki T, Birkeland KI; CaReMe Cardiorenal Investigators. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. Diabetes Obes Metab 2022;24:1277-87. [PMID: 35322567 DOI: 10.1111/dom.14698] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 450 |
Igarashi A, Maruyama-Sakurai K, Kubota A, Akiyama H, Yajima T, Kohsaka S, Miyata H. Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan. Diabetes Ther 2022;13:1367-81. [PMID: 35710646 DOI: 10.1007/s13300-022-01270-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 451 |
Gitto M, Kotinas AS, Terzi R, Oliva A, Zagoreo J, Reimers B, Stefanini GG, Mirani M, Favacchio G, Condorelli G, Panico C. Biochemical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population. J Cardiovasc Pharmacol 2022;80:140-7. [PMID: 35436244 DOI: 10.1097/FJC.0000000000001280] [Reference Citation Analysis]
|
| 452 |
Khunti K, Jabbour S, Cos X, Mudaliar S, Mende C, Bonaca M, Fioretto P. Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. Diabetes Obes Metab 2022;24:1187-96. [PMID: 35238129 DOI: 10.1111/dom.14684] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 453 |
González-Albarrán O, Morales C, Pérez-Maraver M, Aparicio-Sánchez JJ, Simó R. Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D. Diabetes Ther 2022;13:35-49. [PMID: 35704167 DOI: 10.1007/s13300-022-01276-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 454 |
Schütt K, Forst T, Birkenfeld AL, Zirlik A, Müller-wieland D, Marx N. Diabetes mellitus und Herz. Diabetologie 2022;18:657-660. [DOI: 10.1007/s11428-022-00916-2] [Reference Citation Analysis]
|
| 455 |
Inada A, Inada O, Yasunami Y, Arakawa K, Nabeshima Y, Fukatsu A. Amelioration of Murine Diabetic Nephropathy with a SGLT2 Inhibitor Is Associated with Suppressing Abnormal Expression of Hypoxia-Inducible Factors. The American Journal of Pathology 2022;192:1028-1052. [DOI: 10.1016/j.ajpath.2022.03.015] [Reference Citation Analysis]
|
| 456 |
Brown B, Gielissen KA, Soares S, Gao CA, Moeller J, Windish D. Anthropomorphic Character Animations Versus Digital Chalk Talks in a Resident Diabetes Pharmacotherapy Curriculum: a Randomized Controlled Trial. J Gen Intern Med 2022;37:2251-8. [PMID: 35710669 DOI: 10.1007/s11606-022-07510-8] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 457 |
Ke C, Narayan KMV, Chan JCN, Jha P, Shah BR. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nat Rev Endocrinol 2022;18:413-32. [PMID: 35508700 DOI: 10.1038/s41574-022-00669-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 458 |
García-maset R, Bover J, Segura de la Morena J, Goicoechea Diezhandino M, Cebollada del Hoyo J, Escalada San Martin J, Fácila Rubio L, Gamarra Ortiz J, García-donaire JA, García-matarín L, Gràcia Garcia S, Isabel Gutiérrez Pérez M, Hernández Moreno J, Mazón Ramos P, Montañés Bermudez R, Muñoz Torres M, de Pablos-velasco P, Pérez-maraver M, Suárez Fernández C, Tranche Iparraguirre S, Luis Górriz J. Information and consensus document for the detection and management of chronic kidney disease. Nefrología (English Edition) 2022. [DOI: 10.1016/j.nefroe.2022.07.003] [Reference Citation Analysis]
|
| 459 |
Waijer SW, Vart P, Cherney DZI, Chertow GM, Jongs N, Langkilde AM, Mann JFE, Mosenzon O, McMurray JJV, Rossing P, Correa-Rotter R, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia 2022;65:1085-97. [PMID: 35445820 DOI: 10.1007/s00125-022-05694-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 460 |
Lim JH, Kwon S, Jeon Y, Kim YH, Kwon H, Kim YS, Lee H, Kim YL, Kim CD, Park SH, Lee JS, Yoo KD, Son HE, Jeong JC, Lee J, Lee JP, Cho JH. The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients. Transplantation 2022. [PMID: 35768908 DOI: 10.1097/TP.0000000000004228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 461 |
Nusca A, Piccirillo F, Bernardini F, De Filippis A, Coletti F, Mangiacapra F, Ricottini E, Melfi R, Gallo P, Cammalleri V, Napoli N, Ussia GP, Grigioni F. Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. IJMS 2022;23:7261. [DOI: 10.3390/ijms23137261] [Reference Citation Analysis]
|
| 462 |
Issa VS. Is There Room for New Drugs in the Treatment of Advanced Heart Failure: SGLT2i? ABC: Heart Failure & Cardiomyopathy 2022;2:195-197. [DOI: 10.36660/abchf.20220030] [Reference Citation Analysis]
|
| 463 |
Ahmed R, de Souza RJ, Li V, Anand SS. Assessing non-white ethnic participation in type 2 diabetes mellitus randomized clinical trials: A Meta-Analysis.. [DOI: 10.1101/2022.06.28.22275821] [Reference Citation Analysis]
|
| 464 |
Bae JP, Kadziola ZA, Liu D, Chinthammit C, Boye KS, Mather KJ. An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations. Diabetes Ther 2022. [PMID: 35764911 DOI: 10.1007/s13300-022-01289-x] [Reference Citation Analysis]
|
| 465 |
Younes AM, Salem M, Maraey A, Nomigolzar S, Sewell K, Khalil M, Elzanaty A, Saeyeldin A, Dar M. Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis. Int J Cardiol 2022:S0167-5273(22)01012-9. [PMID: 35777490 DOI: 10.1016/j.ijcard.2022.06.059] [Reference Citation Analysis]
|
| 466 |
Williams BM, Cliff CL, Lee K, Squires PE, Hills CE. The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy. Front Physiol 2022;13:907504. [PMID: 35755447 DOI: 10.3389/fphys.2022.907504] [Reference Citation Analysis]
|
| 467 |
Kroopnick JM, Davis SN. The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes. Expert Opin Pharmacother 2022;:1-13. [PMID: 35765193 DOI: 10.1080/14656566.2022.2089021] [Reference Citation Analysis]
|
| 468 |
Shetty SS, Krumerman A. Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions. Cardiovasc Diabetol 2022;21:119. [PMID: 35764968 DOI: 10.1186/s12933-022-01552-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 469 |
Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, Yeh YH, Kuo CT, See LC, Lip GYH. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovasc Diabetol 2022;21:118. [PMID: 35765074 DOI: 10.1186/s12933-022-01549-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 470 |
Almutairi M, Chan JSF, Ussher JR. New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease. Front Physiol 2022;13:904626. [DOI: 10.3389/fphys.2022.904626] [Reference Citation Analysis]
|
| 471 |
Mody R, Meyers J, Yu M, Davis K, Levine JA. Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Curr Med Res Opin 2022;:1-11. [PMID: 35758147 DOI: 10.1080/03007995.2022.2085962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 472 |
Fisher, M, Llano, and A, Mckay G. SGLT2 Inhibitors. Diabetes Drug Notes 2022. [DOI: 10.1002/9781119785033.ch5] [Reference Citation Analysis]
|
| 473 |
Palma R, Pronio A, Romeo M, Scognamiglio F, Ventriglia L, Ormando VM, Lamazza A, Pontone S, Federico A, Dallio M. The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. JCM 2022;11:3649. [DOI: 10.3390/jcm11133649] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 474 |
Pérez-belmonte LM, Sanz-cánovas J, García de Lucas MD, Ricci M, Avilés-bueno B, Cobos-palacios L, Pérez-velasco MA, López-sampalo A, Bernal-lópez MR, Jansen-chaparro S, Miramontes-gonzález JP, Gómez-huelgas R. Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Front Endocrinol 2022;13:851035. [DOI: 10.3389/fendo.2022.851035] [Reference Citation Analysis]
|
| 475 |
Baker HE, Tune JD, Mather KJ, Blaettner BS, Clark HE, Li F, Li X, Kowala MC, Fliegel L, Goodwill AG. Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na+/H+ exchanger-1. Int J Cardiol 2022:S0167-5273(22)01006-3. [PMID: 35753619 DOI: 10.1016/j.ijcard.2022.06.054] [Reference Citation Analysis]
|
| 476 |
Wan Azman SS, Sukor N, Abu Shamsi MY, Ismail I, Kamaruddin NA. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. Front Endocrinol (Lausanne) 2022;13:867647. [PMID: 35712244 DOI: 10.3389/fendo.2022.867647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 477 |
Hanson P, Arkill KP, Merry CL, Hussain MS, Meersmann T, Randeva HS, Pavlovskaya GE, O'Hare P, Barber TM. Novel perspectives of sodium handling in type 2 diabetes mellitus. Expert Rev Endocrinol Metab 2022;:1-9. [PMID: 35729865 DOI: 10.1080/17446651.2022.2092094] [Reference Citation Analysis]
|
| 478 |
Noel JA, Hougen I, Sood MM. The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD. Front Neurol 2022;13:823569. [DOI: 10.3389/fneur.2022.823569] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 479 |
Matsusaka Y, Chen X, Arias-loza P, Werner RA, Nose N, Sasaki T, Rowe SP, Pomper MG, Lapa C, Higuchi T, Vasdev N. In Vivo Functional Assessment of Sodium-Glucose Cotransporters (SGLTs) Using [18F]Me4FDG PET in Rats. Molecular Imaging 2022;2022:1-7. [DOI: 10.1155/2022/4635171] [Reference Citation Analysis]
|
| 480 |
Madan S, Norman PA, Wald R, Neyra JA, Meraz-Muñoz A, Harel Z, Silver SA. Use of Guideline-Based Therapy for Diabetes, Coronary Artery Disease, and Chronic Kidney Disease After Acute Kidney Injury: A Retrospective Observational Study. Can J Kidney Health Dis 2022;9:20543581221103682. [PMID: 35721395 DOI: 10.1177/20543581221103682] [Reference Citation Analysis]
|
| 481 |
Sinclair AJ, Pennells D, Abdelhafiz AH. Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus-a choice determined by metabolic phenotype. Aging Clin Exp Res 2022. [PMID: 35723859 DOI: 10.1007/s40520-022-02142-8] [Reference Citation Analysis]
|
| 482 |
Correale M, Mazzeo P, Tricarico L, Croella F, Fortunato M, Magnesa M, Amatruda M, Alfieri S, Ferrara S, Ceci V, Dattilo G, Mele M, Iacoviello M, Brunetti ND. Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction. Clin Drug Investig 2022. [PMID: 35726047 DOI: 10.1007/s40261-022-01166-2] [Reference Citation Analysis]
|
| 483 |
Hua R, Ding N, Guo H, Wu Y, Yuan Z, Li T. Contrast-Induced Acute Kidney Injury in Patients on SGLT2 Inhibitors Undergoing Percutaneous Coronary Interventions: A Propensity-Matched Analysis. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.918167] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 484 |
Salukhov VV, Kovalevskaya EA. Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-10-10-21] [Reference Citation Analysis]
|
| 485 |
Song ZH, Wang XL, Wang XF, Liu J, Luo SQ, Xu SS, Cheng X, Bai J, Dong LM, Zhang C, Zhou JB. Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective. Front Endocrinol (Lausanne) 2022;13:900114. [PMID: 35707460 DOI: 10.3389/fendo.2022.900114] [Reference Citation Analysis]
|
| 486 |
Oe Y, Vallon V. The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1. Kidney and Dialysis 2022;2:349-368. [DOI: 10.3390/kidneydial2020032] [Reference Citation Analysis]
|
| 487 |
Zhang F, Ji L, Hong T, Guo L, Li Y, Zhu Z, Liu X, Liu F, Tang L, Zhang Y, Li J, Lü Q, Tong N. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. J Evid Based Med 2022. [PMID: 35715995 DOI: 10.1111/jebm.12474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 488 |
Ishibashi F, Kosaka A, Tavakoli M. Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study. Front Endocrinol 2022;13:864332. [DOI: 10.3389/fendo.2022.864332] [Reference Citation Analysis]
|
| 489 |
Au PCM, Tan KCB, Cheung BMY, Wong ICK, Li HL, Cheung CL. Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes. J Clin Endocrinol Metab 2022;107:e2962-70. [PMID: 35303075 DOI: 10.1210/clinem/dgac164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 490 |
Irion CI, Williams M, Capcha JC, Eisenberg T, Lambert G, Takeuchi LM, Seo G, Yousefi K, Kanashiro-Takeuchi R, Webster KA, Young KC, Hare JM, Shehadeh LA. Col4a3-/- Mice on Balb/C Background Have Less Severe Cardiorespiratory Phenotype and SGLT2 Over-Expression Compared to 129x1/SvJ and C57Bl/6 Backgrounds. Int J Mol Sci 2022;23:6674. [PMID: 35743114 DOI: 10.3390/ijms23126674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 491 |
Kim CH, Hwang IC, Choi HM, Ahn CH, Yoon YE, Cho GY. Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus. Int J Cardiol 2022:S0167-5273(22)00927-5. [PMID: 35716949 DOI: 10.1016/j.ijcard.2022.06.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 492 |
Echouffo-Tcheugui JB, Ndumele CE, Zhang S, Florido R, Matsushita K, Coresh J, Skali H, Shah AM, Selvin E. Diabetes and Progression of Heart Failure: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol 2022;79:2285-93. [PMID: 35680178 DOI: 10.1016/j.jacc.2022.03.378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 493 |
Jhalani NB. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review. Adv Ther 2022. [PMID: 35699903 DOI: 10.1007/s12325-022-02169-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 494 |
Olszewski J, Kozon K, Patyra A. Flozins in heart failure – a new reimbursement indication. pps 2022;20:19-25. [DOI: 10.56782/pps.35] [Reference Citation Analysis]
|
| 495 |
de Sá JR, Rangel EB, Canani LH, Bauer AC, Escott GM, Zelmanovitz T, Bertoluci MC, Silveiro SP. The 2021-2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD. Diabetol Metab Syndr 2022;14:81. [PMID: 35690830 DOI: 10.1186/s13098-022-00843-8] [Reference Citation Analysis]
|
| 496 |
Przezak A, Bielka W, Pawlik A. Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities. Int J Mol Sci 2022;23:6500. [PMID: 35742943 DOI: 10.3390/ijms23126500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 497 |
Yan H, Wen Y, Liu B. Renoprotective mechanisms of SGLT2 inhibitor in diabetic kidney disease. Diabetic Nephropathy 2022;0. [DOI: 10.2478/dine-2022-0009] [Reference Citation Analysis]
|
| 498 |
Salukhov VV, Galstyan GR, Ilyinskay TA. Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives. Diabetes mellitus 2022;25:275-287. [DOI: 10.14341/dm12855] [Reference Citation Analysis]
|
| 499 |
Ni X, Zhang L, Feng X, Tang L. New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. Front Pharmacol 2022;13:877797. [DOI: 10.3389/fphar.2022.877797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 500 |
Seo B, Su J, Song Y. Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies. Eur J Clin Pharmacol. [DOI: 10.1007/s00228-022-03327-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 501 |
Power DA, Rosenson RS. Secondary Prevention of Atherosclerotic Cardiovascular Disease. In: Dangas GD, Di Mario C, Thiele H, Barlis P, Addo T, Claessen B, Hengstenberg C, Kipshidze N, editors. Interventional Cardiology. Wiley; 2022. pp. 475-82. [DOI: 10.1002/9781119697367.ch44] [Reference Citation Analysis]
|
| 502 |
Cheng K, Guo Q, Yang W, Wang Y, Sun Z, Wu H. Mapping Knowledge Landscapes and Emerging Trends of the Links Between Bone Metabolism and Diabetes Mellitus: A Bibliometric Analysis From 2000 to 2021. Front Public Health 2022;10:918483. [DOI: 10.3389/fpubh.2022.918483] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 503 |
Morris D. Updated NICE guidelines on type 2 diabetes – what's new? Independent Nurse 2022;2022:12-16. [DOI: 10.12968/indn.2022.6.12] [Reference Citation Analysis]
|
| 504 |
Alcidi G, Goffredo G, Correale M, Brunetti ND, Iacoviello M. Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. J Clin Med 2022;11:3192. [PMID: 35683578 DOI: 10.3390/jcm11113192] [Reference Citation Analysis]
|
| 505 |
Al Rifai M, Newby LK, Nair AP, Misra A, Rogers JG, Fedson S, Virani SS. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? Curr Atheroscler Rep 2022. [PMID: 35653033 DOI: 10.1007/s11883-022-01038-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 506 |
Wang X, Zhang C; Cardiovascular Group, Geriatrics Branch, Chinese Medical Association., Editing Group of the Chinese Expert Consensus on the Diagnosis and Treatment of Chronic Heart Failure in Elderly Patients. Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021). Aging Med (Milton) 2022;5:78-93. [PMID: 35792618 DOI: 10.1002/agm2.12215] [Reference Citation Analysis]
|
| 507 |
Zhu S, Bai Q, Li L, Xu T. Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.05.057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 508 |
Yamaji K, Shiomi H, Morimoto T, Matsumura-nakano Y, Ehara N, Sakamoto H, Takeji Y, Yoshikawa Y, Yamamoto K, Kato ET, Imada K, Tada T, Taniguchi R, Nishikawa R, Tada T, Uegaito T, Ogawa T, Yamada M, Takeda T, Eizawa H, Tamura N, Tambara K, Suwa S, Shirotani M, Tamura T, Inoko M, Nishizawa J, Natsuaki M, Sakai H, Yamamoto T, Kanemitsu N, Ohno N, Ishii K, Marui A, Tsuneyoshi H, Terai Y, Nakayama S, Yamazaki K, Takahashi M, Tamura T, Esaki J, Miki S, Onodera T, Mabuchi H, Furukawa Y, Tanaka M, Komiya T, Soga Y, Hanyu M, Domei T, Ando K, Kadota K, Minatoya K, Nakagawa Y, Kimura T, Kimura T, Shiomi H, Matsuda M, Takeuchi Y, Mitsuoka H, Uegaito T, Nakagawa Y, Tamura T, Konishi T, Ootani S, Fujiwara H, Takatsu Y, Sato Y, Taniguchi R, Kataoka K, Inoko M, Nohara R, Nakano K, Miyamoto S, Kunihiko N, Murakami T, Takeda T, Ishida K, Nobuyoshi M, Yamaji K, Yasumoto H, Iwabuchi M, Ando K, Domei T, Kato M, Tatami R, Shirotani M, Hattori R, Kita T, Furukawa Y, Ehara N, Kihara Y, Eizawa H, Kato H, Ishii K, Aoyama T, Sakurai T, Kawanami M, Suyama T, Tada E, Tanaka M, Inada T, Uzui H, Nakano A, Lee J, Onodera T, Takizawa A, Ryuzo N, Shinoda E, Takahashi M, Yamada M, Horie M, Yamamoto T, Takashima H, Sakai H, Tamura T, Toyofuku M, Kotoura H, Miura A, Takahashi M, Matoba Y, Takumi T, Tei C, Hamasaki S, Doi O, Kambara H, Kaburagi S, Sakamoto H, Tada T, Mitsudo K, Kadota K, Tada T, Miki S, Mizoguchi T, Akira Y, Kaneda K, Ogawa H, Sugamura K, Sugiyama S, Aoyama T, Doyama K, Araki M, Hattori R, Suwa S, Sakata R, Ikeda T, Marui A, Minatoya K, Yamazaki K, Onoe M, Ogawa T, Yamanaka K, Iwakura A, Ohno N, Fujiwara K, Hanyu M, Hanyu M, Soga K, Marui A, Matsushita T, Nishiwaki N, Yoshida Y, Tamura N, Okada Y, Nasu M, Koyama T, Nakayama S, Tanaka K, Koshiji T, Morioka K, Shimamoto M, Yamazaki F, Terai Y, Nishizawa J, Aota M, Kanemitsu N, Hara H, Tabata T, Imoto Y, Yamamoto H, Matsuda K, Nara M, Tsuneyoshi H, Komiya T, Nakajima H, Esaki J, Kawasuji M, Moriyama S, Tambara K, Arimura S, Fujino Y, Hanazawa M, Hibi C, Kato R, Kinoshita Y, Kitagawa K, Kitamura M, Kuwahara T, Sachiko M, Miki I, Minematsu S, Nishida S, Okamoto N, Saeki A, Sasae H, Sato Y, Takahashi A, Takinami E, Tezuka S, Tsuda M, Tsumori M, Uchida Y, Yamamoto Y, Yamauchi M, Yamazaki I, Yoshimoto M, Abe M, Fuki M, Hayano M, Kato E, Kato Y, Matsumura-nakano Y, Nakajima T, Nakatsuma K, Natsuaki M, Shiomi H, Tada T, Takeji Y, Tazaki J, Tokushige A, Watanabe H, Yaku H, Yamaji K, Yamamoto E, Yamamoto K, Yamashita Y, Yoshikawa Y. Modifiers of the Risk of Diabetes for Long-Term Outcomes After Coronary Revascularization. JACC: Asia 2022;2:294-308. [DOI: 10.1016/j.jacasi.2021.12.012] [Reference Citation Analysis]
|
| 509 |
Lyu B, Singh T, Astor BC. Epidemiology and Outcomes for the Chronic Kidney Disease. nephsap 2022;21:121-134. [DOI: 10.1681/nsap.00042022] [Reference Citation Analysis]
|
| 510 |
Xiang Y. Integrating traditional Chinese medicine and western medicine for cardiovascular disease. Sci Sin -Vitae 2022;52:832-839. [DOI: 10.1360/ssv-2021-0388] [Reference Citation Analysis]
|
| 511 |
Cagliostro M, Hundal P, Ting P, Patel S, Sudarshan S, Thomas J, Morris K, Mancini DM, Moss N, Lala A, Ravichandran A, Mitter SS. Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus. American Heart Journal Plus: Cardiology Research and Practice 2022;18:100154. [DOI: 10.1016/j.ahjo.2022.100154] [Reference Citation Analysis]
|
| 512 |
Rhee EJ. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone? Endocrinol Metab (Seoul) 2022;37:415-29. [PMID: 35798548 DOI: 10.3803/EnM.2022.304] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 513 |
Bae J, Liu D, Chinthammit C, Kadziola Z, Boye K, Mather K. Type 2 diabetes pharmacotherapy trends in high-risk subgroups. Diabetes Obes Metab 2022;24:1166-71. [PMID: 35243741 DOI: 10.1111/dom.14678] [Reference Citation Analysis]
|
| 514 |
Shen X, Shen X. Promise of sodium-glucose co-transporter-2 inhibitors in heart failure with mildly reduced ejection fraction. ESC Heart Fail 2022. [PMID: 35642772 DOI: 10.1002/ehf2.14005] [Reference Citation Analysis]
|
| 515 |
Balletshofer B, Böckler D, Diener H, Heckenkamp J, Ito W, Katoh M, Lawall H, Malyar N, Oberländer Y, Reimer P, Rittig K, Zähringer M, die DGG, die DGA, die DeGIR, die DDG. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. Diabetologie 2022;18:402-411. [DOI: 10.1007/s11428-022-00904-6] [Reference Citation Analysis]
|
| 516 |
Shimizu N, Ogawa A, Hayashi A, Shichiri M. Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors. Journal of Diabetes and its Complications 2022. [DOI: 10.1016/j.jdiacomp.2022.108225] [Reference Citation Analysis]
|
| 517 |
Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, Cannon CP, Mahaffey KW, Schutte AE, Neal B, Arnott C. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab 2022;24:1072-83. [PMID: 35166429 DOI: 10.1111/dom.14671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 518 |
Hammond MM, Everitt IK, Khan SS. New strategies and therapies for the prevention of heart failure in high-risk patients. Clin Cardiol 2022;45 Suppl 1:S13-25. [PMID: 35789013 DOI: 10.1002/clc.23839] [Reference Citation Analysis]
|
| 519 |
O’brien H, Travis C. Pharmacology. Primary Care: Clinics in Office Practice 2022;49:315-326. [DOI: 10.1016/j.pop.2021.11.010] [Reference Citation Analysis]
|
| 520 |
Goh LGH, Sun J, Ong BSK, Khoo D, Sum CF, Ng K. Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study. J Diabetes Metab Disord 2022;21:521-55. [PMID: 35673518 DOI: 10.1007/s40200-022-01004-4] [Reference Citation Analysis]
|
| 521 |
Schechter M, Fischer M, Mosenzon O. Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach. Diabetes Obes Metab 2022;24:969-82. [PMID: 35212443 DOI: 10.1111/dom.14675] [Reference Citation Analysis]
|
| 522 |
Kubota Y, Shimizu W. Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. JACC: Asia 2022;2:287-293. [DOI: 10.1016/j.jacasi.2022.03.009] [Reference Citation Analysis]
|
| 523 |
Scheen AJ. Inhibiteurs des SGLT2 et risque d’amputations des membres inférieurs : plus de peur que de mal ? Médecine des Maladies Métaboliques 2022;16:336-342. [DOI: 10.1016/j.mmm.2022.01.015] [Reference Citation Analysis]
|
| 524 |
Aberer F, Pieber TR, Eckstein ML, Sourij H, Moser O. Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. Pharmaceutics 2022;14:1180. [DOI: 10.3390/pharmaceutics14061180] [Reference Citation Analysis]
|
| 525 |
Yagyu H, Shimano H. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. J Diabetes Investig 2022. [PMID: 35638331 DOI: 10.1111/jdi.13859] [Reference Citation Analysis]
|
| 526 |
Sen T, Koshino A, Neal B, Bijlsma MJ, Arnott C, Li J, Hansen MK, Ix JH, Heerspink HJL. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial. Diabetes Obes Metab 2022. [PMID: 35635326 DOI: 10.1111/dom.14779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 527 |
Bonanad C, Fernández-Olmo R, García-Blas S, Alarcon JA, Díez-Villanueva P, Mansilla CR, García-Pardo H, Toledo P, Ayesta A, Pereira E, Carol A, Castro-Conde A, de Pablo-Zarzoso C, Martínez-Sellés M, Arrarte V, Campuzano R, Ariza-Solé A. Cardiovascular prevention in elderly patients. J Geriatr Cardiol 2022;19:377-92. [PMID: 35722032 DOI: 10.11909/j.issn.1671-5411.2022.05.004] [Reference Citation Analysis]
|
| 528 |
Liu H, Sridhar VS, Perkins BA, Rosenstock J, Cherney DZI. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. Curr Diab Rep 2022. [PMID: 35633439 DOI: 10.1007/s11892-022-01471-2] [Reference Citation Analysis]
|
| 529 |
Young TK, Toussaint ND, Di Tanna GL, Arnott C, Hockham C, Kang A, Schutte AE, Perkovic V, Mahaffey KW, Agarwal R, Bakris GL, Charytan DM, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Zhang H, Jardine MJ, Infante M. Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. Journal of Diabetes Research 2022;2022:1-12. [DOI: 10.1155/2022/9998891] [Reference Citation Analysis]
|
| 530 |
Lapteva AE, Nasonova SN, Zhirov IV, Tereshchenko SN. SGLT2 inhibitors in acute decompensated heart failure, what do we know? Terapevticheskii arkhiv 2022;94:565-71. [DOI: 10.26442/00403660.2022.04.201449] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 531 |
Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med 2022;386:2024-34. [PMID: 35613023 DOI: 10.1056/NEJMra2115011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 16] [Article Influence: 43.0] [Reference Citation Analysis]
|
| 532 |
Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol 2022;21:83. [PMID: 35614469 DOI: 10.1186/s12933-022-01512-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 533 |
Udell JA, Jones WS, Petrie MC, Harrington J, Anker SD, Bhatt DL, Hernandez AF, Butler J. Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week. J Am Coll Cardiol 2022;79:2058-68. [PMID: 35589167 DOI: 10.1016/j.jacc.2022.03.353] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 534 |
Wang A, Li Z, Zhuo S, Gao F, Zhang H, Zhang Z, Ren G, Ma X. Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. Front Cardiovasc Med 2022;9:857952. [DOI: 10.3389/fcvm.2022.857952] [Reference Citation Analysis]
|
| 535 |
Segar MW, Kolkailah AA, Frederich R, Pong A, Cannon CP, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Liu CC, Maldonado M, Liu J, Cater NB, Pandey A, Cherney DZI. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes. Diabetes Obes Metab 2022. [PMID: 35603908 DOI: 10.1111/dom.14769] [Reference Citation Analysis]
|
| 536 |
Reis J, Teixeira AR, Gonçalves AV, Moreira RI, Silva TP, Timóteo AT, Ferreira RC. Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients. J Clin Med 2022;11. [PMID: 35629062 DOI: 10.3390/jcm11102935] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 537 |
Yang A, Chen H, Mirabelli M. Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes. Journal of Diabetes Research 2022;2022:1-10. [DOI: 10.1155/2022/2420857] [Reference Citation Analysis]
|
| 538 |
Lin S, Chen C, Wang K, Wu K, Li S. Association of Dietary Fish and n-3 Unsaturated Fatty Acid Consumption with Diabetic Nephropathy from a District Hospital in Northern Taiwan. Nutrients 2022;14:2148. [DOI: 10.3390/nu14102148] [Reference Citation Analysis]
|
| 539 |
Provenzano M, Maritati F, Abenavoli C, Bini C, Corradetti V, La Manna G, Comai G. Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease. Int J Mol Sci 2022;23:5719. [PMID: 35628528 DOI: 10.3390/ijms23105719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 540 |
Li C, Yu J, Hockham C, Perkovic V, Neuen BL, Badve SV, Houston L, Lee VYJ, Barraclough JY, Fletcher RA, Mahaffey KW, Heerspink HJL, Cannon CP, Neal B, Arnott C. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. Diabetes Obes Metab 2022. [PMID: 35589614 DOI: 10.1111/dom.14772] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 541 |
Yin Z, Zheng H, Guo Z. Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.902923] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 542 |
De Nicola L, Cozzolino M, Genovesi S, Gesualdo L, Grandaliano G, Pontremoli R. Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease? J Nephrol 2022. [PMID: 35583597 DOI: 10.1007/s40620-022-01336-7] [Reference Citation Analysis]
|
| 543 |
Nikolaou PE, Mylonas N, Makridakis M, Makrecka-Kuka M, Iliou A, Zerikiotis S, Efentakis P, Kampoukos S, Kostomitsopoulos N, Vilskersts R, Ikonomidis I, Lambadiari V, Zuurbier CJ, Latosinska A, Vlahou A, Dimitriadis G, Iliodromitis EK, Andreadou I. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect? Basic Res Cardiol 2022;117:27. [PMID: 35581445 DOI: 10.1007/s00395-022-00934-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 544 |
Rotbain Curovic V, Houlind MB, Hansen TW, Eugen-Olsen J, Laursen JC, Eickhoff MK, Persson F, Rossing P. Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor. Front Pharmacol 2022;13:799915. [PMID: 35571091 DOI: 10.3389/fphar.2022.799915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 545 |
Akuta N, Kawamura Y, Fujiyama S, Saito S, Muraishi N, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kumada H. Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study. Hepatol Commun 2022. [PMID: 35581956 DOI: 10.1002/hep4.2005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 546 |
Rosa CM, Campos DHS, Reyes DRA, Damatto FC, Kurosaki LY, Pagan LU, Gomes MJ, Corrêa CR, Fernandes AAH, Okoshi MP, Okoshi K. Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus. Antioxidants (Basel) 2022;11. [PMID: 35624845 DOI: 10.3390/antiox11050982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 547 |
Chen G, Li X, Cui Q, Zhou Y, Zhao B, Mei D, Xuemei. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study. Int Urol Nephrol 2022. [PMID: 35579781 DOI: 10.1007/s11255-022-03211-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 548 |
Martens P, Mathieu C, Vanassche T. The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. Acta Cardiol 2022;:1-13. [PMID: 35575294 DOI: 10.1080/00015385.2022.2076307] [Reference Citation Analysis]
|
| 549 |
Yoneda M, Kobayashi T, Honda Y, Ogawa Y, Kessoku T, Imajo K, Nogami A, Taguri M, Kirikoshi H, Saito S, Nakajima A. Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. Hepatol Commun 2022. [PMID: 35578445 DOI: 10.1002/hep4.1993] [Reference Citation Analysis]
|
| 550 |
Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol 2022;21:74. [PMID: 35568946 DOI: 10.1186/s12933-022-01516-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 551 |
Chen X, Yang Q, Bai W, Yao W, Liu L, Xing Y, Meng C, Qi P, Dang Y, Qi X. Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure. Front Pharmacol 2022;13:873108. [DOI: 10.3389/fphar.2022.873108] [Reference Citation Analysis]
|
| 552 |
Mukhopadhyay P, Sanyal D, Chatterjee P, Pandit K, Ghosh S. Different SGLT 2 inhibitors: Can they prevent death? Endocr Pract 2022:S1530-891X(22)00513-4. [PMID: 35569736 DOI: 10.1016/j.eprac.2022.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 553 |
McCann M, O'Brien A, Larbalestier R, Davis T. Sodium-glucose cotransport-2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management. Intern Med J 2022;52:876-9. [PMID: 35538006 DOI: 10.1111/imj.15772] [Reference Citation Analysis]
|
| 554 |
Moneer O, Daly G, Skydel JJ, Nyhan K, Lurie P, Ross JS, Wallach JD. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study. BMJ 2022;377:e069400. [PMID: 35537738 DOI: 10.1136/bmj-2021-069400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 555 |
Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, Langkilde AM, Mahaffey KW, McGuire DK, Neal B, Perkovic V, Pong A, Sabatine MS, Raz I, Toyama T, Wanner C, Wheeler DC, Wiviott SD, Zinman B, Heerspink HJL. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation 2022;145:1460-70. [PMID: 35394821 DOI: 10.1161/CIRCULATIONAHA.121.057736] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 556 |
Oraii A, Healey JS, Benz AP, Pandey AK, Wong JA, Fonguh S, Wang J, Conen D, Gerstein H, Connolly SJ, McIntyre WF. Association of Eligibility for a Sodium-Glucose Co-transporter 2 Inhibitor and Cardiovascular Events in Patients with Atrial Fibrillation. Can J Cardiol 2022:S0828-282X(22)00288-4. [PMID: 35562018 DOI: 10.1016/j.cjca.2022.05.004] [Reference Citation Analysis]
|
| 557 |
Kulvinder Kochar K, Gautam A, Mandeep S. An update on the approaches of avoidance of propagation of chronic kidney disease resulting in reversal or possible need or avoidance of kidney transplantation - a systematic review. J Clini Nephrol 2022;6:040-057. [DOI: 10.29328/journal.jcn.1001089] [Reference Citation Analysis]
|
| 558 |
Hsu WC, Lin CS, Chen JF, Chang CM. The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus. J Clin Med 2022;11. [PMID: 35566779 DOI: 10.3390/jcm11092653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 559 |
Kovalchuk A. V., Zinich O. V., Prybyla O. V., Kushnareva N. M., Kovalchuk V. M., Shyshkan-shyshova K. O.. OSTEOCALCIN ROLE IN THE REGULATION OF INSULIN SECRETION AND OSTEOTROPIC EFFECTS OF DIFFERENT CLASSES OF ANTI-DIABETIC DRUGS (LITERATURE REVIEW AND OWN RESEARCH). RS Global - World Science 2022. [DOI: 10.31435/rsglobal_ws/30042022/7803] [Reference Citation Analysis]
|
| 560 |
Block TJ, Batu D, Cooper ME. Recent advances in the pharmacotherapeutic management of diabetic kidney disease. Expert Opin Pharmacother 2022;:1-13. [PMID: 35522659 DOI: 10.1080/14656566.2022.2054699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 561 |
Nakamura A. Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic β-Cell Mass and Function. Int J Mol Sci 2022;23:5104. [PMID: 35563495 DOI: 10.3390/ijms23095104] [Reference Citation Analysis]
|
| 562 |
La Grotta R, de Candia P, Olivieri F, Matacchione G, Giuliani A, Rippo MR, Tagliabue E, Mancino M, Rispoli F, Ferroni S, Berra CC, Ceriello A, Prattichizzo F. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cell Mol Life Sci 2022;79:273. [PMID: 35503137 DOI: 10.1007/s00018-022-04289-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 563 |
Borkum M, Jamal A, Suneet Singh R, Levin A. The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients. Perit Dial Int. [DOI: 10.1177/08968608221096556] [Reference Citation Analysis]
|
| 564 |
Jeon H, Lee A, Ha K. Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications. BioChip J. [DOI: 10.1007/s13206-022-00057-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 565 |
Miyazaki R, Miyagi K. Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases. BMC Nephrol 2022;23:168. [PMID: 35501824 DOI: 10.1186/s12882-022-02793-9] [Reference Citation Analysis]
|
| 566 |
Evans M, Morgan AR, Bain SC, Davies S, Dashora U, Sinha S, Seidu S, Patel DC, Beba H, Strain WD. Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Ther 2022;13:889-911. [PMID: 35349120 DOI: 10.1007/s13300-022-01242-y] [Reference Citation Analysis]
|
| 567 |
Teo YN, Ting AZH, Teo YH, Chong EY, Tan JTA, Syn NL, Chia AZQ, Ong HT, Cheong AJY, Li TY, Poh KK, Yeo TC, Chan MY, Wong RCC, Chai P, Sia CH. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials. Am J Cardiovasc Drugs 2022;22:299-323. [PMID: 35316484 DOI: 10.1007/s40256-022-00528-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 568 |
Borah AK, Ahmed SA, Borah JC. Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy. Phytomedicine Plus 2022;2:100225. [DOI: 10.1016/j.phyplu.2022.100225] [Reference Citation Analysis]
|
| 569 |
Barrios V, Campuzano Ruiz R, Castro Conde A, Cosín-sales J. Conocimiento del cardiólogo clínico sobre diabetes mellitus tipo 2 de alto riesgo. ¿Qué sabemos y cómo podemos mejorar? REC: CardioClinics 2022. [DOI: 10.1016/j.rccl.2022.04.003] [Reference Citation Analysis]
|
| 570 |
Yau K, Dharia A, Alrowiyti I, Cherney DZ. Prescribing SGLT2 Inhibitors in Patients with Chronic Kidney Disease: Expanding Indications and Practical Considerations. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.04.094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 571 |
Napoli R, D’assante R, Miniero M, Salzano A, Cittadini A. Anabolic Deficiencies in Heart Failure. Cardiology Clinics 2022;40:149-59. [DOI: 10.1016/j.ccl.2021.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 572 |
Heiss C, Olinic DM, Belch JJF, Brodmann M, Mazzolai L, Stanek A, Madaric J, Krentz A, Schlager O, Lichtenberg M, Frank U; European Society of Vascular Medicine. Management of chronic peripheral artery disease patients with indication for endovascular revascularization. Vasa 2022;51:121-37. [PMID: 35418243 DOI: 10.1024/0301-1526/a000998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 573 |
Xie B, Ramirez W, Mills AM, Huckestein BR, Anderson M, Pangburn MM, Lang EY, Mullet SJ, Chuan BW, Guo L, Sipula I, O'donnell CP, Wendell SG, Scott I, Jurczak MJ. Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice. Current Research in Physiology 2022. [DOI: 10.1016/j.crphys.2022.05.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 574 |
Di Fusco SA, Gronda E, Mocini E, Lucà F, Bisceglia I, De Luca L, Caldarola P, Cipriani M, Corda M, De Nardo A, Francese GM, Napoletano C, Navazio A, Riccio C, Roncon L, Tizzani E, Nardi F, Urbinati S, Valente S, Gulizia MM, Gabrielli D, Oliva F, Imperoli G, Colivicchi F. ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation. Eur Heart J Suppl 2022;24:C272-7. [PMID: 35602255 DOI: 10.1093/eurheartj/suac017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 575 |
Mostaza J, Pintó X, Armario P, Masana L, Real J, Valdivielso P, Arrobas-velilla T, Baeza-trinidad R, Calmarza P, Cebollada J, Civera-andrés M, Cuende Melero J, Díaz-díaz J, Fernández Pardo J, Guijarro C, Jericó C, Laclaustra M, Lahoz C, López-miranda J, Martínez-hervás S, Muñiz-grijalvo O, Páramo J, Pascual V, Pedro-botet J, Pérez-martínez P, Plana N, Puzo J, Sánchez Chaparro M, Vila L. SEA 2022 standards for the comprehensive control of cardiovascular risk. Clínica e Investigación en Arteriosclerosis (English Edition) 2022;34:130-179. [DOI: 10.1016/j.artere.2022.06.002] [Reference Citation Analysis]
|
| 576 |
Pilla SJ, Shahidzadeh Yazdi Z, Taylor SI. Individualized Glycemic Goals for Older Adults Are a Moving Target. Diabetes Care 2022;45:1029-31. [PMID: 35561130 DOI: 10.2337/dci22-0004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 577 |
Chadha M, Das AK, Deb P, Gangopadhyay KK, Joshi S, Kesavadev J, Kovil R, Kumar S, Misra A, Mohan V. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting. Diabetes Ther 2022;13:1097-114. [PMID: 35334083 DOI: 10.1007/s13300-022-01219-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 578 |
Akwo EA, Chen H, Liu G, Triozzi JL, Tao R, Yu Z, Chung CP, Giri A, Ikizler TA, Stein CM, Siew ED, Feng Q, Robinson-cohen C, Hung AM. Phenome-Wide Association Study of UMOD gene variants and differential associations with clinical outcomes across populations in the Million Veteran Program a multiethnic biobank. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.05.011] [Reference Citation Analysis]
|
| 579 |
Rhee JJ, Han J, Montez-Rath ME, Kim SH, Cullen MR, Stafford RS, Winkelmayer WC, Chertow GM. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease. Diabetes Obes Metab 2022;24:928-37. [PMID: 35118793 DOI: 10.1111/dom.14657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 580 |
Mostaza JM, Pintó X, Armario P, Masana L, Real JT, Valdivielso P, Arrobas-Velilla T, Baeza-Trinidad R, Calmarza P, Cebollada J, Civera-Andrés M, Cuende Melero JI, Díaz-Díaz JL, Fernández Pardo J, Guijarro C, Jericó C, Laclaustra M, Lahoz C, López-Miranda J, Martínez-Hervás S, Muñiz-Grijalvo O, Páramo JA, Pascual V, Pedro-Botet J, Pérez-Martínez P, Plana N, Puzo J, Sánchez Chaparro MÁ, Vila L. SEA 2022 Standards for Global Control of Cardiovascular Risk. Clin Investig Arterioscler 2022;34:130-79. [PMID: 35090775 DOI: 10.1016/j.arteri.2021.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 581 |
Blüher M, Ceriello A, Davies M, Rodbard H, Sattar N, Schnell O, Tonchevska E, Giorgino F. Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come? Endocrino Diabet & Metabol 2022;5. [DOI: 10.1002/edm2.330] [Reference Citation Analysis]
|
| 582 |
Wilding JPH, Evans M, Fernando K, Gorriz JL, Cebrian A, Diggle J, Hicks D, James J, Newland-Jones P, Ali A, Bain S, Da Porto A, Patel D, Viljoen A, Wheeler DC, Del Prato S. The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Ther 2022;13:847-72. [PMID: 35307801 DOI: 10.1007/s13300-022-01228-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 583 |
Taha MB, Rao N, Vaduganathan M, Cainzos-Achirica M, Nasir K, Patel KV. Implementation of Cardiometabolic Centers and Training Programs. Curr Diab Rep 2022;22:203-12. [PMID: 35316465 DOI: 10.1007/s11892-022-01459-y] [Reference Citation Analysis]
|
| 584 |
McQuarrie EP, Gillis KA, Mark PB. Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy? Curr Opin Nephrol Hypertens 2022;31:272-7. [PMID: 35220316 DOI: 10.1097/MNH.0000000000000786] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 585 |
Antlanger M, Domenig O, Kaltenecker CC, Kovarik JJ, Rathkolb V, Müller MM, Schwaiger E, Hecking M, Poglitsch M, Säemann MD, Kopecky C. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial. Diabetes Obes Metab 2022;24:816-26. [PMID: 34984822 DOI: 10.1111/dom.14639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 586 |
Sata SS, Spratt SE, Edmonston DL, Pagidipati N. Clinical progress note: Indications for and management of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in hospitalized patients. J Hosp Med 2022;17:360-3. [PMID: 35535917 DOI: 10.1002/jhm.12798] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 587 |
García-maset R, Bover J, Segura de la Morena J, Goicoechea Diezhandino M, Cebollada del Hoyo J, Escalada San Martín J, Fácila Rubio L, Gamarra Ortiz J, García-donaire JA, García-matarín L, Gràcia Garcia S, Gutiérrez Pérez MI, Hernández Moreno J, Mazón Ramos P, Montañés Bermudez R, Muñoz Torres M, Pablos-velasco PD, Pérez-maraver M, Suárez Fernández C, Tranche Iparraguirre S, Górriz JL, García-maset R, Bover J, Segura J, Goicoechea M, Cebollada del Hoyo J, Escalada San Martín J, Fácila Rubio L, Gamarra Ortiz J, García-donaire JA, García-matarín L, Gràcia Garcia S, Isabel Gutiérrez Pérez M, Hernández Moreno J, Mazón Ramos P, Montañés Bermudez R, Muñoz Torres M, Pedro de Pablos-velasco, Pérez-maraver M, Suárez Fernández C, Tranche Iparraguirre S, Luis Górriz J. Documento de información y consenso para la detección y manejo de la enfermedad renal crónica. Nefrología 2022;42:233-64. [DOI: 10.1016/j.nefro.2021.07.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 588 |
Husain M, Consoli A, De Remigis A, Pettersson Meyer AS, Rasmussen S, Bain S. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovasc Diabetol 2022;21:64. [PMID: 35484580 DOI: 10.1186/s12933-022-01489-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 589 |
Edward JA, Josey K, Bahn G, Caplan L, Reusch JEB, Reaven P, Ghosh D, Raghavan S. Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis. Cardiovasc Diabetol 2022;21:58. [PMID: 35477454 DOI: 10.1186/s12933-022-01496-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 590 |
Češka R. What connects SGLT2 inhibitors, diabetes mellitus, heart failure and empagliflozin? Vnitr Lek 2022;68:195-196. [DOI: 10.36290/vnl.2022.039] [Reference Citation Analysis]
|
| 591 |
Wei W, Liu J, Chen S, Xu X, Guo D, He Y, Huang Z, Wang B, Huang H, Li Q, Chen J, Chen H, Tan N, Liu Y. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis. Front Endocrinol (Lausanne) 2022;13:850836. [PMID: 35330914 DOI: 10.3389/fendo.2022.850836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 592 |
Dawood AF, Alzamil NM, Hewett PW, Momenah MA, Dallak M, Kamar SS, Abdel Kader DH, Yassin H, Haidara MA, Maarouf A, Al-Ani B. Metformin Protects against Diabetic Cardiomyopathy: An Association between Desmin-Sarcomere Injury and the iNOS/mTOR/TIMP-1 Fibrosis Axis. Biomedicines 2022;10. [PMID: 35625721 DOI: 10.3390/biomedicines10050984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 593 |
Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther 2022;7:131. [PMID: 35459215 DOI: 10.1038/s41392-022-00955-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 594 |
Balletshofer B, Böckler D, Diener H, Heckenkamp J, Ito W, Katoh M, Lawall H, Malyar N, Oberländer Y, Reimer P, Rittig K, Zähringer M. Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. Exp Clin Endocrinol Diabetes 2022. [PMID: 35453152 DOI: 10.1055/a-1624-3631] [Reference Citation Analysis]
|
| 595 |
Premji R, Nylen ES, Naser N, Gandhi S, Burman KD, Sen S. Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome. Metab Syndr Relat Disord 2022. [PMID: 35452324 DOI: 10.1089/met.2022.0004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 596 |
Chang WT, Shih JY, Lin YW, Chen ZC, Kan WC, Lin TH, Hong CS. Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3. Arch Toxicol 2022. [PMID: 35438302 DOI: 10.1007/s00204-022-03298-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 597 |
Sonmez A, Sabbour H, Echtay A, Rahmah AM, Alhozali AM, Sabaan FS, Haddad FH, Iraqi H, Elebrashy I, Assaad SN, Bayat Z, Osar Siva Z, Hassanein M. Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations. Journal of Diabetes. [DOI: 10.1111/1753-0407.13266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 598 |
Niu Y, Zhang Y, Zhang W, Lu J, Chen Y, Hao W, Zhou J, Wang L, Xie W. Canagliflozin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through Inhibiting NF-κB Signaling and Upregulating Bif-1. Front Pharmacol 2022;13:820541. [PMID: 35418866 DOI: 10.3389/fphar.2022.820541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 599 |
Martínez-Montoro JI, García-Fontana B, García-Fontana C, Muñoz-Torres M. Evaluation of Quality and Bone Microstructure Alterations in Patients with Type 2 Diabetes: A Narrative Review. J Clin Med 2022;11. [PMID: 35456299 DOI: 10.3390/jcm11082206] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 600 |
Hernandez M, Sullivan RD, Mccune ME, Reed GL, Gladysheva IP. Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion. Diagnostics 2022;12:989. [DOI: 10.3390/diagnostics12040989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 601 |
Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence? Therapeutic Advances in Endocrinology 2022;13:204201882210900. [DOI: 10.1177/20420188221090001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 602 |
Guirguis H, Beroukhim Afrahimi S, Pham C. The Use of SGLT-2 Inhibitors Coupled With a Strict Low-Carbohydrate Diet: A Set-Up for Inducing Severe Diabetic Ketoacidosis. Clin Med Insights Case Rep 2022;15:117954762210900. [DOI: 10.1177/11795476221090045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 603 |
Schnell O, Battelino T, Bergenstal R, Blüher M, Böhm M, Brosius F, Carr RD, Ceriello A, Forst T, Giorgino F, Guerci B, Heerspink HJL, Itzhak B, Ji L, Kosiborod M, Lalić N, Lehrke M, Marx N, Nauck M, Rodbard HW, Rosano GMC, Rossing P, Rydén L, Santilli F, Schumm-Draeger PM, Vandvik PO, Vilsbøll T, Wanner C, Wysham C, Standl E. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol 2022;21:50. [PMID: 35395808 DOI: 10.1186/s12933-022-01481-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 604 |
Mishriky BM, Cummings DM, Powell JR. Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes. Prim Care Diabetes 2022:S1751-9918(22)00073-0. [PMID: 35396200 DOI: 10.1016/j.pcd.2022.03.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 605 |
Shou X, Wang Y, Duan C, Yuan G, Wei N, Yang Y, Hu Y. Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis. Curr Probl Cardiol 2022;:101194. [PMID: 35395332 DOI: 10.1016/j.cpcardiol.2022.101194] [Reference Citation Analysis]
|
| 606 |
Prázný M. The position of SGLT2 inhibitors in current medical practice - update 2022. Vnitr Lek 2022;68:96-103. [DOI: 10.36290/vnl.2022.019] [Reference Citation Analysis]
|
| 607 |
Hitsuwari T, Tsurutani Y, Yamane T, Sunouchi T, Horikoshi H, Hirose R, Hoshino Y, Watanabe S, Katsuragawa S, Saitou J. Two Cases of Thyrotoxicosis and Euglycemic Diabetic Ketoacidosis Under Sodium-glucose Transport Protein 2 Inhibitor Treatment. Intern Med 2022. [PMID: 35370232 DOI: 10.2169/internalmedicine.8830-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 608 |
Akasaka H, Sugimoto K, Shintani A, Taniuchi S, Yamamoto K, Iwakura K, Okamura A, Takiuchi S, Fukuda M, Kamide K, Fujio Y, Nakatani S, Ogihara T, Rakugi H; EXCEED investigators. Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study. Geriatr Gerontol Int 2022;22:298-304. [PMID: 35212104 DOI: 10.1111/ggi.14363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 609 |
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology 2022. [DOI: 10.1016/j.jacc.2021.12.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 45] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 610 |
L.j. Visseren F, Mach F, M. Smulders Y, Carballo D, C. Koskinas K, Bäck M, Benetos A, Biffi A, Manuel Boavida J, Capodanno D, Cosyns B, Crawford C, H. Davos C, Desormais I, Di Angelantonio E, H. Franco O, Halvorsen S, Richard Hobbs F, Hollander M, A. Jankowska E, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, P. Tsioufis K, van Dis I, C. van Gelder I, Wanner C, Williams B. Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2021.10.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 611 |
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology 2022. [DOI: 10.1016/j.jacc.2021.12.012] [Cited by in Crossref: 70] [Cited by in F6Publishing: 34] [Article Influence: 70.0] [Reference Citation Analysis]
|
| 612 |
Kulkarni AS, Aleksic S, Berger DM, Sierra F, Kuchel GA, Barzilai N. Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization. Aging Cell 2022;21:e13596. [PMID: 35343051 DOI: 10.1111/acel.13596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 613 |
Capolongo G, Capasso G, Viggiano D. A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics. Int J Mol Sci 2022;23:3915. [PMID: 35409276 DOI: 10.3390/ijms23073915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 614 |
Scheen AJ. Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies. Diabetes Epidemiology and Management 2022;6:100054. [DOI: 10.1016/j.deman.2022.100054] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 615 |
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun J, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America Guideline for the Management of Heart Failure: Executive Summary. Journal of Cardiac Failure 2022. [DOI: 10.1016/j.cardfail.2022.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 616 |
Lim S, Sohn M, Shin Y, Ferrannini E. Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects. Diabetes Obes Metab 2022;24:757-62. [PMID: 34908220 DOI: 10.1111/dom.14627] [Reference Citation Analysis]
|
| 617 |
Mcdonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JG, Coats AJ, Crespo-leiro MG, Farmakis D, Gilard M, Heyman S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CS, Lyon AR, Mcmurray JJ, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GM, Ruschitzka F, Skibelund AK. Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2021.11.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 618 |
von Lewinski D, Tripolt NJ, Sourij H, Pferschy PN, Oulhaj A, Alber H, Gwechenberger M, Martinek M, Seidl S, Moertl D, Nürnberg M, Roithinger FX, Steinwender C, Stühlinger M, Zirlik A, Benedikt M, Kolesnik E, Wallner M, Rohrer U, Manninger M, Scherr D; ERASe study group. Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A phase III study. Am Heart J 2022;246:152-60. [PMID: 35045327 DOI: 10.1016/j.ahj.2022.01.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 619 |
Pallarés Carratalá V, Escobar Cervantes C. Respuesta a «Seguridad y efectividad de la dapagliflozina con otro inhibidor del SGLT-2: ¿Qué decisión debemos tomar?». Medicina de Familia SEMERGEN 2022;48:220-222. [DOI: 10.1016/j.semerg.2022.01.012] [Reference Citation Analysis]
|
| 620 |
Tang H, Kimmel SE, Smith SM, Cusi K, Shi W, Gurka M, Winterstein AG, Guo J. Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care 2022;45:1007-12. [PMID: 35349656 DOI: 10.2337/dc21-1722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 621 |
Cortinovis M, Perico N, Ruggenenti P, Remuzzi A, Remuzzi G. Glomerular hyperfiltration. Nat Rev Nephrol 2022. [PMID: 35365815 DOI: 10.1038/s41581-022-00559-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 622 |
Ouchi M, Morita A, Satoh K, Kobayashi S, Terada M, Kon H, Hayashi K, Suzuki T, Oba K, Sugihara H, Yasutake M, Anzai N, Fujita T. Effects of 1,5-anhydro-D-glucitol on insulin secretion both in in vitro and ex vivo pancreatic preparations. Journal of Pharmacological Sciences 2022. [DOI: 10.1016/j.jphs.2022.03.005] [Reference Citation Analysis]
|
| 623 |
van Ruiten CC, Hesp AC, van Raalte DH. Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.03.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 624 |
Mottl AK, Alicic R, Argyropoulos C, Brosius FC, Mauer M, Molitch M, Nelson RG, Perreault L, Nicholas SB. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis 2022;79:457-79. [PMID: 35144840 DOI: 10.1053/j.ajkd.2021.09.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 625 |
Palmer BF, Clegg DJ. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clin Proc 2022;97:761-76. [PMID: 35287953 DOI: 10.1016/j.mayocp.2022.01.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 626 |
Kittleson MM. A Clinician's Guide to the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure. Journal of Cardiac Failure 2022. [DOI: 10.1016/j.cardfail.2022.03.346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 627 |
Docherty KF, Anand IS, Chiang C, Chopra VK, Desai AS, Kitakaze M, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Langkilde AM, Jhund PS, Mcmurray JJ. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC: Asia 2022;2:139-153. [DOI: 10.1016/j.jacasi.2022.02.004] [Reference Citation Analysis]
|
| 628 |
Mazin I, Chernomordik F, Fefer P, Matetzky S, Beigel R. The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. J Clin Med 2022;11:1904. [PMID: 35407513 DOI: 10.3390/jcm11071904] [Reference Citation Analysis]
|
| 629 |
Nakamura K, Miyoshi T, Yoshida M, Akagi S, Saito Y, Ejiri K, Matsuo N, Ichikawa K, Iwasaki K, Naito T, Namba Y, Yoshida M, Sugiyama H, Ito H. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. Int J Mol Sci 2022;23:3587. [PMID: 35408946 DOI: 10.3390/ijms23073587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 630 |
van Husen G, Virdone S, Pieper K, Kayani G, Fox KAA. Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis. Eur Heart J Digit Health 2022;3:181-94. [PMID: 36713019 DOI: 10.1093/ehjdh/ztac011] [Reference Citation Analysis]
|
| 631 |
Kietaibl A, Fasching P, Glaser K, Petter-puchner AH. New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature. Front Surg 2022;9:828649. [DOI: 10.3389/fsurg.2022.828649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 632 |
Shi FH, Li H, Shen L, Xu L, Ge H, Gu ZC, Lin HW, Pu J. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function. J Clin Endocrinol Metab 2022;107:1191-203. [PMID: 34791312 DOI: 10.1210/clinem/dgab834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 633 |
Attachaipanich T, Chattipakorn SC, Chattipakorn N. Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure. J Cell Physiol 2022. [PMID: 35324001 DOI: 10.1002/jcp.30727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 634 |
Chrysant SG, Chrysant GS. Beneficial cardiovascular and remodeling effects of SGLT2 inhibitors: pathophysiologic mechanisms. Expert Rev Cardiovasc Ther 2022. [PMID: 35320057 DOI: 10.1080/14779072.2022.2057949] [Reference Citation Analysis]
|
| 635 |
Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 2022;21:47. [PMID: 35321742 DOI: 10.1186/s12933-022-01476-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 636 |
Wang Y, Yao M, Wang J, Liu H, Zhang X, Zhao L, Hu X, Guan H, Lyu Z. Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis. Front Endocrinol 2022;13:818537. [DOI: 10.3389/fendo.2022.818537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 637 |
Jiang Y, Yang P, Fu L, Sun L, Shen W, Wu Q. Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials. Front Endocrinol 2022;13:802992. [DOI: 10.3389/fendo.2022.802992] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 638 |
Hu Y, Xu Q, Li H, Meng Z, Hao M, Ma X, Lin W, Kuang H. Dapagliflozin Reduces Apoptosis of Diabetic Retina and Human Retinal Microvascular Endothelial Cells Through ERK1/2/cPLA2/AA/ROS Pathway Independent of Hypoglycemic. Front Pharmacol 2022;13:827896. [PMID: 35281932 DOI: 10.3389/fphar.2022.827896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 639 |
Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Front Pharmacol 2022;13:800490. [PMID: 35281930 DOI: 10.3389/fphar.2022.800490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 640 |
Wang X, Wang Z, Liu D, Jiang H, Cai C, Li G, Yu G. Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease. Front Pharmacol 2022;13:839640. [PMID: 35281938 DOI: 10.3389/fphar.2022.839640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 641 |
Al‐bazz D, Wilding JP. Adjunctive Therapy, Including Pharmacotherapy. Clinical Obesity in Adults and Children 2022. [DOI: 10.1002/9781119695257.ch21] [Reference Citation Analysis]
|
| 642 |
Montero N, Oliveras L, Soler MJ, Cruzado JM. Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics. Clin Kidney J 2022;15:5-13. [PMID: 35265335 DOI: 10.1093/ckj/sfab131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 643 |
Koo BK, Lim S. Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease. Clinical Obesity in Adults and Children 2022. [DOI: 10.1002/9781119695257.ch13] [Reference Citation Analysis]
|
| 644 |
Yu F, McLean B, Badiwala M, Billia F. Heart Failure and Drug Therapies: A Metabolic Review. Int J Mol Sci 2022;23:2960. [PMID: 35328390 DOI: 10.3390/ijms23062960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 645 |
Hsiao F, Lin C, Yu C, Tung Y, Chu P. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.794707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 646 |
Pinto LC, Rados DV, Remonti LR, Viana MV, Leitão CB, Gross JL. Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. Arch Endocrinol Metab 2022;66:68-76. [PMID: 35263050 DOI: 10.20945/2359-3997000000440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 647 |
Rafaqat S, Rafaqat S, Rafaqat S. Pathophysiological aspects of insulin resistance in Atrial Fibrillation: novel therapeutic approaches. Int J Arrhythm 2022;23. [DOI: 10.1186/s42444-021-00057-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 648 |
Keller DM, Ahmed N, Tariq H, Walgamage M, Walgamage T, Mohammed A, Chou JT, Kałużna-Oleksy M, Lesiak M, Straburzyńska-Migaj E. SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review. J Clin Med 2022;11:1470. [PMID: 35329796 DOI: 10.3390/jcm11061470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 649 |
Ghosal S, Sinha B. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis. Diabetes Res Clin Pract 2022;:109824. [PMID: 35271879 DOI: 10.1016/j.diabres.2022.109824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 650 |
Bourque G, Hiremath S. Rethinking Resistant Hypertension. J Clin Med 2022;11:1455. [PMID: 35268545 DOI: 10.3390/jcm11051455] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 651 |
Benko J, Samoš M, Bolek T, Prídavková D, Jurica J, Péč MJ, Galajda P, Mokáň M, Zhao R. Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research 2022;2022:1-10. [DOI: 10.1155/2022/3366109] [Reference Citation Analysis]
|
| 652 |
Alkabbani W, Pelletier R, Beazely MA, Labib Y, Quan B, Gamble JM. Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. Drug Saf 2022. [PMID: 35247195 DOI: 10.1007/s40264-022-01166-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 653 |
Čertíková Chábová V, Zakiyanov O. Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes. Int J Mol Sci 2022;23:2812. [PMID: 35269954 DOI: 10.3390/ijms23052812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 654 |
Lin YH, Lin CH, Huang YY, Tai AS, Fu SC, Chen ST, Lin SH. Risk factors of first and recurrent genitourinary tract infection in patients withtype 2 diabetes treated with SGLT2 inhibitors: a retrospective cohort study. Diabetes Res Clin Pract 2022;:109816. [PMID: 35247527 DOI: 10.1016/j.diabres.2022.109816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 655 |
Gerardo González-González J, Cesar Solis R, Díaz González-Colmenero A, Raygoza-Cortez K, Moreno-Peña PJ, Sánchez AL, McCoy RG, Singh Ospina N, Maraka S, Brito JP, Rodriguez-Gutierrez R. Effect of metformin on microvascular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2022;:109821. [PMID: 35247521 DOI: 10.1016/j.diabres.2022.109821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 656 |
Nishi L, Ghossein C, Srivastava A. Increasing SGLT2 Inhibitor Use in CKD: Perspectives and Presentation of a Clinical Pathway. Kidney Medicine 2022. [DOI: 10.1016/j.xkme.2022.100446] [Reference Citation Analysis]
|
| 657 |
Patorno E, Pawar A, Wexler DJ, Glynn RJ, Bessette LG, Paik JM, Najafzadeh M, Brodovicz KG, Déruaz-Luyet A, Schneeweiss S. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab 2022;24:442-54. [PMID: 34729891 DOI: 10.1111/dom.14593] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 658 |
Falkentoft AC, Andersen J, Malik ME, Selmer C, Gæde PH, Staehr PB, Hlatky MA, Fosbøl E, Køber L, Torp-pedersen C, Gislason GH, Gerds TA, Schou M, Bruun NE, Ruwald A. Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study. The Lancet Regional Health - Europe 2022;14:100308. [DOI: 10.1016/j.lanepe.2022.100308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 659 |
Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, Ter Maaten JM, Damman K. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation 2022;145:693-712. [PMID: 35226558 DOI: 10.1161/CIRCULATIONAHA.121.052792] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 660 |
Caruso I, Leonardini A, Caizzi G, Vicenti G, Caporusso M, Guarini F, Bernardis M, Moretti B, Giorgino F. Diabetic foot: clinical approach. Minerva Orthop 2022;73. [DOI: 10.23736/s2784-8469.21.04108-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 661 |
Gollmer J, Zirlik A, Bugger H. SOP Der herzkranke Diabetespatient. Kardiologie up2date 2022;18:13-18. [DOI: 10.1055/a-1224-0954] [Reference Citation Analysis]
|
| 662 |
Hofbauer LC, Busse B, Eastell R, Ferrari S, Frost M, Müller R, Burden AM, Rivadeneira F, Napoli N, Rauner M. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol 2022;10:207-20. [PMID: 35101185 DOI: 10.1016/S2213-8587(21)00347-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 46.0] [Reference Citation Analysis]
|
| 663 |
Huang C, Hao Z, Wang Z, Zhao X, Wang H, Li F, Liu S, Pan Y. A fully integrated graphene-polymer field-effect transistor biosensing device for on-site detection of glucose in human urine. Materials Today Chemistry 2022;23:100635. [DOI: 10.1016/j.mtchem.2021.100635] [Reference Citation Analysis]
|
| 664 |
Yi TW, Levin A. Sex, Gender, and Cardiovascular Disease in Chronic Kidney Disease. Semin Nephrol 2022;42:197-207. [PMID: 35718366 DOI: 10.1016/j.semnephrol.2022.04.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 665 |
Scholtes RA, Muskiet MH, van Baar MJ, Hesp AC, Greasley PJ, Hammarstedt A, Karlsson C, Hallow KM, Danser AJ, Heerspink HJ, van Raalte DH. The adaptive renal response for volume homeostasis during two weeks of dapagliflozin treatment in people with type 2 diabetes and preserved renal function on a sodium-controlled diet. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 666 |
Kassis-george H, Verlinden NJ, Fu S, Kanwar M. Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations. TCRM 2022;Volume 18:315-22. [DOI: 10.2147/tcrm.s357422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 667 |
Lin C, Cai X, Ji L. Cardiovascular benefits beyond urinary glucose excretion: A hypothesis generated from two meta-analyses. Diabetes Obes Metab 2022;24:550-4. [PMID: 34726334 DOI: 10.1111/dom.14596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 668 |
Sridhar VS, Yau K, Benham JL, Campbell DJT, Cherney DZI. Sex and Gender Related Differences in Diabetic Kidney Disease. Semin Nephrol 2022;42:170-84. [PMID: 35718364 DOI: 10.1016/j.semnephrol.2022.04.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 669 |
Zheng R, Xu Y, Li M, Lu J, Xu M, Wang T, Zhao Z, Wang S, Lin H, Zhang X, Bi Y, Wang W, Ning G. Pan‐risk factor for a comprehensive cardiovascular health management. Journal of Diabetes. [DOI: 10.1111/1753-0407.13258] [Reference Citation Analysis]
|
| 670 |
March KL, Lukas JG, Berei TJ, Shah SP, Cave BE. SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses. Crit Care Nurs Q 2022;45:189-98. [PMID: 35212658 DOI: 10.1097/CNQ.0000000000000401] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 671 |
Lv XH, Cong XX, Nan JL, Lu XM, Zhu QL, Shen J, Wang BB, Wang ZT, Zhou RY, Chen WA, Su L, Chen X, Li ZZ, Lin YN. Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice. Acta Pharmacol Sin 2022. [PMID: 35217814 DOI: 10.1038/s41401-022-00878-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 672 |
Narcisse DI, Katzenberger DR, Gutierrez JA. Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence. Curr Cardiol Rep 2022. [PMID: 35201560 DOI: 10.1007/s11886-022-01677-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 673 |
van der Hoek S, Stevens J. Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level. Front Pharmacol 2022;13:837993. [DOI: 10.3389/fphar.2022.837993] [Reference Citation Analysis]
|
| 674 |
Janjusevic M, Fluca AL, Gagno G, Pierri A, Padoan L, Sorrentino A, Beltrami AP, Sinagra G, Aleksova A. Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis. Int J Mol Sci 2022;23:2336. [PMID: 35216451 DOI: 10.3390/ijms23042336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 675 |
Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böhm M, Butler J, Carapetis J, Ceconi C, Chioncel O, Coats A, Crespo-Leiro MG, de Simone G, Drexel H, Emdin M, Farmakis D, Halle M, Heymans S, Jaarsma T, Jankowska E, Lainscak M, Lam CSP, Løchen ML, Lopatin Y, Maggioni A, Matrone B, Metra M, Noonan K, Pina I, Prescott E, Rosano G, Seferovic PM, Sliwa K, Stewart S, Uijl A, Vaartjes I, Vermeulen R, Verschuren WM, Volterrani M, Von Haehling S, Hoes A. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Prev Cardiol 2022;29:275-300. [PMID: 35083485 DOI: 10.1093/eurjpc/zwab147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 676 |
Li N, Zhou G, Zheng Y, Lv D, Zhu X, Wei P, Zheng M, Liu S, Zhou E, Sun W, Zhang L. Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis. PLoS One 2022;17:e0261986. [PMID: 35020750 DOI: 10.1371/journal.pone.0261986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 677 |
Cinquegrani G, Spigoni V, Fantuzzi F, Bonadonna RC, Dei Cas A. Empagliflozin does not reverse lipotoxicity-induced impairment in human myeloid angiogenic cell bioenergetics. Cardiovasc Diabetol 2022;21:27. [PMID: 35177077 DOI: 10.1186/s12933-022-01461-4] [Reference Citation Analysis]
|
| 678 |
Upadhya B, Kozak PM, Stacey RB, Vasan RS. Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. Curr Hypertens Rep 2022;24:1-20. [PMID: 35165832 DOI: 10.1007/s11906-022-01166-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 679 |
Santamaría Olmo R, Pendón Ruiz de Mier MV, Rodelo Haad C. Chronic kidney disease and vascular risk - what's new? Hipertens Riesgo Vasc 2022;39:3-7. [PMID: 35152979 DOI: 10.1016/j.hipert.2022.01.001] [Reference Citation Analysis]
|
| 680 |
Swapnasrita S, Carlier A, Layton AT. Sex-Specific Computational Models of Kidney Function in Patients With Diabetes. Front Physiol 2022;13:741121. [PMID: 35153824 DOI: 10.3389/fphys.2022.741121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 681 |
Lyu B, Grams ME, Chang A, Inker LA, Coresh J, Shin JI. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization. Am J Cardiol 2022;165:124-30. [PMID: 34937658 DOI: 10.1016/j.amjcard.2021.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 682 |
Singhal R, Hechanova LA. SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes. Curr Cardiol Rep 2022. [PMID: 35147891 DOI: 10.1007/s11886-022-01637-0] [Reference Citation Analysis]
|
| 683 |
Schwemmlein J, Maack C, Bertero E. Mitochondria as Therapeutic Targets in Heart Failure. Curr Heart Fail Rep 2022. [PMID: 35147851 DOI: 10.1007/s11897-022-00539-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 684 |
van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 2022. [PMID: 35145275 DOI: 10.1038/s41581-022-00535-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 685 |
Bitar ZI, Maadarani OS, Alabdali F, Teama A, Elsawah W, Mohsen MJ, Elzoueiry MM. Sodium–glucose cotransporter‐2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 686 |
Gunasekar SK, Xie L, Kumar A, Hong J, Chheda PR, Kang C, Kern DM, My-Ta C, Maurer J, Heebink J, Gerber EE, Grzesik WJ, Elliot-Hudson M, Zhang Y, Key P, Kulkarni CA, Beals JW, Smith GI, Samuel I, Smith JK, Nau P, Imai Y, Sheldon RD, Taylor EB, Lerner DJ, Norris AW, Klein S, Brohawn SG, Kerns R, Sah R. Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes. Nat Commun 2022;13:784. [PMID: 35145074 DOI: 10.1038/s41467-022-28435-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 687 |
Zampieri M, Argirò A, Allinovi M, Perfetto F, Cappelli F. SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Intern Emerg Med 2022. [PMID: 35137306 DOI: 10.1007/s11739-022-02944-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 688 |
Htoo PT, Buse J, Cavender M, Wang T, Pate V, Edwards J, Stürmer T. Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. J Am Heart Assoc 2022;:e022376. [PMID: 35132865 DOI: 10.1161/JAHA.121.022376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 689 |
Song Y, Guo F, Liu Y, Huang F, Fan X, Zhao L, Qin G. Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease. Bioengineered 2022;13:3911-29. [PMID: 35129424 DOI: 10.1080/21655979.2022.2031391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 690 |
Hayakawa T, Kato K, Kobuchi S, Kataoka K, Sakaeda T. Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus. Pharmaceuticals 2022;15:203. [DOI: 10.3390/ph15020203] [Reference Citation Analysis]
|
| 691 |
Georgianos PI, Vaios V, Roumeliotis S, Leivaditis K, Eleftheriadis T, Liakopoulos V. Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease. JPM 2022;12:223. [DOI: 10.3390/jpm12020223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 692 |
Katakami N, Mita T, Maeda N, Sato Y, Watada H, Shimomura I; The UTOPIA Study Investigators. Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial. Cardiovasc Diabetol 2022;21. [DOI: 10.1186/s12933-022-01451-6] [Reference Citation Analysis]
|
| 693 |
Bailey CJ, Day C, Bellary S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr Diab Rep 2022. [PMID: 35113333 DOI: 10.1007/s11892-021-01442-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 694 |
Abdelhamid M, Kandil H, Hassanin M, Shaheen S, Sobhy M, ElEtreby A, Hasan-Ali H, Mahfouz H, Nasr G, Shawky I, Emil S, ElSetiha M, Hasssan M, Sadek Y, Karim MA, Asham A, Ghaleb M, Samir A, Shokry K. Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction. ESC Heart Fail 2022. [PMID: 35118822 DOI: 10.1002/ehf2.13811] [Reference Citation Analysis]
|
| 695 |
Varadhan L, Saravanan P, Ali SN, Hanif W, Patel V. Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept. Clin Drug Investig 2022. [PMID: 35107773 DOI: 10.1007/s40261-021-01105-7] [Reference Citation Analysis]
|
| 696 |
Vaduganathan M, Sattar N, Xu J, Butler J, Mahaffey KW, Neal B, Shaw W, Rosenthal N, Pfeifer M, Hansen MK, Januzzi JL. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. Journal of the American College of Cardiology 2022;79:432-44. [DOI: 10.1016/j.jacc.2021.11.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 697 |
Rau M, Thiele K, Hartmann NK, Möllmann J, Wied S, Hohl M, Marx N, Lehrke M. Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study. Bone Reports 2022. [DOI: 10.1016/j.bonr.2022.101175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 698 |
Seidu S, Cos X, Brunton S, Harris S, Jansson S, Mata-cases M, Neijens A, Topsever P, Khunti K. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 699 |
El Hussein MT, Bell N. Sodium-Glucose Cotransporter-2 Inhibitors: Heart Failure and Renal Protection Indications. The Journal for Nurse Practitioners 2022;18:179-84. [DOI: 10.1016/j.nurpra.2021.09.002] [Reference Citation Analysis]
|
| 700 |
Wu T, Wong CK, Tang EH, Man KK, Wong SK, Ho Au IC, Tse ET, Chan EW, Grieve E, Wu O, Ng EK, Wong IC. The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: A retrospective cohort study. Surgery for Obesity and Related Diseases 2022. [DOI: 10.1016/j.soard.2022.02.008] [Reference Citation Analysis]
|
| 701 |
Alexander JT, Staab EM, Wan W, Franco M, Knitter A, Skandari MR, Bolen S, Maruthur NM, Huang ES, Philipson LH, Winn AN, Thomas CC, Zeytinoglu M, Press VG, Tung EL, Gunter K, Bindon B, Jumani S, Laiteerapong N. Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. J Gen Intern Med 2022;37:439-48. [PMID: 34850334 DOI: 10.1007/s11606-021-07227-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 702 |
Bhagirath VC, Nash D, Wan D, Anand SS. Building your Peripheral Artery Disease Tool Kit: Medical Management of PAD in 2022. Canadian Journal of Cardiology 2022. [DOI: 10.1016/j.cjca.2022.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 703 |
Rao S. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Adv Ther 2022;39:845-61. [PMID: 34881413 DOI: 10.1007/s12325-021-01989-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 704 |
Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications 2022;36:108101. [PMID: 34922811 DOI: 10.1016/j.jdiacomp.2021.108101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 705 |
Mehmet Ekici, Güngör H, Karayığıt MÖ, Turgut NH, Koҫkaya M, Karataș Ö, Üner AG. Cardioprotective Effect of Empagliflozin in Rats with Isoproterenol-Induced Myocardial Infarction: Evaluation of Lipid Profile, Oxidative Stress, Inflammation, DNA Damage, and Apoptosis. Biol Bull Russ Acad Sci 2022;49:S159-S172. [DOI: 10.1134/s1062359022130039] [Reference Citation Analysis]
|
| 706 |
Xiang B, Yu Z, Zhou X. Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis. Front Cardiovasc Med 2021;8:787810. [PMID: 35097007 DOI: 10.3389/fcvm.2021.787810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 707 |
Vart P, Correa-rotter R, Hou FF, Jongs N, Chertow GM, Langkilde AM, Mcmurray JJ, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Douthat W, Escudero E, Isidto R, Khullar D, Bajaj HS, Wheeler DC, Heerspink HJ. Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease Across Major Geographic Regions. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.01.1060] [Reference Citation Analysis]
|
| 708 |
Echouffo-tcheugui JB, Selvin E. Eligibility and Response to Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Therapy. Journal of the American College of Cardiology 2022;79:445-7. [DOI: 10.1016/j.jacc.2021.11.028] [Reference Citation Analysis]
|
| 709 |
Wallenius K, Kroon T, Hagstedt T, Löfgren L, Sörhede-Winzell M, Boucher J, Lindén D, Oakes ND. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation and increases ketosis. J Lipid Res 2022;:100176. [PMID: 35120993 DOI: 10.1016/j.jlr.2022.100176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 710 |
Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Chin K, Kimura M, Saito N, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Machimura H, Hishiki T, Umezawa S, Shimura H, Nakajima S, Yamamoto H, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 711 |
Khine A, Kwok J, Lin E. Time to Invest in the Future: Assessing the Cost-Effectiveness of Empagliflozin in Diabetic Kidney Disease. American Journal of Kidney Diseases 2022. [DOI: 10.1053/j.ajkd.2021.11.003] [Reference Citation Analysis]
|
| 712 |
Saikia D, Kumar S. Low glucose metabolizing capacity and not insulin resistance is primary etiology of Type 2 Diabetes Mellitus: A hypothesis. Medical Hypotheses 2022. [DOI: 10.1016/j.mehy.2022.110804] [Reference Citation Analysis]
|
| 713 |
Guedes M, Pecoits-Filho R. Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist's point of view. J Intern Med 2022;291:165-80. [PMID: 34914852 DOI: 10.1111/joim.13424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 714 |
Scheen AJ. Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors ? Diabetes Metab 2022;:101325. [PMID: 35121148 DOI: 10.1016/j.diabet.2022.101325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 715 |
Zughaib MT, Patel K, Leka M, Affas S. Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip. Cureus. [DOI: 10.7759/cureus.21768] [Reference Citation Analysis]
|
| 716 |
Kolesnik E, Scherr D, Rohrer U, Benedikt M, Manninger M, Sourij H, von Lewinski D. SGLT2 Inhibitors and Their Antiarrhythmic Properties. Int J Mol Sci 2022;23:1678. [PMID: 35163599 DOI: 10.3390/ijms23031678] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 717 |
Gronda EG, Vanoli E, Iacoviello M, Urbinati S, Caldarola P, Colivicchi F, Gabrielli D. Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes. Heart Fail Rev. [DOI: 10.1007/s10741-021-10211-9] [Reference Citation Analysis]
|
| 718 |
Hasan SS, Aslam Q, Islam I, Kow CS, Babar ZUD. Metformin-based single pill drug combinations for type 2 diabetes in primary care England: A time trend analysis. Prim Care Diabetes 2022:S1751-9918(22)00023-7. [PMID: 35115253 DOI: 10.1016/j.pcd.2022.01.008] [Reference Citation Analysis]
|
| 719 |
Yeong T, Mai AS, Lim OZ, Ng CH, Chin YH, Tay P, Lin C, Muthiah M, Khoo CM, Dalakoti M, Loh P, Chan M, Yeo T, Foo R, Wong R, Chew NW, Lin W. Can glucose‐lowering medications improve outcomes in non‐diabetic heart failure patients? A Bayesian network meta‐analysis. ESC Heart Failure. [DOI: 10.1002/ehf2.13822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 720 |
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; Authors/Task Force Members:., ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. [PMID: 35083827 DOI: 10.1002/ejhf.2333] [Cited by in Crossref: 205] [Cited by in F6Publishing: 193] [Article Influence: 205.0] [Reference Citation Analysis]
|
| 721 |
Kimura A, Kamimura K, Ohkoshi-Yamada M, Shinagawa-Kobayashi Y, Goto R, Owaki T, Oda C, Shibata O, Morita S, Sakai N, Abe H, Yokoo T, Sakamaki A, Kamimura H, Terai S. Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. Biochem Biophys Res Commun 2022;596:76-82. [PMID: 35121372 DOI: 10.1016/j.bbrc.2022.01.086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 722 |
Xuan MY, Piao SG, Ding J, Nan QY, Piao MH, Jiang YJ, Zheng HL, Jin JZ, Li C. Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction. Front Pharmacol 2021;12:798381. [PMID: 35069210 DOI: 10.3389/fphar.2021.798381] [Reference Citation Analysis]
|
| 723 |
Zhao L, Zhan Z, Ning J, Qiu M. Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Front Pharmacol 2022;12:751496. [DOI: 10.3389/fphar.2021.751496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 724 |
Peng L, Chen Y, Shi S, Wen H. Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management. Stem Cell Res Ther 2022;13:25. [PMID: 35073973 DOI: 10.1186/s13287-021-02696-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 725 |
Sukhareva OY, Zuraeva ZT, Shamhalova MS. Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails. Diabetes mellitus 2022;24:553-564. [DOI: 10.14341/dm12864] [Reference Citation Analysis]
|
| 726 |
Pavlicek V. Natrium-Glukose-Kotransporter-2-Inhibitoren und Frakturen bei Diabetes mellitus Typ 2. Diabetologe. [DOI: 10.1007/s11428-022-00858-9] [Reference Citation Analysis]
|
| 727 |
Liu L, Luo H, Liang Y, Tang J, Shu Y, Khalaf OI. Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-κB. Computational and Mathematical Methods in Medicine 2022;2022:1-11. [DOI: 10.1155/2022/3293054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 728 |
Lusk KA, Benitez RM, Carter J, Diocee H, Snoga JL. The role of SGLT2 inhibitors in heart failure. AJPPS 2022;1:2. [DOI: 10.25259/ajpps_5_2021] [Reference Citation Analysis]
|
| 729 |
Zhang J, Huan Y, Leibensperger M, Seo B, Song Y. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. Kidney360 2022;3:477-87. [PMID: 35582188 DOI: 10.34067/KID.0006672021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 730 |
Inoue M, Tanaka Y, Matsushita S, Shimozaki Y, Ayame H, Akutsu H. Xenogeneic-Free Human Intestinal Organoids for Assessing Intestinal Nutrient Absorption. Nutrients 2022;14:438. [DOI: 10.3390/nu14030438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 731 |
Zhuo M, Li J, Buckley LF, Tummalapalli SL, Mount DB, Steele DJR, Lucier DJ, Mendu ML. Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis. Kidney360 2022;3:455-64. [PMID: 35582176 DOI: 10.34067/KID.0007862021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 732 |
King NE, Brittain E. Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulm Circ 2022;12:e12028. [PMID: 35506082 DOI: 10.1002/pul2.12028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 733 |
Truche AS, Bailly S, Fabre O, Legrand R, Zaoui P. A Specific High-Protein Weight Loss Program Does Not Impair Renal Function in Patients Who Are Overweight/Obese. Nutrients 2022;14:384. [PMID: 35057566 DOI: 10.3390/nu14020384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 734 |
İnce İ, Altinay L. The effect of diabetes on mid-term survival of open heart surgery patients aged over 70 years. Journal of Health Sciences and Medicine 2022;5:184-8. [DOI: 10.32322/jhsm.1022665] [Reference Citation Analysis]
|
| 735 |
Llorens-cebrià C, Molina-van den Bosch M, Vergara A, Jacobs-cachá C, Soler MJ. Antioxidant Roles of SGLT2 Inhibitors in the Kidney. Biomolecules 2022;12:143. [DOI: 10.3390/biom12010143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 736 |
Kobayashi K, Toyoda M, Hatori N, Sato K, Miyakawa M, Tamura K, Kanamori A. The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. J Diabetes Res 2021;2021:6573369. [PMID: 35028319 DOI: 10.1155/2021/6573369] [Reference Citation Analysis]
|
| 737 |
Lee DSU, Lee H. Adherence and persistence rates of major antidiabetic medications: a review. Diabetol Metab Syndr 2022;14:12. [PMID: 35033161 DOI: 10.1186/s13098-022-00785-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 738 |
Sawaf H, Thomas G, Taliercio JJ, Nakhoul G, Vachharajani TJ, Mehdi A. Therapeutic Advances in Diabetic Nephropathy. J Clin Med 2022;11:378. [PMID: 35054076 DOI: 10.3390/jcm11020378] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 739 |
Muñoz-Córdova F, Hernández-Fuentes C, Lopez-Crisosto C, Troncoso MF, Calle X, Guerrero-Moncayo A, Gabrielli L, Chiong M, Castro PF, Lavandero S. Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies. Front Cardiovasc Med 2021;8:707336. [PMID: 35004869 DOI: 10.3389/fcvm.2021.707336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 740 |
Razuk V, Chiarito M, Cao D, Nicolas J, Pivato CA, Camaj A, Power D, Beerkens F, Jones D, Alter A, Mathew A, Spirito A, Contreras JP, Dangas GD, Mehran R. SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2022:pvac001. [PMID: 35021205 DOI: 10.1093/ehjcvp/pvac001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 741 |
Lam D, Nadkarni GN, Mosoyan G, Neal B, Mahaffey KW, Rosenthal N, Hansen MK, Heerspink HJL, Fleming F, Coca SG. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. Am J Nephrol 2022;53:21-31. [PMID: 35016188 DOI: 10.1159/000519920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 742 |
Cappetta D, De Angelis A, Bellocchio G, Telesca M, Cianflone E, Torella D, Rossi F, Urbanek K, Berrino L. Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey. Front Cardiovasc Med 2021;8:810791. [PMID: 35004918 DOI: 10.3389/fcvm.2021.810791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 743 |
Li L, Li G, Chen H, Feng Z, Zhang L, Chen L, Fan L. Role of Diabetes Mellitus in Acute Coronary Syndrome Patients with Heart Failure and Midrange Ejection Fraction Who Have Undergone Percutaneous Coronary Intervention: A 3-Year Case-Series Follow-Up Retrospective Study. Diabetes Metab Syndr Obes 2021;14:4931-44. [PMID: 35002266 DOI: 10.2147/DMSO.S339209] [Reference Citation Analysis]
|
| 744 |
Rizzo MR, Di Meo I, Polito R, Auriemma MC, Gambardella A, di Mauro G, Capuano A, Paolisso G. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment. Pharmacol Res 2022;176:106062. [PMID: 35017046 DOI: 10.1016/j.phrs.2022.106062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 745 |
Park CH, Lee B, Han M, Rhee WJ, Kwak MS, Yoo TH, Shin JS. Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells. Cell Death Discov 2022;8:12. [PMID: 35013111 DOI: 10.1038/s41420-021-00801-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 746 |
Lee YT, Hsu CN, Fu CM, Wang SW, Huang CC, Li LC. Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting. Front Pharmacol 2021;12:781379. [PMID: 34992535 DOI: 10.3389/fphar.2021.781379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 747 |
Fadah K, Alashi A, Deoker A. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients. Curr Cardiol Rep 2022. [PMID: 35000149 DOI: 10.1007/s11886-021-01619-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 748 |
Fonseca-Correa JI, Correa-Rotter R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med (Lausanne) 2021;8:777861. [PMID: 34988095 DOI: 10.3389/fmed.2021.777861] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 749 |
Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. Nat Rev Cardiol 2022. [PMID: 34997200 DOI: 10.1038/s41569-021-00663-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 750 |
Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Hatori Y, Sato K, Miyakawa M, Tamura K, Kanamori A. Polypharmacy influences the renal composite outcome in patients treated with sodium-glucose cotransporter 2 inhibitors. Clin Transl Sci 2022. [PMID: 34989473 DOI: 10.1111/cts.13222] [Reference Citation Analysis]
|
| 751 |
Hazem RM, Ibrahim AZ, Ali DA, Moustafa YM. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. Int Immunopharmacol 2022;104:108503. [PMID: 34998036 DOI: 10.1016/j.intimp.2021.108503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 752 |
Stewart M. An overview of the oral medicines used in the management of type 2 diabetes. Nurs Stand 2022;37:54-60. [PMID: 34846106 DOI: 10.7748/ns.2021.e11804] [Reference Citation Analysis]
|
| 753 |
Shin H, Schneeweiss S, Glynn RJ, Patorno E. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes. Pharmacoepidemiol Drug Saf 2022. [PMID: 34985178 DOI: 10.1002/pds.5406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 754 |
Bhattarai M, Salih M, Regmi M, Al-Akchar M, Deshpande R, Niaz Z, Kulkarni A, Siddique M, Hegde S. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis. JAMA Netw Open 2022;5:e2142078. [PMID: 34985519 DOI: 10.1001/jamanetworkopen.2021.42078] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 755 |
Katsenos AP, Davri AS, Simos YV, Nikas IP, Bekiari C, Paschou SA, Peschos D, Konitsiotis S, Vezyraki P, Tsamis KI. New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs. Expert Opin Investig Drugs 2022;:1-19. [PMID: 34941464 DOI: 10.1080/13543784.2022.2022122] [Reference Citation Analysis]
|
| 756 |
Tsutsui H. Treating Cardiodiabetic Continuum by SGLT2 Inhibitors: From Diabetes Mellitus to Heart Failure. Cardiometab Syndr J 2022;2:128. [DOI: 10.51789/cmsj.2022.2.e14] [Reference Citation Analysis]
|
| 757 |
Giaccari A, Pontremoli R, Perrone Filardi P. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice. Int J Cardiol 2022:S0167-5273(21)02054-4. [PMID: 34979145 DOI: 10.1016/j.ijcard.2021.12.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 758 |
Rim J, Gallini J, Jasien C, Cui X, Phillips L, Trammell A, Sadikot RT. Use of Oral Anti-Diabetic Drugs and Risk of Hospital and Intensive Care Unit Admissions for Infections. The American Journal of the Medical Sciences 2022. [DOI: 10.1016/j.amjms.2022.01.003] [Reference Citation Analysis]
|
| 759 |
Uskach T. Empagliflozin as a part of optimal medical therapy for chronic heart failure. Kardio vestn 2022;17:16. [DOI: 10.17116/cardiobulletin20221702116] [Reference Citation Analysis]
|
| 760 |
Mende CW. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv Ther 2022;39:148-64. [PMID: 34846711 DOI: 10.1007/s12325-021-01994-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 761 |
Sirhan W, Piran R. Therapeutic peptidomimetics in metabolic diseases. Peptide and Peptidomimetic Therapeutics 2022. [DOI: 10.1016/b978-0-12-820141-1.00023-6] [Reference Citation Analysis]
|
| 762 |
Endo Y, Fujita M, Ikewaki K. Intestinal Cholesterol Absorption in Diabetes Mellitus. JAT 2022. [DOI: 10.5551/jat.ed220] [Reference Citation Analysis]
|
| 763 |
Roux CL, Sudlow A, Pournaras D. Combining metabolic surgery with medications for type 2 diabetes: Is there a benefit? J Bariatr Surg 2022;0:0. [DOI: 10.4103/jbs.jbs_16_22] [Reference Citation Analysis]
|
| 764 |
Raju A, Pimple P, Stafkey-Mailey D, Farrelly E, Shetty S. Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis. Diabetes Ther 2022;13:25-42. [PMID: 34727356 DOI: 10.1007/s13300-021-01173-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 765 |
Arioglu-inan E, Kayki-mutlu G. Diuretic Agents. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00162-6] [Reference Citation Analysis]
|
| 766 |
Qiu M, Ding LL, Zhou HR. Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs. Am J Cardiovasc Drugs 2022;22:69-81. [PMID: 34231123 DOI: 10.1007/s40256-021-00484-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 767 |
Wan S, Chen HH. Precision Medicine for Diabetes and Cardiovascular Disease. Precision Medicine in Diabetes 2022. [DOI: 10.1007/978-3-030-98927-9_2] [Reference Citation Analysis]
|
| 768 |
de Lima JG, Nóbrega LHC, de Lima NN. Oral Therapies for Type 2 Diabetes. Endocrinology and Diabetes 2022. [DOI: 10.1007/978-3-030-90684-9_30] [Reference Citation Analysis]
|
| 769 |
Adamczak M, Ritz E, Wiecek A. Carbohydrate metabolism in chronic renal disease. Nutritional Management of Renal Disease 2022. [DOI: 10.1016/b978-0-12-818540-7.00005-7] [Reference Citation Analysis]
|
| 770 |
Inagaki N, Nangaku M, Sakata Y, Sasaki K, Mori-Anai K, Iwasaki T, Hamada K. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance. Adv Ther 2022;39:674-91. [PMID: 34853985 DOI: 10.1007/s12325-021-01984-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 771 |
Mou L, Hu P, Cao X, Chen Y, Xu Y, He T, Wei Y, He R. Comparison of bovine serum albumin glycation by ribose and fructose in vitro and in vivo. Biochim Biophys Acta Mol Basis Dis 2022;1868:166283. [PMID: 34601015 DOI: 10.1016/j.bbadis.2021.166283] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 772 |
American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S144-74. [PMID: 34964815 DOI: 10.2337/dc22-S010] [Cited by in Crossref: 138] [Cited by in F6Publishing: 124] [Article Influence: 138.0] [Reference Citation Analysis]
|
| 773 |
Thavendiranathan P, Negishi K. Detection of subclinical heart failure. ASE's Comprehensive Strain Imaging 2022. [DOI: 10.1016/b978-0-323-75947-2.00011-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 774 |
Fu EL, Clase CM, Janse RJ, Lindholm B, Dekker FW, Jardine MJ, Carrero J. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice. International Journal of Cardiology 2022. [DOI: 10.1016/j.ijcard.2022.01.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 775 |
Müller-wieland D, Marx N. Herz und Diabetes. Klinische Kardiologie 2022. [DOI: 10.1007/978-3-662-62939-0_12-1] [Reference Citation Analysis]
|
| 776 |
Shammas NW. Putting It All Together: An Algorithmic Approach to Treat Patients with Peripheral Arterial Disease. Peripheral Arterial Interventions 2022. [DOI: 10.1007/978-3-031-09741-6_19] [Reference Citation Analysis]
|
| 777 |
Wolf G. Diabetische Nephropathie. Therapie-Handbuch - Nephrologie 2022. [DOI: 10.1016/b978-3-437-23854-3.00005-1] [Reference Citation Analysis]
|
| 778 |
Chen W, Chen Y. Cardiometabolic Syndrome and Vascular Calcification. Cardiometab Syndr J 2022;2:1. [DOI: 10.51789/cmsj.2022.2.e2] [Reference Citation Analysis]
|
| 779 |
Conway B, Goddard J, Jaap A, Patrick A. Management of Diabetic Nephropathy. Primer on Nephrology 2022. [DOI: 10.1007/978-3-030-76419-7_38] [Reference Citation Analysis]
|
| 780 |
Ruggenenti P, Kraus BJ, Inzucchi SE, Zinman B, Hantel S, Mattheus M, von Eynatten M, Remuzzi G, Koitka-Weber A, Wanner C. Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine 2022;43:101240. [PMID: 35005582 DOI: 10.1016/j.eclinm.2021.101240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 781 |
Deedwania P. SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics. Am J Cardiovasc Drugs 2022;22:1-4. [PMID: 34458960 DOI: 10.1007/s40256-021-00495-5] [Reference Citation Analysis]
|
| 782 |
Wu H, Batuman V. Novel Treatments and the Future of DKD: What Is on the Horizon? Diabetes and Kidney Disease 2022. [DOI: 10.1007/978-3-030-86020-2_28] [Reference Citation Analysis]
|
| 783 |
Romeo GR, Silva PS, Cavallerano J. Diabetes Mellitus. Albert and Jakobiec's Principles and Practice of Ophthalmology 2022. [DOI: 10.1007/978-3-030-42634-7_294] [Reference Citation Analysis]
|
| 784 |
Zerovnik S, Kos M, Locatelli I. Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors. Acta Diabetol 2022;59:233-41. [PMID: 34609620 DOI: 10.1007/s00592-021-01805-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 785 |
Hesp AC, Smits MM, van Bommel EJ, Muskiet MH, Tonneijck L, Nieuwdorp M, Kramer MH, Joles JA, Bjornstad P, van Raalte DH. Kidney hemodynamic profile and systemic vascular function in adults with type 2 diabetes: Analysis of three clinical trials. Journal of Diabetes and its Complications 2022. [DOI: 10.1016/j.jdiacomp.2022.108127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 786 |
Zaghloul N, Awaisu A, Mahfouz A, Alyafei S, Elewa H. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country. Int J Clin Pharm 2022;44:1342-50. [PMID: 36169802 DOI: 10.1007/s11096-022-01464-x] [Reference Citation Analysis]
|
| 787 |
Arrieta F, Pedro-botet J, Iglesias P, Obaya JC, Montanez L, Maldonado GF, Becerra A, Navarro J, Perez J, Petrecca R, Pardo JL, Ribalta J, Sánchez-margalet V, Duran S, Tébar FJ, Aguilar M. Diabetes mellitus y riesgo cardiovascular: actualización de las recomendaciones del Grupo de Trabajo de Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2021). Clínica e Investigación en Arteriosclerosis 2022;34:36-55. [DOI: 10.1016/j.arteri.2021.05.002] [Reference Citation Analysis]
|
| 788 |
Arrieta F, Pedro-botet J, Iglesias P, Obaya JC, Montanez L, Maldonado GF, Becerra A, Navarro J, Perez J, Petrecca R, Pardo JL, Ribalta J, Sánchez-margalet V, Duran S, Tébar FJ, Aguilar M. Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021). Clínica e Investigación en Arteriosclerosis (English Edition) 2022;34:36-55. [DOI: 10.1016/j.artere.2022.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 789 |
Wells QS, Farber-eger E, Lipworth L, Dluzniewski P, Dent R, Umeijiego J, Cohen SS. Characterizing a Clinical Trial – Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction. CLEP 2022;Volume 14:39-49. [DOI: 10.2147/clep.s341919] [Reference Citation Analysis]
|
| 790 |
叶 炳. Efficacy of Dapagliflozin on Type 2 Diabetic Patients with Chronic Heart Failure and Its Effect on Thickness of Epicardial Adipose Tissue. ACRVM 2022;10:1-7. [DOI: 10.12677/acrvm.2022.101001] [Reference Citation Analysis]
|
| 791 |
Eng E, Quaggin S. Putting it All Together: Practical Approach to the Patient with Diabetic Kidney Disease. Diabetes and Kidney Disease 2022. [DOI: 10.1007/978-3-030-86020-2_29] [Reference Citation Analysis]
|
| 792 |
Victor FM, de Lima Andrade SR, Bandeira F. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State. Endocrinology and Diabetes 2022. [DOI: 10.1007/978-3-030-90684-9_33] [Reference Citation Analysis]
|
| 793 |
Stewart E, Selzer A. Preoperative optimization of diabetes. Int Anesthesiol Clin 2022;60:8-15. [PMID: 34897217 DOI: 10.1097/AIA.0000000000000351] [Reference Citation Analysis]
|
| 794 |
Ojha U, Reyes L, Eyenga F, Oumbe D, Watkowska J, Saint-Jacques H. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. Am J Cardiovasc Drugs 2022;22:35-46. [PMID: 34189716 DOI: 10.1007/s40256-021-00486-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 795 |
Radaideh Q, Shammas NW. Pharmacologic Interventions in Patients with Peripheral Arterial Disease. Peripheral Arterial Interventions 2022. [DOI: 10.1007/978-3-031-09741-6_4] [Reference Citation Analysis]
|
| 796 |
Jang SY, Yang DH. Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure. Int J Heart Fail 2022;4:75. [DOI: 10.36628/ijhf.2021.0039] [Reference Citation Analysis]
|
| 797 |
Müller N, Busch M, Wolf G. Antidiabetika zur Progressionshemmung der Nephropathie. Nephrologe 2022;17:34-43. [DOI: 10.1007/s11560-021-00515-0] [Reference Citation Analysis]
|
| 798 |
Meredith A, Starks S, Etelamaki C, Albertson S, Triboletti J, Pence L, Walroth T, Mcgrew K, Gonzalvo J. Evaluation of Sodium-Glucose Cotransporter-2 Inhibitor Use in an Underserved Ambulatory Care Population With Type 2 Diabetes. ADCES in Practice 2022;10:16-24. [DOI: 10.1177/2633559x211056918] [Reference Citation Analysis]
|
| 799 |
Chen D, Fulcher J, Scott ES, Jenkins AJ. Precision Medicine Approaches for Management of Type 2 Diabetes. Precision Medicine in Diabetes 2022. [DOI: 10.1007/978-3-030-98927-9_1] [Reference Citation Analysis]
|
| 800 |
Aggarwal N, Ali S, Navaneethan SD. Diabetes and Kidney Disease: A Review of the Clinical Practice Guidelines. Diabetes and Kidney Disease 2022. [DOI: 10.1007/978-3-030-86020-2_2] [Reference Citation Analysis]
|
| 801 |
Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böhm M, Butler J, Carapetis J, Ceconi C, Chioncel O, Coats A, Crespo-Leiro MG, de Simone G, Drexel H, Emdin M, Farmakis D, Halle M, Heymans S, Jaarsma T, Jankowska E, Lainscak M, Lam CSP, Løchen ML, Lopatin Y, Maggioni A, Matrone B, Metra M, Noonan K, Pina I, Prescott E, Rosano G, Seferovic PM, Sliwa K, Stewart S, Uijl A, Vaartjes I, Vermeulen R, Monique Verschuren WM, Volterrani M, von Heahling S, Hoes A. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Heart Fail 2022;24:143-68. [PMID: 35083829 DOI: 10.1002/ejhf.2351] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 802 |
Maiolino G, Rossato M, Vettor R. Risk factors and pharmacological therapy in patients with vascular disease. Vascular Surgery 2022. [DOI: 10.1016/b978-0-12-822113-6.00021-8] [Reference Citation Analysis]
|
| 803 |
Anam AK, Inzucchi SE. Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. Polycystic Ovary Syndrome 2022. [DOI: 10.1007/978-3-030-92589-5_26] [Reference Citation Analysis]
|
| 804 |
Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, Davies S, Dashora U, Yousef Z, Patel DC, Strain WD. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. Adv Ther 2022;39:33-43. [PMID: 34739697 DOI: 10.1007/s12325-021-01927-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 805 |
Talha KM, Fonarow GC, Virani SS, Butler J. Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist Debakey Cardiovasc J 2022;18:40-53. [PMID: 36561085 DOI: 10.14797/mdcvj.1155] [Reference Citation Analysis]
|
| 806 |
Demidowich AP, Batty K, Zilbermint M. Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions. Diabetes Spectr 2022;35:440-51. [PMID: 36561646 DOI: 10.2337/dsi22-0013] [Reference Citation Analysis]
|
| 807 |
Li APZ, Kariyawasam D. Type 2 Diabetes Mellitus. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00098-0] [Reference Citation Analysis]
|
| 808 |
Kataria A, Argyropoulos C. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors. Diabetes and Kidney Disease 2022. [DOI: 10.1007/978-3-030-86020-2_25] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 809 |
姜 玉. Research Progress on the Protective Effect of SGLT2 Inhibitor on Kidney. ACM 2022;12:3926-3930. [DOI: 10.12677/acm.2022.125569] [Reference Citation Analysis]
|
| 810 |
Garimella PS, Weiner DE, Sarnak MJ. Prevention and management of cardiovascular disease in kidney disease and kidney failure. Nutritional Management of Renal Disease 2022. [DOI: 10.1016/b978-0-12-818540-7.00020-3] [Reference Citation Analysis]
|
| 811 |
Kedyk A, Kutsyn O. Metabolic effects of empagliflozine. DOMS 2022. [DOI: 10.57105/2415-7252-2022-5-04] [Reference Citation Analysis]
|
| 812 |
Freichel M, Klinge A. Diabetes mellitus. Arzneiverordnungs-Report 2022 2022. [DOI: 10.1007/978-3-662-66303-5_10] [Reference Citation Analysis]
|
| 813 |
Ren B, Chen M. Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis. Therapeutic Advances in Endocrinology 2022;13:204201882211424. [DOI: 10.1177/20420188221142450] [Reference Citation Analysis]
|
| 814 |
Yoshida Y, Shimizu I, Minamino T. Capillaries as a Therapeutic Target for Heart Failure. JAT. [DOI: 10.5551/jat.rv17064] [Reference Citation Analysis]
|
| 815 |
Tran BA, Updike WH, Bullers K, Serag-Bolos E. Sodium-Glucose Cotransporter 2 Inhibitor Use Associated With Fournier's Gangrene: A Review of Case Reports and Spontaneous Post-Marketing Cases. Clin Diabetes 2022;40:78-86. [PMID: 35221476 DOI: 10.2337/cd21-0015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 816 |
Lee D, Zonszein J. Outpatient Management of Type 2 Diabetes Mellitus. A Case-Based Guide to Clinical Endocrinology 2022. [DOI: 10.1007/978-3-030-84367-0_40] [Reference Citation Analysis]
|
| 817 |
Coward RJ. Kidney Disease Section – The Emerging Importance of Cellular Insulin Resistance in Diabetic Kidney Disease. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00272-8] [Reference Citation Analysis]
|
| 818 |
American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S195-207. [PMID: 34964847 DOI: 10.2337/dc22-S013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 52.0] [Reference Citation Analysis]
|
| 819 |
American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S175-84. [PMID: 34964873 DOI: 10.2337/dc22-S011] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 68.0] [Reference Citation Analysis]
|
| 820 |
Khan MS, Bakris GL, Packer M, Shahid I, Anker SD, Fonarow GC, Wanner C, Weir MR, Zannad F, Butler J. Kidney function assessment and endpoint ascertainment in clinical trials. Eur Heart J 2021:ehab832. [PMID: 34966917 DOI: 10.1093/eurheartj/ehab832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 821 |
Shubrook JH, Neumiller JJ, Wright E. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations. Postgrad Med 2021;:1-12. [PMID: 34817311 DOI: 10.1080/00325481.2021.2009726] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 822 |
Li Y, Xu G. Sodium Glucose Cotransporter 1 (SGLT1) Inhibitors in Cardiovascular Protection: Mechanism Progresses and Challenges. Pharmacol Res 2021;:106049. [PMID: 34971725 DOI: 10.1016/j.phrs.2021.106049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 823 |
Vella A. Choosing Medications for Type 2 Diabetes – What Weighting Should Be Given to Cardiovascular Risk Reduction? Clinical Dilemmas in Diabetes 2021. [DOI: 10.1002/9781119603207.ch14] [Reference Citation Analysis]
|
| 824 |
Xu J, Hirai T, Koya D, Kitada M. Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. J Clin Med 2021;11:137. [PMID: 35011882 DOI: 10.3390/jcm11010137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 825 |
Nashawi M, Ahmed MS, Amin T, Abualfoul M, Chilton R. Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy. World J Cardiol 2021;13:676-94. [PMID: 35070111 DOI: 10.4330/wjc.v13.i12.676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 826 |
Delanaye P, Wissing KM, Scheen AJ. Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. Clin Kidney J 2021;14:2463-71. [PMID: 34950459 DOI: 10.1093/ckj/sfab096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 827 |
Takase B. Picturing Vascular Health in Patients with Type 2 Diabetes Mellitus: Review based on the Special Lecture 2021. Vasc Fail 2021;5:1-6. [DOI: 10.30548/vascfail.5.1_1] [Reference Citation Analysis]
|
| 828 |
Haloot J, Krokar L, Badin A. Effect of SLGT2 Inhibitors on Patients with Atrial Fibrillation. J Atr Fibrillation 2021;14:20200502. [PMID: 34950375 DOI: 10.4022/jafib.20200502] [Reference Citation Analysis]
|
| 829 |
Yabiku K. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front Endocrinol (Lausanne) 2021;12:768850. [PMID: 34950104 DOI: 10.3389/fendo.2021.768850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 830 |
Liao XX, Li WQ, Peng ZK, Yu HB, Tan J. Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis. J Clin Pharm Ther 2021. [PMID: 34939679 DOI: 10.1111/jcpt.13588] [Reference Citation Analysis]
|
| 831 |
Konstantina C, Dimitris P, Eleni M, Fotis T, Dimitris K, Costas T, Costas T. Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials. Eur J Intern Med 2021:S0953-6205(21)00428-3. [PMID: 34953655 DOI: 10.1016/j.ejim.2021.12.018] [Reference Citation Analysis]
|
| 832 |
Rivera PA, Rodríguez-Zúñiga MJM, Caballero-Alvarado J, Fiestas F. Glycated hemoglobin as a surrogate for evaluating the effectiveness of drugs in diabetes mellitus trials: a systematic review and trial-level meta-analysis. Int J Technol Assess Health Care 2021;38:e12. [PMID: 34933703 DOI: 10.1017/S0266462321001689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 833 |
Cheong AJY, Teo YN, Teo YH, Syn NL, Ong HT, Ting AZH, Chia AZQ, Chong EY, Chan MY, Lee CH, Lim AYL, Kong WKF, Wong RCC, Chai P, Sia CH. SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials. Obesity (Silver Spring) 2022;30:117-28. [PMID: 34932882 DOI: 10.1002/oby.23331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 834 |
Fadiran O, Nwabuo C. The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure. Cureus 2021;13:e19379. [PMID: 34925982 DOI: 10.7759/cureus.19379] [Reference Citation Analysis]
|
| 835 |
Qiu M, Zhao LM, Zhan ZL. Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials. Front Endocrinol (Lausanne) 2021;12:743807. [PMID: 34925229 DOI: 10.3389/fendo.2021.743807] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 836 |
Tauber P, Sinha F, Berger RS, Gronwald W, Dettmer K, Kuhn M, Trum M, Maier LS, Wagner S, Schweda F. Empagliflozin Reduces Renal Hyperfiltration in Response to Uninephrectomy, but Is Not Nephroprotective in UNx/DOCA/Salt Mouse Models. Front Pharmacol 2021;12. [DOI: 10.3389/fphar.2021.761855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 837 |
Mgbemena O, Zhang Y, Velarde G. Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article. Cureus 2021;13:e19398. [PMID: 34926000 DOI: 10.7759/cureus.19398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 838 |
Carrera MJ, Moliner P, Llauradó G, Enjuanes C, Conangla L, Chillarón JJ, Ballesta S, Climent E, Comín-Colet J, Flores-Le Roux JA. Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Heart Failure: A Prospective Study. J Clin Med 2021;11:6. [PMID: 35011747 DOI: 10.3390/jcm11010006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 839 |
Cheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, Zhang X, Lin W, Wu X. Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. Sci Rep 2021;11:24263. [PMID: 34930986 DOI: 10.1038/s41598-021-03773-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 840 |
Ke Q, Shi C, Lv Y, Wang L, Luo J, Jiang L, Yang J, Zhou Y. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney. FASEB J 2022;36:e22078. [PMID: 34918381 DOI: 10.1096/fj.202100909RR] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 841 |
Gandhi GY, Mooradian AD. Management of Hyperglycemia in Older Adults with Type 2 Diabetes. Drugs Aging 2021. [PMID: 34921341 DOI: 10.1007/s40266-021-00910-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 842 |
Du Y, Bai L, Fan B, Ding H, Ding H, Hou L, Ma H, Xing N, Wang F. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis. Prim Care Diabetes 2021:S1751-9918(21)00223-0. [PMID: 34930687 DOI: 10.1016/j.pcd.2021.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 843 |
Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol 2021;20:236. [PMID: 34915880 DOI: 10.1186/s12933-021-01430-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 844 |
Castillo Moraga MJ, Turégano-Yedro M, Pallarés-Carratalá V, Seoane-Vicente MC, Serrano Cumplido A, Ruiz-García A, Martin-Rioobó E, Escobar-Cervantes C, Polo-García J, Barrios V; en nombre del Grupo de Trabajo de Hipertensión Arterial y Enfermedad Cardiovascular de SEMERGEN. [SEMERGEN positioning on approaching chronic heart failure in primary care]. Semergen 2021:S1138-3593(21)00344-0. [PMID: 34924298 DOI: 10.1016/j.semerg.2021.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 845 |
Scheen AJ, Delanaye P. Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Rev Endocrinol Metab 2021;:1-12. [PMID: 34908510 DOI: 10.1080/17446651.2022.2014322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 846 |
Seo MS, An JR, Kang M, Heo R, Park H, Han ET, Han JH, Chun W, Park WS. Mechanisms underlying the vasodilatory effects of canagliflozin in the rabbit thoracic aorta: Involvement of the SERCA pump and Kv channels. Life Sci 2021;287:120101. [PMID: 34715136 DOI: 10.1016/j.lfs.2021.120101] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 847 |
Chiang B, Chew DP, De Pasquale CG. Outcome trial data on sodium glucose cotransporter-2 inhibitors: Putting clinical benefits and risks in perspective. Int J Cardiol 2021:S0167-5273(21)02007-6. [PMID: 34920045 DOI: 10.1016/j.ijcard.2021.12.015] [Reference Citation Analysis]
|
| 848 |
Kotsis V, Martinez F, Trakatelli C, Redon J. Impact of Obesity in Kidney Diseases. Nutrients 2021;13:4482. [PMID: 34960033 DOI: 10.3390/nu13124482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 849 |
Kotskaya AV, Salaychuk EV, Kudinov VI, Terentyev VP, Lankina MS. Variability of arterial pressure and cardiac rhythm in patients with coronary heart disease and diabetes mellitus: Effect of sodium-glucose co-transporter 2 inhibitor. I P Pavlov Russian Medical Biological Herald 2021;29:489-496. [DOI: 10.17816/pavlovj72376] [Reference Citation Analysis]
|
| 850 |
Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, Mann JFE, Nauck MA, Rasmussen S, Rossing P, Wolthers B, Zinman B, Perkovic V. Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials. Circulation 2021. [PMID: 34903039 DOI: 10.1161/CIRCULATIONAHA.121.055459] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 851 |
Calabrese AM, Calsolaro V, Rogani S, Okoye C, Caraccio N, Monzani F. Optimal Type 2 Diabetes Mellitus Management and Active Ageing. Endocrines 2021;2:523-39. [DOI: 10.3390/endocrines2040047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 852 |
Khasanov NR. Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations. Russ J Cardiol 2021;26:4807. [DOI: 10.15829/1560-4071-2021-4807] [Reference Citation Analysis]
|
| 853 |
Narongkiatikhun P, Chattipakorn SC, Chattipakorn N. Mitochondrial dynamics and diabetic kidney disease: Missing pieces for the puzzle of therapeutic approaches. J Cell Mol Med 2021. [PMID: 34889040 DOI: 10.1111/jcmm.17116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 854 |
Kolb H, Kempf K, Röhling M, Lenzen-Schulte M, Schloot NC, Martin S. Ketone bodies: from enemy to friend and guardian angel. BMC Med 2021;19:313. [PMID: 34879839 DOI: 10.1186/s12916-021-02185-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 27] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 855 |
Tian Q, Guo K, Deng J, Zhong Y, Yang L. Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis. J Cell Mol Med 2021. [PMID: 34878225 DOI: 10.1111/jcmm.17115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 856 |
Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace 2021;23:1873-91. [PMID: 34411235 DOI: 10.1093/europace/euab184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 857 |
Sen T, Li J, Neuen BL, Arnott C, Neal B, Perkovic V, Mahaffey KW, Shaw W, Canovatchel W, Hansen MK, Heerspink HJL. Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. J Am Heart Assoc 2021;10:e021661. [PMID: 34854308 DOI: 10.1161/JAHA.121.021661] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 858 |
Salvatore T, Galiero R, Caturano A, Vetrano E, Rinaldi L, Coviello F, Di Martino A, Albanese G, Marfella R, Sardu C, Sasso FC. Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. Biomolecules 2021;11:1834. [PMID: 34944478 DOI: 10.3390/biom11121834] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 859 |
Qiu M, Wei W, Wei XB, Liu SY. Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes. Eur J Clin Pharmacol 2021. [PMID: 34860262 DOI: 10.1007/s00228-021-03261-3] [Reference Citation Analysis]
|
| 860 |
Takada S, Sabe H, Kinugawa S. Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies. Am J Physiol Heart Circ Physiol 2021. [PMID: 34860594 DOI: 10.1152/ajpheart.00100.2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 861 |
Lin KJ, Wang TJ, Chen SD, Lin KL, Liou CW, Lan MY, Chuang YC, Chuang JH, Wang PW, Lee JJ, Wang FS, Lin HY, Lin TK. Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease-Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants (Basel) 2021;10:1935. [PMID: 34943038 DOI: 10.3390/antiox10121935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 862 |
Fisher M. Clinical relevance of recent outcome trials with antidiabetic drugs. Pract Diab 2021;38:3-6. [DOI: 10.1002/pdi.2363] [Reference Citation Analysis]
|
| 863 |
Ito D, Inoue K, Saito D, Hamaguchi K, Kaneko K, Sumita T, Inukai K, Inoue I, Shimada A. Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial. Diabetes Ther 2021;12:3201-15. [PMID: 34709582 DOI: 10.1007/s13300-021-01176-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 864 |
Matsuba I, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Kanamori A. Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes. Diabetes Obes Metab 2021;23:2614-22. [PMID: 34338409 DOI: 10.1111/dom.14508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 865 |
Fang L, Duan J, Geng J, Liu Z, Dong J. Sodium-glucose cotransporter 2 (SGLT2) inhibitors for the prevention and treatment of diabetic kidney disease: A network meta-analysis of randomized controlled trials. Diabetic Nephropathy 2021;1:114-124. [DOI: 10.2478/dine-2022-0012] [Reference Citation Analysis]
|
| 866 |
Gajjela H, Kela I, Kakarala CL, Hassan M, Belavadi R, Gudigopuram SVR, Raguthu CC, Modi S, Sange I. Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go. Cureus 2021;13:e20359. [PMID: 35028235 DOI: 10.7759/cureus.20359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 867 |
Napoli N. Nephropathy and chronic renal insufficiency. JGG 2021;69:262-4. [DOI: 10.36150/2499-6564-n455] [Reference Citation Analysis]
|
| 868 |
Hörtenhuber T. Juveniler Typ-2-Diabetes mellitus – eine unterschätzte Hochrisikoerkrankung. J Klin Endokrinol Stoffw 2021;14:145-149. [DOI: 10.1007/s41969-021-00151-y] [Reference Citation Analysis]
|
| 869 |
Schinzari F, Tesauro M, Cardillo C. Vasodilator Dysfunction in Human Obesity: Established and Emerging Mechanisms. J Cardiovasc Pharmacol 2021;78:S40-52. [PMID: 34840258 DOI: 10.1097/FJC.0000000000001108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 870 |
Akuta N, Kawamura Y, Arase Y, Saitoh S, Muraishi N, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Ikeda K, Kumada H, Suzuki F, Suzuki Y. Histological impact at 5 years after the start of sodium-glucose cotransporter 2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus. Acta hepatologica Japonica 2021;62:820-822. [DOI: 10.2957/kanzo.62.820] [Reference Citation Analysis]
|
| 871 |
Romero A, Llauradó G, González-clemente J. Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes. Endocrinología, Diabetes y Nutrición (English ed ) 2021;68:741-750. [DOI: 10.1016/j.endien.2021.11.031] [Reference Citation Analysis]
|
| 872 |
Gomez-sanchez CM, Wu BX, Gotts JE, Chang RW. Euglycemic diabetic ketoacidosis following major vascular surgery is a new item on the differential for postoperative acidosis. Journal of Vascular Surgery Cases, Innovations and Techniques 2021;7:778-780. [DOI: 10.1016/j.jvscit.2021.10.006] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 873 |
Yu M, Kim G. SGLT2 Inhibition for Diabetic and Non-diabetic Kidney Disease. Korean J Med 2021;96:455-462. [DOI: 10.3904/kjm.2021.96.6.455] [Reference Citation Analysis]
|
| 874 |
Kuriyama S, Matsumoto K, Hirao M, Miho O. Why do SGLT2 Inhibitors Act as Cardio-renal Protective even in Non-diabetics? Jpn J Clin Pharmacol Ther 2021;52:157-164. [DOI: 10.3999/jscpt.52.157] [Reference Citation Analysis]
|
| 875 |
Stewart M. An overview of the oral medicines used in the management of type 2 diabetes. Nursing Standard 2021. [DOI: 10.7748/ns.2021.11804] [Reference Citation Analysis]
|
| 876 |
Barbarash OL, Komarov AL, Panchenko EP, Staroverov II, Shahnovich RM, Yavelov IS. Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Evrazijskij kardiologičeskij žurnal 2021. [DOI: 10.38109/2225-1685-2021-4-6-59] [Reference Citation Analysis]
|
| 877 |
Tilinca MC, Tiuca RA, Tilea I, Varga A. The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. J Pers Med 2021;11:1249. [PMID: 34945721 DOI: 10.3390/jpm11121249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 878 |
Al-Shamasi AA, Elkaffash R, Mohamed M, Rayan M, Al-Khater D, Gadeau AP, Ahmed R, Hasan A, Eldassouki H, Yalcin HC, Abdul-Ghani M, Mraiche F. Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases. Int J Mol Sci 2021;22:12677. [PMID: 34884494 DOI: 10.3390/ijms222312677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 879 |
Chang R, Liu SY, Zhao LM. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27802. [PMID: 34964748 DOI: 10.1097/MD.0000000000027802] [Reference Citation Analysis]
|
| 880 |
Manigrasso MB, Rabbani P, Egaña-Gorroño L, Quadri N, Frye L, Zhou B, Reverdatto S, Ramirez LS, Dansereau S, Pan J, Li H, D'Agati VD, Ramasamy R, DeVita RJ, Shekhtman A, Schmidt AM. Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Sci Transl Med 2021;13:eabf7084. [PMID: 34818060 DOI: 10.1126/scitranslmed.abf7084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 881 |
Pahud de Mortanges A, Salvador D Jr, Laimer M, Muka T, Wilhelm M, Bano A. The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review. Front Pharmacol 2021;12:751214. [PMID: 34803693 DOI: 10.3389/fphar.2021.751214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 882 |
Pabel S, Hamdani N, Singh J, Sossalla S. Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. Front Physiol 2021;12:752370. [PMID: 34803735 DOI: 10.3389/fphys.2021.752370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 883 |
Heerspink HJL, Law G, Psachoulia K, Connolly K, Whatling C, Ericsson H, Knöchel J, Lindstedt EL, MacPhee I. Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD. Kidney Int Rep 2021;6:2803-10. [PMID: 34805632 DOI: 10.1016/j.ekir.2021.08.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 884 |
Seki H, Kuratani N, Shiga T, Iwasaki Y, Karita K, Yasuda K, Yorozu T. Multicentre prospective observational study of sodium-glucose cotransporter-2 inhibitor-associated postoperative ketoacidosis: the SAPKA study protocol. BMJ Open 2021;11:e049592. [PMID: 34815277 DOI: 10.1136/bmjopen-2021-049592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 885 |
Caruso I, Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents. Metabolism 2021;127:154937. [PMID: 34808144 DOI: 10.1016/j.metabol.2021.154937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 886 |
Teo YN, Teo YH, Syn NL, Yoong CSY, Cheong AJY, Wee CF, Lim YC, Lee CH, Yeo TC, Chai P, Wong RCC, Lin W, Sia CH. Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clin Drug Investig 2021. [PMID: 34797518 DOI: 10.1007/s40261-021-01098-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 887 |
Li N, Lv D, Zhu X, Wei P, Gui Y, Liu S, Zhou E, Zheng M, Zhou D, Zhang L. Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis. Front Med (Lausanne) 2021;8:728089. [PMID: 34790672 DOI: 10.3389/fmed.2021.728089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 888 |
Murashima M, Tanaka T, Kasugai T, Tomonari T, Ide A, Ono M, Mizuno M, Suzuki T, Hamano T. Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice. J Diabetes Investig 2021. [PMID: 34797947 DOI: 10.1111/jdi.13717] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 889 |
Katsurada K, Nandi SS, Sharma NM, Patel KP. Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves. Circ Heart Fail 2021;:CIRCHEARTFAILURE121008365. [PMID: 34789005 DOI: 10.1161/CIRCHEARTFAILURE.121.008365] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 890 |
Krutikov ES, Tsvetkov VA, Chistyakova SI, Akaev RO. Efficiency of empagliflosin in combined nephroprotective therapy in patients with type 2 diabetes mellitus. Nefrologiâ (St -Peterbg ) 2021;25:56-62. [DOI: 10.36485/1561-6274-2021-25-6-56-62] [Reference Citation Analysis]
|
| 891 |
Zhang N, Wang Y, Tse G, Korantzopoulos P, Letsas KP, Zhang Q, Li G, Lip GYH, Liu T. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. Eur J Prev Cardiol 2021:zwab173. [PMID: 34792124 DOI: 10.1093/eurjpc/zwab173] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 892 |
Prudencio J, Cajudoy P, Waddell D. Optimization of Medication Regimens in Patients with Type 2 Diabetes and Clinical Atherosclerotic Cardiovascular Disease. Pharmacy (Basel) 2021;9:186. [PMID: 34842818 DOI: 10.3390/pharmacy9040186] [Reference Citation Analysis]
|
| 893 |
Mohebi R, Januzzi JL. Cardiovascular benefit of SGLT2 inhibitors. Crit Rev Clin Lab Sci 2021;:1-14. [PMID: 34784839 DOI: 10.1080/10408363.2021.1993439] [Reference Citation Analysis]
|
| 894 |
Huang CC, Chou CA, Chen WY, Yang JL, Lee WC, Chen JB, Lee CT, Li LC. Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice. Int J Mol Sci 2021;22:12408. [PMID: 34830289 DOI: 10.3390/ijms222212408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 895 |
Kim HM, Hwang IC, Choi W, Yoon YE, Cho GY. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction. Sci Rep 2021;11:22342. [PMID: 34785723 DOI: 10.1038/s41598-021-01759-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 896 |
Galati G, Sabouret P, Germanova O, Bhatt DL. Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. Eur Cardiol 2021;16:e40. [PMID: 34777580 DOI: 10.15420/ecr.2021.22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 897 |
Hong S, Park JH, Han K, Lee CB, Kim DS, Yu SH. Blood Pressure and Cardiovascular Disease in Older Patients With Diabetes: Retrospective Cohort Study. J Am Heart Assoc 2021;10:e020999. [PMID: 34726076 DOI: 10.1161/JAHA.121.020999] [Reference Citation Analysis]
|
| 898 |
Elserafy AS, Reda A, Farag E, Mostafa T, Farag N, Elbahry A, Sanad O, Bendary A, Elkersh A, Attia I, Selim M, Khamis H, Issak ER. Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction. Clin Drug Investig 2021;41:1027-36. [PMID: 34780022 DOI: 10.1007/s40261-021-01095-6] [Reference Citation Analysis]
|
| 899 |
Gómez-Huelgas R, Sanz-Cánovas J, Cobos-Palacios L, López-Sampalo A, Pérez-Belmonte LM. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. Eur J Intern Med 2021:S0953-6205(21)00383-6. [PMID: 34799233 DOI: 10.1016/j.ejim.2021.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 900 |
Sangha V, Lipska K, Lin Z, Inzucchi SE, McGuire DK, Krumholz HM, Khera R. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. Circ Cardiovasc Qual Outcomes 2021. [PMID: 34779654 DOI: 10.1161/CIRCOUTCOMES.121.008381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 901 |
Indraratna P, Khasanova E, Gulsin GS, Tzimas G, Takagi H, Park KH, Lin FY, Shaw LJ, Lee SE, Narula J, Bax JJ, Chang HJ, Leipsic J; PARADIGM investigators. Plaque progression: Where, why, and how fast? A review of what we have learned from the analysis of patient data from the PARADIGM registry. J Cardiovasc Comput Tomogr 2021:S1934-5925(21)00464-0. [PMID: 34824029 DOI: 10.1016/j.jcct.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 902 |
Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, Del Prato S, Lopes RD, Niemoeller E, Khurmi NS, Baek S, Gerstein HC. Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation 2021. [PMID: 34775781 DOI: 10.1161/CIRCULATIONAHA.121.057934] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 903 |
Gul W, Naem E, Elawad S, Elhadd T. Successful use of the sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with renal transplant and diabetes: a case series and literature review. Cardiovasc Endocrinol Metab 2021;10:222-4. [PMID: 34765893 DOI: 10.1097/XCE.0000000000000246] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 904 |
Chen C, Peng H, Li M, Lu X, Huang M, Zeng Y, Dong G. Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:664533. [PMID: 34759887 DOI: 10.3389/fendo.2021.664533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 905 |
Kawai Y, Uneda K, Yamada T, Kinguchi S, Kobayashi K, Azushima K, Kanaoka T, Toya Y, Wakui H, Tamura K. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis. Diabetes Res Clin Pract 2021;183:109146. [PMID: 34780865 DOI: 10.1016/j.diabres.2021.109146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 906 |
Rodionov RN, Peters F, Marschall U, L'Hoest H, Jarzebska N, Behrendt CA. Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis. Eur J Vasc Endovasc Surg 2021:S1078-5884(21)00770-X. [PMID: 34782230 DOI: 10.1016/j.ejvs.2021.09.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 907 |
Georgiou P, Shi W, Serhiyenia T, Akram A, Proute MC, Pradeep R, Kerolos ME, Khan S. Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review. Cureus 2021;13:e18485. [PMID: 34754647 DOI: 10.7759/cureus.18485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 908 |
Ena J, Carretero-Gómez J, Zapatero-Gaviria A, Carrasco-Sánchez FJ, Del Romero-Sánchez M, González-Becerra C, Blazquez-Encinar JC, Iguzquiza-Pellejero MJ, de Escalante Yangüela B, Gómez-Huelgas R; Spanish Society for Internal Medicine Diabetes, Obesity, and Nutrition Workgroup. Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study. Rev Clin Esp (Barc) 2021;221:517-28. [PMID: 34752263 DOI: 10.1016/j.rceng.2019.12.015] [Reference Citation Analysis]
|
| 909 |
Puglisi S, Rossini A, Poli R, Dughera F, Pia A, Terzolo M, Reimondo G. Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Front Endocrinol (Lausanne) 2021;12:738848. [PMID: 34745006 DOI: 10.3389/fendo.2021.738848] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 910 |
Chun KJ, Jung HH. SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials. Kidney Med 2021;3:732-744.e1. [PMID: 34746739 DOI: 10.1016/j.xkme.2021.04.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 911 |
Zhuo M, Paik JM, Wexler DJ, Bonventre JV, Kim SC, Patorno E. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes. Am J Kidney Dis 2021:S0272-6386(21)00953-7. [PMID: 34762974 DOI: 10.1053/j.ajkd.2021.09.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 912 |
Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky AC, Itzhak B, Lalic NM, Prattichizzo F, Schnell O, Seferović PM, Valensi P, Standl E; D&CVD EASD Study Group. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol 2021;20:218. [PMID: 34740359 DOI: 10.1186/s12933-021-01408-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 913 |
Berg DD, Kolkailah AA, Sarraju A, Kerchberger AM, Eljalby M, McGuire DK. Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes. Curr Diab Rep 2021;21:45. [PMID: 34741199 DOI: 10.1007/s11892-021-01417-0] [Cited by in Crossref: 1] |
